0001213900-22-056075.txt : 20220915 0001213900-22-056075.hdr.sgml : 20220915 20220915090031 ACCESSION NUMBER: 0001213900-22-056075 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220915 DATE AS OF CHANGE: 20220915 FILER: COMPANY DATA: COMPANY CONFORMED NAME: China Health Industries Holdings, Inc. CENTRAL INDEX KEY: 0001309057 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 860827216 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51060 FILM NUMBER: 221244582 BUSINESS ADDRESS: STREET 1: 3199-1 LONGXIANG ROAD, SONGBEI DISTRICT STREET 2: HARBIN CITY CITY: HEILONGJIANG PROVINCE STATE: F4 ZIP: 150028 BUSINESS PHONE: 011-86-451-51719407 MAIL ADDRESS: STREET 1: 3199-1 LONGXIANG ROAD, SONGBEI DISTRICT STREET 2: HARBIN CITY CITY: HEILONGJIANG PROVINCE STATE: F4 ZIP: 150028 FORMER COMPANY: FORMER CONFORMED NAME: UNIVERSAL FOG INC DATE OF NAME CHANGE: 20050617 FORMER COMPANY: FORMER CONFORMED NAME: EDMONDS 6 INC. DATE OF NAME CHANGE: 20041118 10-K 1 f10k2022_chinahealth.htm ANNUAL REPORT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended June 30, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________

Commission file number: 000-51060

CHINA HEALTH INDUSTRIES HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

Delaware		86-0827216
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

3199-1 Longxiang Road, Songbei District, Harbin City
Heilongjiang Province
People’s Republic of China		150028
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: 86-451-88100688

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Not applicable		Not applicable		Not applicable

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.0001 par value
Title of Class

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes ☒ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☒		Smaller reporting company ☒
		Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No

The aggregate market value of the voting and non-voting common stock of the issuer held by non-affiliates as of December 31, 2021 was approximately $5,436,329 (45,032,549 shares of common stock held by non-affiliates) based upon the closing price of the common stock on such date.

As of September 15, 2022, there were 65,539,737 shares of common stock, par value $0.0001 issued and outstanding.

Table of Contents

Part I		1

Item 1	Business	1

Item 1A	Risk Factors	17

Item 1B	Unresolved Staff Comments	17

Item 2	Properties	17

Item 3	Legal Proceedings	17

Item 4	Mine Safety Disclosures	17

Part II		18

Item 5	Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	18

Item 6	[Reserved]	19

Item 7	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

Item 7A	Quantitative and Qualitative Disclosures About Market Risk	25

Item 8	Financial Statements and Supplementary Data	25

Item 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	26

Item 9A	Controls and Procedures	26

Item 9B	Other Information	27

Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.	27

Part III		28

Item 10	Directors, Executive Officers and Corporate Governance	28

Item 11	Executive Compensation	34

Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	36

Item 13	Certain Relationships and Related Transactions, and Director Independence	37

Item 14	Principal Accountant Fees and Services	37

Part IV		38

Item 15	Exhibits and Financial Statement Schedules	38

PART I

Item 1. Business.

Our History and Corporate Structure

China Health Industries Holdings, Inc. (“China Health US”) was incorporated in the State of Arizona on July 11, 1996 and was the successor of the business known as Arizona Mist, Inc. which began in 1989. On May 9, 2005, it entered into a stock purchase agreement and share exchange (effecting a reverse merger) with Edmonds 6, Inc. (“Edmonds 6”), a Delaware corporation, and changed its name to Universal Fog, Inc. Pursuant to this agreement, Universal Fog, Inc. (which has been in continuous operation since 1996) became a wholly-owned subsidiary of Edmonds 6.

China Health Industries Holdings Limited (“China Health HK”) was incorporated on July 20, 2007 in Hong Kong under the Companies Ordinance as a limited liability company. China Health HK was formed for the purpose of seeking and consummating a merger or acquisition with a business entity organized as a private corporation, partnership, or sole proprietorship as defined by FASB ACS Topic 915 (“Development Stage Entities”).

Harbin Humankind Biology Technology Co., Limited (“Humankind”) was incorporated in Harbin City, Heilongjiang Province, the People’s Republic of China (the “PRC”) on December 14, 2003, as a limited liability company under the Company Law of the PRC. Humankind is engaged in the manufacturing and sale of health products.

On August 20, 2007, the sole shareholder of China Health HK entered into a share purchase agreement (the “Share Purchase Agreement”) with the owners of Humankind. Pursuant to the Share Purchase Agreement, China Health HK purchased 100% of the ownership in Humankind for a cash consideration of $60,408 (the “Share Purchase”). Subsequent to the completion of the Share Purchase, Humankind became a wholly-owned subsidiary of China Health HK. The Share Purchase was accounted for as a “reverse merger” since the owner of Humankind owned a majority of the outstanding shares of China Health HK’s common stock immediately following the execution of the Share Purchase Agreement, it was deemed to be the accounting acquirer in the reverse merger. Consequently, the assets and liabilities and the historical operations that have been reflected in the financial statements for periods prior to the Share Purchase are those of Humankind and have been recorded at the historical cost basis. After completion of the Share Purchase, China Health HK’s consolidated financial statements include the assets and liabilities of both China Health HK and Humankind, the historical operations of Humankind, and the operations of China Health HK and its subsidiaries from the closing date of the Share Purchase onward.

On October 14, 2008, Humankind set up a 99% owned subsidiary, Harbin Huimeijia Medicine Company (“Huimeijia”), with its primary business being manufacturing and distributing medicine. Mr. Xin Sun, the Company’s majority owner, owns 1% of Huimeijia. Huimeijia is consolidated in the consolidated financial statements of China Health HK.

On December 31, 2008, China Health HK entered into a reverse merger with Universal Fog, Inc., a U.S. publicly traded shell company (the “Transaction”). China Health HK is the acquirer in the Transaction, and the Transaction was treated as a recapitalization of China Health US. After the Transaction and a 20:1 reverse stock split, Mr. Xin Sun owned 61,203,088 shares of common stock, representing 98.3% of the 62,234,737 total outstanding shares of common stock of China Health US. On April 7, 2009, Mr. Sun transferred 28,200,000 shares of common stock to 296 individuals, leaving him with 33,003,088 shares of common stock of China Health US, or approximately 53.03% of the total outstanding shares of common stock. Universal Fog, Inc. changed its name to China Health Industries Holdings, Inc. on February 19, 2009.

On November 22, 2013, Humankind completed the acquisition of Heilongjiang Huimeijia Pharmaceutical Co., Ltd. (“HLJ Huimeijia”) for a total purchase price of $16,339,869 (RMB100,000,000). HLJ Huimeijia was founded on October 30, 2003, and is engaged in the manufacturing and distribution of tincture, ointments, rubber paste (including hormones), topical solution, suppositories, liniment (including traditional Chinese medicine extractions), enemas and oral liquids. HLJ Huimeijia’s predecessor is Heilongjiang Xue Du Pharmaceutical Co., Ltd., which has established its brand name in the market through its supply of high-quality medical products. HLJ Huimeijia is categorized as a “high and new technology” enterprise by the Science Technology Department in Heilongjiang Province. HLJ Huimeijia has 21 products which have been approved by, and have received approval numbers issued by, the National Medical Products Administration (“NMPA”). In addition, HLJ Huimeijia is the holder of one patent for utility models, five patents for external design and three trademarks in China, including the Chinese brand name of “Xue Du” which has an established reputation among customers in northeastern China.

On December 24, 2014, Humankind entered into a stock transfer agreement (the “Original Agreement”) with (i) Xiuzheng Pharmaceutical Group Co., Ltd. a company incorporated under the laws of the PRC and located in Jilin province (“Xiuzheng Pharmacy” or the “Buyer”), (ii) Mr. Xin Sun, the CEO of the Company, and (iii) Huimeijia, a subsidiary of Humankind that is 99% owned by Humankind and 1% owned by Mr. Xin Sun. Pursuant to the Original Agreement, Humankind and Mr. Xin Sun (collectively, the “Equity Holders”), would sell their respective equity interests in Huimeijia to Xiuzheng Pharmacy.

On October 12, 2016, the four parties agreed to rescind the Supplementary Agreement and entered into a new supplementary agreement pursuant to which the parties agreed to execute the transfer of the equity interests based on the Original Agreement, and the Equity Holders sold their respective equity interests in Huimeijia to Xiuzheng Pharmacy for total cash consideration of RMB 8,000,000 (approximately $1,306,186 USD, the “Purchase Price”) to the Equity Holders. As of October 12, 2016, Huimeijia had completed changes in its business registration, and Xiuzheng Pharmacy had obtained a new business license issued by the local State Administration of Industry and Commerce in Harbin (“Harbin SAIC”) for Huimeijia, in which Huimeijia’s ownership was recorded as held by Xiuzheng Pharmacy, and the legal representative (a person that is authorized to take most corporate actions on behalf of a company under PRC corporate laws) of Huimeijia had been appointed by the Buyer.

China Health US, China Health HK, Humankind and HLJ Huimeijia are collectively referred herein to as the “Company.”

As of June 30, 2022, the Company’s corporate structure was as follows:

Business Overview

Our principal business operations are conducted through our wholly-owned subsidiaries, Humankind and HLJ Huimeijia.

The Company owns a GMP-certified plant and production facilities and has the capacity to produce 21 different NMPA-approved medicines, 14 NMPA-approved health supplement products and 8 hemp derivative products in soft capsule, hard capsule, tablet, granule, oral liquid forms. These products address the needs of some key sectors in China, including the feminine, geriatric, and children’s markets.

HLJ Huimeijia was founded on October 30, 2003 and its latest GMP certificate is effective until April 24, 2023. HLJ Huimeijia engages in the manufacture and distribution of tincture, ointments, rubber paste, including hormones, topical solution, suppositories, enemas, oral liquids, and liniment, including traditional Chinese medicine extractions. HLJ Huimeijia’s predecessor was Heilongjiang Xue Du Pharmaceutical Co., Ltd., which established brand recognition in the market through its supply of high-quality drug products. HLJ Huimeijia is a “high and new technology” enterprise that provides the most comprehensive types of topical medical products in Heilongjiang Province, a northeastern province of China.

We sell our products directly to end customers through our own sales personnel as well as our sales agents, operating primarily in Anhui, Zhejiang, Shanghai, Jiangsu, Beijing and Gansu, where most of our revenues are generated. However, there is no such sales for the fiscal year 2022,which was primarily due to Humankind’s enterprise transformation, and the lock down of factory due to COVID-19. Humankind is using existing materials to research and develop new products. Humankind decided to transform the primary business to CBD extractive project, because the government intended to support the company research in CBD aspect. However, by the end of fiscal year 2022, the support guidelines had not been published. Although the research process is slow and unpredictable due to the zero-case policy and periodic quarantines caused by COVID-19 resurgence, we expect the CBD extractive project to be completed by the end of calendar year of 2022 (“Transformation”). We do not currently sell our products online, but we expect to do so in the future.

There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as such, the extent of the business disruption and the related financial impact cannot be reasonably estimated at this time.

Products

We are licensed to sell our products, including our medical drugs, only in the PRC.

(i) Hemp Derivative Products

We have developed the following products that are derived from hemp and obtained business license to manufacture and sell these products. We have begun to sell these products since May 2018. Hemp Oil, Hemp Protein Powder, Hemp Polypeptide and Collagen Peptide are sold through Humankind. Other products are sold through HLJ Huimeijia. The revenue of the Hemp Oil, Hemp Protein Powder and Hemp Polypeptide accounted for nil and 89.88% of the total revenues for the fiscal year of 2022 and 2021, respectively.

Serial No.		Name
1		Hemp Oil
2		Hemp Protein Powder
3		Hemp Polypeptide
4		Collagen Peptide
5		Natural Hemp Essence Repair Lotion
6		Natural Hemp Revitalizing Essence
7		Natural Hemp Anit-aging Brightening Eye Cream
8		Natural Hemp Frozen Age Nourishing Cream

(ii) Health Products

Our “QunLe” brand Sailuozhi soft capsule, a supplement made from frog oil, soybean isoflavone, procyanidine (made from grape seeds) and vitamin E, is for freckle removal and skin moisture. “QunLe” brand Sailuozhi soft capsulechanged name to “QunLe” brand Frog Oil, Soybean Isoflavone and Vitamin E Soft Capsul, register number is G20070356, which expired on April 6, 2026.

On May 12, 2010, we received a patent for this product (Patent No. 200610010394.4) under the name “Run Chao” (which has since been changed to “QunLe”) with the National Bureau of Intellectual Property.

Pursuant to a technology transfer agreement dated October 12, 2007 (the “2007 Technology Transfer Agreement”), we purchased a health product known as “Kindlink” brand propolis and black ant capsule made from propolis, black ant, acanthopanax and astragalus root from Beijing Jindelikang Bio-Technology Co., Ltd (“Jindelikang”). The change of the ownership has been approved by the NMPA. This product is intended to boost one’s immunity. The certification number issued by the NMPA on August 20, 2004, for the license to manufacture the product is GuoShiJianZi G20040906. We have no continuing obligations under the 2007 Technology Transfer Agreement.

Pursuant to a technology transfer agreement dated January 18, 2013 (the “2013 Technology Transfer Agreement”), we purchased 12 health products from Guangzhou Aoda Biology Beauty Healthy Technology Co., Ltd, a non-affiliated party. These twelve products are the following:

-	Dr. Xiao Brand Honeysuckle Pearl Capsule (Guo Shi Jian Zi G20100656), which is designed to be effective in acne removal;

-	Dr. Xiao Brand Multivitamin Tablet (Guo Shi Jian Zi G20080176), which is a multivitamin and mineral supplement;

-	Dr. Xiao Brand Zhengdian Capsule (Guo Shi Jian Zi 20070261), which is designed to be effective in relieving eyestrain;

-	Dr. Xiao Brand Shengui Capsule (Guo Shi Jian Zi G20080297), which is designed to be effective in increasing bone density;

-	Dr. Xiao Brand Multivitamin Tablet (Woman) (Guo Shi Jian Zi G20070338), which is an iron and multivitamin supplement;

-	Dr. Xiao Brand Shikong Soft Capsule (Guo Shi Jian Zi 20080096), which is designed to be effective in improving memory;

-	Dr. Xiao Brand Huangjingdanggui Tablet (Guo Shi Jian Zi G20080201), which is designed to be effective in improving nutritional anemia and chloasma;

-	Dr. Xiao Brand Xingxing Soft Capsule (Guo Shi Jian Zi G20080080), which is designed to be effective in improving memory;

-	Dr. Xiao Brand Vitamin A Fish Oil Soft Capsule (Guo Shi Jian Zi G20080406), which is designed to be effective in relieving eyestrain;

-	Dr. Xiao Brand Colon Cleanser Granules (Guo Shi Jian Zi G20060061), which is designed to be effective in relaxing bowels and promoting the discharge of lead;

-	Dr. Xiao Brand Jianli Soft Capsule (Guo Shi Jian Zi G20050710), which is designed to be effective in increasing immunity and relieving physical fatigue; and

-	LB Brand Xinpin Capsule (Guo Shi Jian Zi G20050770), which is designed to be effective in dispelling chloasma.

The major suppliers of raw materials for our products who exceeded 10% of our total purchases in the fiscal years 2022 and 2021 are the following:

		Purchases
		(in U.S.		% of
	Name of Supplier	Dollars)		Purchases
FY2022	nil
FY2021	Shanxi Yuanshengtai Biotechnology Co. LTD		947,682		39.63	%
	Harbin Qianjin Packaging and Printing Co. LTD		524,996		21.95	%
	Wudi Zhenkang Biotechnology Co. LTD		391,795		16.38	%

In the year ended June 30, 2022, the Company had no suppliers due to its being temporarily out of production. The Company typically signs monthly purchase orders with its major suppliers. All purchase orders with our other suppliers are on similar terms. We shall remit payment to a supplier’s account no later than three business days after receiving raw materials. A supplier shall deliver raw materials no later than three business days after receiving a purchase order. The cost of delivery is borne by the supplier.

(iii) Medical Drugs

HLJ Huimeijia has 21 products with approval numbers issued by the NMPA as following:

	English Name	Efficacy
1	Enema Glycerini	Lubricating laxative. Used for constipation.

2	UmguentumAcidi Borici Camphoratum	Dermerethistica. Used for chilblain.

3	Ge Hong Beriberi Water	Dehumidification insecticide. Used for tinea pedis and tinea manuum caused by damp toxin brewing and binding, and other skin diseases caused by enzyme.

4	Pelvic Inflammation Suppository	Heat-clearing and detoxifying; activating blood to promote menstruation disperse swelling and relieve pain. Used for toxin and blood stasis stagnation in the uterus, distending pain in the lower abdomen, irregular menses, algomenorrhea and leukorrhagia, as well as pelvic inflammation and annexitis with the aforementioned symptoms.

5	Injury and Paralysis Tincture	Warm channel and expelling cold, promoting blood circulation to arrest pain. Used to relieve pain caused by traumatic injury and sprain.

6	Indometacin and Furazolidone Suppositories	Anti – inflammatory painkiller. Used to treat acute hemorrhoid, including internal hemorrhoids, external hemorrhoids, mixed hemorrhoids, anal fissure or archosyrinx and relieve pain; Used to ease pain after the operation of anal fissure, archosyrinx or hemorrhoids.

7	Injury and Rheumatism Relieving Paste	Dispelling rheumatism and relieving pain. Used for headache, rheumatalgia, neuralgia, sprain and muscular soreness.

8	Refining GouPi Cream	Relaxing tendon, invigorating the circulation of blood, dissipating cold and relieving pain. Used for arthralgia and myalgia, acute contusion, sprain, rheumatalgia, arthralgia, hypochondriac pain, muscular soreness, etc.

9	Muskiness Pain Relieving Paste	Expelling wind and removing dampness, relaxing the tendons and unblocking collateral. Used for rheumatic arthralgia, low back cold pain, traumatic injury, etc.

	English Name	Efficacy
10	Muskiness Bone Strengthener Paste	Analgesia and anti-inflammatory. Used for rheumatalgia, arthralgia, backache, neuralgia, muscular soreness, sprain and contusion.

11	Matrine Suppositories	Antibacterial and antiphlogistic drugs. Used for trichomonas and candida vaginitis, chronic cervicitis, pelvic inflammation, etc.

12	Ethacriding Lactate Solution	Disinfectant and preservative drug. Used for disinfection of traumatic and disinfected wounds.

13	Triamcinolone Acetonide and Neomycin Paste	Used for neurodermatitis circumscripta and chronic eczema. Also used for small-scale psoriasis.

14	Double – Coptis Suppository	Course wind and resolving the exterior, heat-clearing and detoxifying. Used for influenza caused by affection of exogenous wind-heat, with symptoms of fever, cough and sore throat. Also used for upper respiratory tract infections and pneumonia, with symptoms of fever, cough and sore throat.

15	Methylrosanilinium Chloride Solution	Disinfectant and preservative drug.

16	Iodine Tincture	Disinfectant and preservative drug.

17	Mercurochrome Solution	Disinfectant and preservative drug.

18	Hydrogen Peroxide Solution	Disinfectant and preservative drug.

19	Halcinonide Cream	Grucocorticoid. External use drug only to be used on the skin. Used for dermatoneuritis and psoriasis.

20	Compound Fluocinonide Tincture	Grucocorticoid. Used for dermatoneuritis and psoriasis.

21	Policresulen Vaginal Suppository	Anti-microbial and hemostasis drug.

Distribution

Most of our products are sold to sales agents. In the fiscal year of 2021, our sales network covered 5 provinces and 2 municipalities in China and our products were mainly sold in Anhui, Zhejiang, Shanghai, Jiangsu, Beijing, Gansu, and Heilongjiang provinces or cities. In the fiscal year of 2022, because of COVID-19 influence and the Transformation, we did not sell our products to sales agents.

E-business

We are in the process of building the infrastructure to conduct our business over the internet. A B2C e-business call and sales center has been established and will become an integral part of our distribution channel in the future. We have employed graduates from Tsinghua University, Harbin Industry University and Harbin Engineering University to develop the ERP (Enterprise Resource Planning), CRM (Customer Relationship Management) and Office Automation software (“OA Software”) for our e-business. The OA Software has been used in our daily operation. The Company plans to sell its products via internet in the fiscal year of 2023.

Our Customers

We sell most of our products to sales agents, who are our customers. The sales agents sell the products to the end users.

Our customers who contributed more than 10% of our consolidated revenues during the past two fiscal years are as follows:

		Sales
		(in U.S.		Percent of
Name	Products Sold	Dollars)		Sales
FY2022	nil
FY2021
Libin Wang	Hemp Oil, Hemp Protein Powder, Hemp Polypeptide, Collagen Peptide		1,478,558		22.53	%
Yufeng Shen	Hemp Oil, Hemp Protein Powder, Hemp Polypeptide, Collagen Peptide		1,185,711		18.07	%
Zhongying Shen	Hemp Oil, Hemp Protein Powder, Hemp Polypeptide, Collagen Peptide		1,054,214		16.06	%
Suqin Zhang	Hemp Oil, Hemp Protein Powder, Hemp Polypeptide, Collagen Peptide		819,996		12.49	%
Guangmin Meng	Hemp Oil, Hemp Protein Powder, Hemp Polypeptide, Collagen Peptide		761,259		11.60	%

In the year end June 30, 2022, the Company had no customers due to the Transformation and the COVID-19.

Manufacture

We manufacture our health food products on a plot of land located in Jin Xing Industrial Park, Songbei District, Harbin. On June 7, 2004, the Company entered into a Land Use Purchase Contract with the local government, pursuant to which the Company agreed to purchase the right to use a piece of land, approximately 8 acres (32,000 square meters), located in Harbin City, Heilongjiang Province for commercial purposes for a fifty-year period from June 7, 2004 through June 6, 2054, for $637,261 (RMB5,248,000). The Company fully paid to the government the consideration for the land use right on June 13, 2004. The Department of Housing and Urban Development of Harbin City approved this transaction. The Company is in the process of applying for the title certificate from the local government. The manufacturing facility on the land is 4,000 square meters and there are five production lines which are sufficient for our purposes. We package our products in bottles, plastic containers and aluminum foil bags there.

Since we acquired HLJ Huimeijia on November 22, 2013, we also manufacture our medicines and drugs using HLJ Huimeijia’s land, approximately 43,350 square meters, located in Hai-lin Economic Development Zone, Mudanjiang City. The manufacturing facilities occupy approximately 5,710 square meters. We plan to build new manufacturing facilities on the land. The expected construction cost is approximately $7,520,000 (RMB 50,000,000).

Our Development Strategy

We will continue to focus on combining our products with traditional Chinese medicine, creating new products such as our hemp-based products, and developing our B2C e-business and chain-stores. We plan to implement health management projects in our future chain-stores throughout China and establish a database of our clients’ health data obtained from our B2C e-business and call center.

We plan to establish a one-stop shop for our customer’s health needs. From conducting a genetic profile of our customer to determine his/her susceptibility to certain types of diseases and then customizing health supplements and organic/green food to meet his/her needs, we plan to cater to our customer’s needs at all levels. With the distribution network we hope to establish through our chain stores and B2C e-businesses, we plan to eventually branch out into the sale and distribution of beauty products and medical appliances.

We plan to open chain stores of up to 100 stores within the next 24 months; establish our oversea sales to North America, South Asia and European Union; acquire pharmaceuticals to enhance marketing network and production capacity and increase investment in research and development of CBD drugs and hemp-based products.

The Future

Within the next ten years, our goals are to:

1. Increase product coverage in target markets to achieve 20%-30% coverage

Our target market is the health industry market. Presently, we believe that our product coverage is approximately 0.2%. We plan to open distribution stores in different provinces of China to expand our coverage. We also plan to sell our products through B2C websites to our customers.

2. Develop to be among top 500 companies in the medicine, health product, health industry in the PRC

Currently, we are not ranked in the top 500 medicine, health product and health industry companies in the PRC. We believe that if our projected increase in revenue is achieved, we will achieve our goal of becoming one of the top 500 medicine, health product, health industry companies in China.

3. Form a diversified management group

Currently, our management group comprises graduates from the most prestigious universities in the PRC, such as Peking University and Renmin University of China. We plan to further diversify our management group by hiring talent both in the PRC and abroad.

4. Enter into the international market and create an internationally famous brand

Currently, our products are sold under the brand names “Qunle”, “Kindlink”, “Huimeijia” and “Dr. Xiao” in the PRC. Our goal is eventually to establish stable sales abroad in countries such as the United States of America, Russia, and Eastern Europe and South-east Asian countries.

Our Business Plan

The plans designed to meet our manufacturing, marketing and profit targets include:

Manufacturing:

(a)

improving the manufacturing techniques and staff training;

(b)

guaranteeing high quality material supply;

(c)

strengthening the working procedure controls;

(d)

implementing GMP to ensure a compliance standard in the food and medical industries;

(e)

ensuring that all employees have adequate training in health regulations.

Marketing:

Adopt an effective marketing strategy to:

(a)

utilize direct distribution of products to chain stores nationwide;

(b)

build business alliances with well-known enterprises to create private label brands;

(c)

expand the marketing of our products beyond the traditional methods.

Product Distribution:

(a)

enlarge our sales and marketing force while developing new markets;

(b)

strengthen the distribution channel by developing promotion strategies and participating in trade shows;

(c)

Develop 3-5 new products to market each year;

(d)

develop new markets through innovation and research.

Our approach to manufacturing, marketing, cost control and products distribution, which is detailed above, is designed to minimize production costs and increase revenue at the same time. We feel that our procedures will enable us to reach our sales goals with an optimal manufacturing cost. The result should yield profits and a return to our investors.

Good Manufacturing Practice or “GMP” is a term that is recognized worldwide for the control and management of manufacturing and quality control testing of foods and pharmaceutical products. An important part of GMP is documentation of every aspect of the process, activities, and operations involved with drug and medical device manufacture. Additionally, GMP requires that all manufacturing and testing equipment has been qualified as suitable for use, and that all operational methodologies and procedures (such as manufacturing, cleaning, and analytical testing) utilized in the drug manufacturing process have been validated (according to predetermined specifications), to demonstrate that they can perform their purported function(s). On December 1, 2019 the newly revised Drug Administration Law (the “New Law”) came into effect. One of the major amendments is the cancellation of GMP certification. The New Law eliminated the requirement that drug administration authorities shall assess drug manufacture enterprises and drug trading enterprises, and issue assessment certificates. Instead, it requires that drug manufacturing enterprises and drug trading enterprises establish and improve the quality management systems of manufacture and trade of drugs, and ensure that the process of manufacturing and trading of drugs always meets all legal requirements. This means a stricter form of supervision is implemented comparing to the prior GMP certificates system and our production lines are subject pilot inspection under the New Law.

The Market for Healthcare and Beauty Products

The health product industry is one of the mainstream industries in the PRC, since it has a high level of recognition and importance. Recently there have been new policies for health products, which control quality, manufacturing, manufacturing environments and techniques.

The Healthcare Product Market in the PRC

With thousands of years of history in health culture and traditional Chinese medicine, the PRC currently utilizes advanced techniques and production capacity to initiate new health care trends, from drugs and medicines to traditional health food and nutritional supplements, and from medical devices to health management and advice. These trends demonstrate huge potential in the PRC’s health products market.

With the rise of the concept of “Great Health”, the per capita expenditure of health products and the consumer group have been significantly improved.

Driven by the change of consumer treatment to prevention, the promotion of health awareness, the refinement of health needs and the pursuit of high-quality health products, the market scale of health products in China broke through RMB100 billion (USD16.2 billion) in 2014 and nearly RMB150 billion (USD22.2 billion) in 2017. Qianzhan Industry Research Institute in China predicted that the market scale of health products in China will reach RMB 243.5 billion (USD37.7 billion) in 2025.

Comparing the consumption habits of Chinese and American health products, we can see that there is still much room for development in China’s market. The penetration rate of health products in the United States is 50%, while that in China is only 20%, and in terms of per capita consumption, China is only one-eighth of that in the United States.

Hemp and its Market and Industry in the PRC

Hemp was originated from the middle and lower reaches of Yellow River with over eight-thousand years’ planting history. The hemp textile technology in our country has matured as early as two thousand years in the Western Han Dynasty. “Plain Color Zen Clothing”, coming up from Han Tombs at Mawangdui and other hemp textile products have become the milestone in the developing history of hemp textile technology.

Hemp, also known as Huoma, Xianma, Kuima, Hanma, Dama. Species that containing less than 0.3% of tetrahydrocannabinol (THC) is considered as Hemp, and more than 0.3% is considered as Marijuana and Hashish internationally. Hemp is a kind of economic plant with special effects and can be grown in large areas in all parts of China. It has low requirements for soil and climate and can grow on relatively barren land. Planting hemp has become a way to get rich and get out of poverty in some poor areas.

Hemp is full of treasures. The skin, stem, seed, root, leaf and flower of hemp have utility value which can be widely applied in the fields of textile, paper-making, food, medicine, construction, transportation, national defense and military industry and so on. As a kind of traditional economic plant, hemp fiber has the functions of moisture absorption and perspiration, natural antimicrobial health care, good quality of adsorption, excellent quality of anti-UV and unique wave adsorption and sound attenuation. The stem of hemp has high degree of lignification and can be used to produce high value biologic additives, viscose fibers, top grade cigarette paper and wooden ceramics and so on. The leaf and flower of hemp can be used to produce various kinds of health products and the seed of hemp can be used to manufacture top grade edible oil, essential oil and hemp protein.

A hemp plant contains over 400 kinds of chemical components and can be divided into cannabinoid and non-cannabinoid compounds. Cannabinol (CBN) in cannabinoid has the functions of anti-inflammatory, analgesia, anti-convulsion and suppressing female hormone secretion. Cannabidiol (CBD) has the functions of anti-inflammatory, sterilization, analgesia, antianxiety, antipsychotic, antioxidation, neural protection, reducing enterocinesia and improving learning and memory ability.

Hemp is the major high-yielding crop of making traditional fiber products in China. It is a kind of high value-added economic crop with a wide range of uses and multi-purpose crop with market prospects that provides fiber, hemp stem and seed. Hemp has many unique natural characteristics, especially its environmental benefits and its natural versatility, which is a valuable kind of crop for ecological economy.

Textiles, clothing, military industry, construction materials, food, medicines, health supplements, cosmetics and skin care products of the downstream of hemp industry in China are relatively well-developed. The bottleneck that restricts the development of downstream industries is that the cultivation of hemp in the upstream has long been the planting mode of scattered peasant households, and has not formed large-scale industrialized cultivation and local initial processing capacity.

After years of development, Chinese consumers have gradually rationalized their attitude and behavior in the consumption of health care products, paying more attention to the safety and efficacy of health care products. At the same time, the government has gradually improved the laws and regulations of the health care industry and tightened its supervision.

The rejuvenation of the modern industry of hemp resulted from the major breakthrough in research and mass production of hemp. Firstly, cultivate new varieties of hemp with low activity of anesthetic in agricultural scientific research. The main component of these varieties of anesthetics is THC and the content of THC is controlled at 0.3% which approximates to non-toxicity. This has led to a renewed understanding and affirmation of the industrial use of hemp, and made the cultivation of hemp mechanize, effectively contributing to the development of hemp industry.

In order to meet the needs of the development of domestic and foreign market, China has successively reactivated the hemp industry projects in Yunnan, Heilongjiang, Shandong, Shanxi, Anhui and Hubei provinces to set up factories and scientific research institutes to carry out research and development of various products. The natural functional advantages of its related products are favored by consumers at home and abroad. The products are exported to countries such as the United States, Canada, Australia, Japan, and Korea. Currently, related products of hemp have also become an export-oriented pillar industry in China.

At present, on the basis of solving scientific and technological problems of deep degumming of hemp, extraction of fine fiber, extraction of CBD, purification of hemp seed oil, extraction of essential oil of hemp, extraction of hemp protein, biocomposites, fiber reinforced composite materials, carry out pilot plant test and industrialized mass production of related products of hemp, and gradually develop the deep comprehensive utilization of hemp products, demonstrating the strength of deep processing in the hemp industry.

Competition in the Healthcare Products Industry

We believe our competitors are:

Harbin DaZhong Pharmaceutical Co., Ltd. (Located in Harbin, Heilongjiang Province);

Tsinghua Unisplendour Corporation Limited (Located in Weihai City, Shandong Province);

Heilongjiang Tianlong Pharmaceuticals Co., Ltd (Located in Heilongjiang Province);

HPGC Renmintongtai Pharmaceuticals Co., Ltd (Located in Heilongjiang Province); and

Yunnan Hansu Biotechnology Co., Ltd. (Located in Yunnan Province).

Our Competitive Advantages and Strategy

We believe that we have the following advantages over our competitors:

●

We have more categories of products and a diversified production line;

●

We have a strong and effective research and development team;

●

We are a self-owned enterprise, and have the support of the local government; and

●

We have a geographical advantage being located in Heilongjiang Province, the center of the healthcare industry in the PRC.

Sales and Marketing

We plan to open more chain stores throughout the PRC. Customers of our stores would be able to enjoy discounts on the price of our products and services. After establishing a sufficient number of stores, we plan to develop a 24-hour delivery system for our B2C e-business.

Intellectual Property

We received a patent (200610010394.4) for our “Qunle” brand Sailuozhi soft capsule from the National Bureau of Intellectual Property. We had initially applied for and used the trade name of “RunChao” soft capsules, but the trade name was changed to “Qunle”, and the change was approved by the National Bureau of Intellectual Property. The expiration date for “Qunle” is May 12, 2030.

Pursuant to a Technology Transfer Agreement dated October 12, 2007 (“Kindlink Technology Transfer Agreement”), we purchased, for a total of RMB350,000, the technology, manufacturing, and trademark rights to the health product known as “Kindlink” brand propolis and black ant capsule made from propolis, black ant, acanthopanax, astragalus root from Jindelikang. The change of the ownership was approved by the NMPA. This product is consumed to boost one’s immunity. The certification number issued by the NMPA on August 20, 2004, to permit the manufacture of the product is GuoShiJianZi G20040906. We have no continuing obligations under the Kindlink Technology Transfer Agreement.

As of the date of this report, we have registered the following 14 trademarks⁽¹⁾:

	Certificate
Trademark	No.	Category	Registrant	Valid Term
“Qunle”	3896026	No.5: Food preparations adapted for medical purposes; Albuminous milk; Dietetic beverages adapted for medical purposes; Milk sugar; Diabetic bread; Albuminous foodstuffs for medical purposes; Food for babies; Dietetic substances adapted for medical use; Nutritional additives for medical purposes	Humankind	7/7/2016 to 7/6/2026

“Wangzu”	4857905	No.30: Molasses for food; Honey; pollen healthy grease; tortoise tuchahoe paste; breed columbine extract; helix alga; non-medical nutrition liquid; non-medical nutrition powder; non-medical nutrition capsule; sugar candy bird’s nest	Humankind	5/14/2018 to 5/13/2028

“Kindlink”	3236981	No.5: Food preparations adapted for medical purposes; Dietetic substances adapted for medical use	Humankind	12/7/2013 to 12/06/2023

“Huimeijia”	5280303	No.5: Medicine for human consumption; Medical nutrition capsule; Fibres (Edible plant) [non-nutritive]; Injection; Raw material drug; Troche; suppository; Food preparations adapted for medical purposes; Dietetic foods adapted for medical purposes; Dietetic substances adapted for medical use	Humankind	7/21/2019 to 7/20/2029

“Huide”	5280304	No.5: Medicines for human consumption; Medical nutrition capsule; Fibres (Edible plant) [non-nutritive]; Injection; Raw material drug; Troche; suppository; Food preparations adapted for medical purposes; Dietetic foods adapted for medical purposes; Dietetic substances adapted for medical use	Humankind	7/21/2019 to 7/20/2029

“KDLK”	3230404	No.5: Food preparations adapted for medical purposes; Dietetic foods adapted for medical purposes; Dietetic substances adapted for medical use	Humankind	9/28/2013 to 9/27/2023

“dr.xiao”	5176731	No.5: Disinfectant; Medicines for veterinary purposes; Insecticide; Sanitary napkin; Medicine health bag; Dental lacquer	Humankind	8/14/2019 to 8/13/2029

“dr.xiao”	1610828	No.30: non-medical nutrition liquid; non-medical nutrition cream; non-medical nutrition powder; Honey; non-medical nutrition capsule; non-medical nutrition gum; Candy for food; Spirulina (non-medical nutrient); Candy; Pollen healthy grease	Humankind	7/28/2021 to 7/27/2031

“DaLeNing”	5053772	No.5: Medicine for human; Chinese patent drugs; Suppository; Tincture; Water aqua; Paste; Liniment; Medical lotion; Patch; Chemical pharmaceuticals preparations	HLJ Huimeijia	5/7/2019 to 5/6/2029

“Xuedu”	5053657	No.5: Medicine for human; Chinese patent drugs; Suppository; Tincture; Water aqua; Paste; Liniment; Medical lotion; Patch; Chemical pharmaceuticals preparations	HLJ Huimeijia	5/7/2019 to 5/6/2029

“Xuedu” with an image	642099	No.5: Paste	HLJ Huimeijia	5/21/2013 to 5/20/2023

“Tai Yan Li”	10014001	No.30: Honey, spirulina (non-medical), non-medical nutrient solution, non-medical nutrient lotion, non-medical nutrient powder, non-medical nutrient capsule, pastry, cereal, flour product.	Humankind	11/28/2012 to 11/27/2022

“Tai Yan Li”	10013969	No.3: Cleanser lotion, soup, anti -bacterial hand soup, cleanser, cosmetics, conditioning gel, polish, essential oil.	Humankind	11/28/2012 to 11/27/2022

“Luo Qian’	8358643	No.3: essential oil, fragrance essential oil, nourishing essential oil, cosmetic mask, cosmetic tools, cosmetics, cosmetic cleanser, perfume, weight-losing cosmetics, banishing essence.	Humankind	6/14/2021 to 6/13/2031

(1)	The trademarks listed here have been spelt in Pinyin for the U.S. readers’ convenience. The original trademarks are in Chinese characters.

We have the right to use the following patents under the approval of National Bureau of Intellectual Property:

					Patent
Categories	Name	Inventor/Designer	Patent No.	Duration	Owner
Invention Patent	Runchao Soft Capsule and Its Manufacturing Method	Xin Sun	ZL200610010394.4	August 10, 2006- August 9, 2026	Xin Sun*

Utility Patent	Heating System in Compression Coaster with Coating Wheels	ZhengJiang Huang	ZL201220485432.2	September 22, 2012- September 21, 2022	HLJ Huimeijia

Design Patent	Packing Box for Pain- relieving Ointment	Jianjun Wang	ZL201230448116.3	September 19, 2012- September 18, 2022	HLJ Huimeijia

Design Patent	Packing Box for Nasal Mucus-releiving Ointment	Jianjun Wang	ZL201230448676.9	September 19, 2012- September 18, 2022	HLJ Huimeijia

Design Patent	Packing Box for Gou Pi Plaster	Jianjun Wang	ZL201230447952.X	September 19, 2012- September 18, 2022	HLJ Huimeijia

Design Patent	Packing Box for Tendons and Bones Strengthening Musk Ointment	Jianjun Wang	ZL201230448670.1	September 19, 2012- September 18, 2022	HLJ Huimeijia

Design Patent	Packing Box for Pain- relieving Musk Ointment	Jianjun Wang	ZL201230448010.3	September 19, 2012- September 18, 2022	HLJ Huimeijia

*	Mr. Sun verbally authorized the Company the right to use the patent.

The following is a list of our patent applications:

The applicant of all the following patents is Humankind, with their inventor being Mr. Xin Sun. In March 2017, we submitted the below patent applications which are currently in the reviewing process and pending for approval.

Serial No.	Name	Application	Technology Field
1	Cannabidiol (CBD) Cataplasmata	Cannabidiol (CBD) is used for relieving muscle pain and its preparation method.	The invention belongs to the research and application field of industrial hemp and relates to a kind of cataplasmata, in particular to Cannabidiol (CBD) which is used for relieving muscle pain and its preparation method.

2	Cannabidiol (CBD) Suspension	Cannabidiol (CBD) Suspension is used for treating arthritis and its preparation method.	The invention relates to the field of pharmaceutical preparations, in particular to a kind of Cannabidiol (CBD) Suspension which is used for treating arthritis and its preparation method.

3	Cannabidiol (CBD) Gel	Cannabidiol (CBD) Gel has the effect of relieving nervous headache and its preparation method.	The invention relates to gel preparations for medicine, in particular to a kind of Cannabidiol (CBD) Gel which has the effect of relieving nervous headache and its preparation method.

4	Cannabidiol (CBD) Paste	Cannabidiol (CBD) Paste has the effect of relieving swelling and pain and its preparation method.	The invention relates to the field of medicine, in particular to a kind of Cannabidiol (CBD) Paste which has the effect of relieving swelling and pain and its preparation method.

5	Cannabidiol (CBD) Soft Capsule	Cannabidiol (CBD) Soft Capsule has the effect of improving diabetes and its preparation method.	The invention relates to the field of soft capsule, in particular to a kind of Cannabidiol (CBD) Soft Capsule which has the effect of improving diabetes and its preparation method.

6	Cannabidiol (CBD) Suppository	Cannabidiol (CBD) Suppository has the effect of heat sterilization and its preparation method.	The invention relates to the field of medicine, in particular to a kind of Cannabidiol (CBD) Suppository which has the effect of heat sterilization and its preparation method.

7	Cannabidiol (CBD) Plaster	Cannabidiol (CBD) Rubber Plaster has the effect of treating old bone disease and its preparation method.	The invention relates to the field of medical plaster, in particular to a kind of Cannabidiol (CBD) Rubber Plaster which has the effect of treating old bone disease and its preparation method.

8	Cannabidiol (CBD) Rubber Plaster	Cannabidiol (CBD) Rubber Plaster has the effect of dispelling wind and eliminating dampness and its preparation method.	The invention relates to the field of medical plaster, in particular to a kind of Cannabidiol (CBD) Rubber Plaster which has the effect of dispelling wind and eliminating dampness and its preparation method.

9	Cannabidiol (CBD) Liquid Pharmaceutical Preparations	Cannabidiol (CBD) Liquid Pharmaceutical Preparations has the anti-anxiety effect and its preparation method.	The invention relates to the field of liquid pharmaceutical preparations, in particular to a kind of Cannabidiol (CBD) Liquid Pharmaceutical Preparations which has the anti-anxiety effect and its preparation method.

10	Moisturizing Cream with Hemp Seed Oil	Moisturizing Cream with Hemp Seed Oil and its preparation method.	The invention relates to the field of cosmetics, in particular to a kind of Moisturizing Cream which contains hemp seed oil and its preparation method.

The laws governing our business are as follows:

	●	Drug administration law of the PRC enacted August 27, 2019

	●	Healthcare registration and administration law, enacted January 7, 2005

	●	Measures for the Administration of Pharmaceutical Trade License, enacted January 4, 2004

	●	Measures for the Supervision Over and Administration of Pharmaceutical Production, enacted May 8, 2004

	●	Food Safety Law of the PRC, enacted June 1, 2009

	●	Regulation on the Implementation of the Food Safety Law of the PRC, enacted July 20, 2009

	●	Regional regulation: Heilongjiang Regional Medicinal Materials Resource Protection Bylaw, enacted January 8, 2005

	●	Good Manufacturing Practice (GMP) Amendment, enacted January 17, 2011

	●	Hemp Industry 3-year Special Action Plan of Heilongjiang Province (2018-2020) and

	●	Hemp Legislation of Heilongjiang Province in May 2017.

In the PRC, a Good Manufacturing Practice Certification (“GMP Certification”) is required for companies that produce medical drugs and health supplements. It is also required to market our medical drugs and health supplements. According to the Administrative Rules of Drug Manufacturing and Certification issued by the NMPA of the PRC on September 7, 2005, the NMPA is responsible for the review and issuance of GMP Certification. To obtain a GMP Certification, a company shall submit its application; the NMPA will then conduct a technical review of the application materials; if such company passes the technical review, the NMPA will inspect the manufacturing site. The NMPA also conducts follow-up inspections on the manufacturing site. After the issuance of the GMP Certification, the NMPA may inspect the manufacturing site from time to time. However, instead of issuing GMP, the NMPA now issues SC Permit to food manufacturers in China, allowing them to manufacture and sell health products. The GMP Certifications of our wholly owned subsidiaries, Humankind, HLJ Huimeijia, are valid through February 14, 2019 and December 31, 2015, respectively. For the GMP Certificate of HLJ Huimeijia, the Company applied for a new certificate, which was obtained on April 25, 2018. Since obtaining the GMP Certification, we have been able to manufacture and market our products without further governmental approval. As Humankind is in the business of manufacturing and selling health products, it is considered as a food manufacturer in China. Humankind received its SC Permit on July 26, 2018, which will expire on September 12, 2021.The Company has applied for extension which is expect to be approved at the end of October 2021. On December 1, 2019 the newly revised Drug Administration Law (the “New Law”) came into effect. One of the major amendments is the cancellation of GMP certification. The New Law eliminated the requirement that drug administration authorities shall assess drug manufacture enterprises and drug trading enterprises, and issue assessment certificates. Instead, it requires that drug manufacturing enterprises and drug trading enterprises establish and improve the quality management systems of manufacture and trade of drugs, and ensure that the process of manufacturing and trading of drugs always meets all legal requirements. This means a stricter form of supervision is implemented comparing to the prior GMP certificates system and our production lines are subject pilot inspection under the New Law.

Employees

As of June 30, 2022, we have 45 full-time employees including 6 officers, 9 administrators, 13 workers, 7 technicians, 5 marketing personals and 5 accountants. Besides, we have 12 sales persons as part-time employees. We believe that we are in compliance with local prevailing wage, contractor licensing and insurance regulations, and have good relations with our employees.

Item 1A. Risk Factors.

We are a smaller reporting company and therefore this item is not applicable to us.

Item 1B. Unresolved Staff Comments.

Not applicable.

Item 2. Properties.

There is no private land ownership in PRC. Enterprises and individuals can pay the government a fee to obtain a right to use a piece of land for commercial purpose or residential purpose for an initial period of 50 years or 70 years, respectively. The land use right can be sold, purchased, and exchanged in the market. The land use right of a successor owner will be reduced by the amount of time consumed by the predecessor owner.

We manufacture our products on a plot of land located in Jin Xing Industrial Park, Songbei District, Harbin. On June 7, 2004, the Company entered into a Land Use Purchase Contract with the local government, pursuant to which the Company agreed to purchase the right to use a piece of land, approximately 8 acres (32,000 square meters), located in Harbin County, Heilongjiang Province for commercial purposes for a fifty-year period from June 7, 2004 through June 6, 2054, for $637,261 (RMB 5,248,000). The Company fully paid to the government the consideration for the land use right on June 13, 2004. The Department of Housing and Urban Development of Harbin City approved this transaction. The Company is in the process of applying for the title certificate from the local government. Due to certain re-zoning conducted by the local government, the estimate time to receive the title certificate is uncertain. The Company is striving to accelerate the process. The manufacturing facility on the land is 4,000 square meters and there are five production lines which are sufficient for our operation. We package our products in bottles, plastic containers and aluminum foil bags.

Item 3. Legal Proceedings.

We do not know of any material, active, pending or threatened proceeding against us or our subsidiaries, nor are we, or any subsidiary, involved as a plaintiff or defendant in any material proceeding or pending litigation.

Item 4. Mine Safety Disclosures.

This item is not applicable to us.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock is quoted over-the-counter on the OTC Markets QB Tier under the ticker “CHHE” and the market for the stock has been relatively inactive. The quotations on the OTC Markets reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not necessarily represent actual transactions.

As of September 15, 2022, we had approximately 502 shareholders of record of our common stock, such number of holders does not include street name holders who hold shares by brokerage firms. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of shareholders. Holders of the common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock.

Dividends

We have not paid dividends on our common stock and do not anticipate to pay such dividends in the foreseeable future. We will rely on dividends from Humankind for our funds and PRC regulations may limit the amount of funds distributed to us from Humankind, which will affect our ability to declare any dividends.

Securities Authorized for Issuance Under Equity Compensation Plans

On March 27, 2015 the Board of Directors (the “Board”) adopted the Company’s 2015 Equity Incentive Plan (the “Plan”), which became effective as of such date. The total number of authorized shares under the Plan is 6,000,000 shares of common stock.

The following table summarizes the number of shares of our common stock authorized for issuance under our Plan as of June 30, 2022.

Equity Compensation Plan Information

Plan category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)		Weighted- average exercise price of outstanding options, warrants and rights (b)		Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column(a)) (c)
Equity compensation plans approved by security holders		-		-		-
Equity compensation plans not approved by security holders		-		-		2,700,000	⁽¹⁾
Total						2,700,000

(1)	The Company granted an aggregate of 3.3 million shares of restricted shares to its CEO and an employee on March 30, 2015. The shares of the Company are quoted on the OTC Markets. As a result, no security holders’ approval is required for the Company’s adoption of an equity compensation plan.

Registrar and Stock Transfer Agent

Our stock transfer agent is Direct Transfer LLC at 1981 Murray Holladay Road, Suite 100, Salt Lake City, UT 84117. Their telephone number is (801) 272-9294, and their fax number is (801) 277-3147.

Shares Eligible for Future Sale

There is no active trading market for our common stock. Future sales of substantial amounts of our common stock in the trading market could adversely affect market prices.

Penny Stock Regulations

Our shares of common stock are subject to the “penny stock” rules of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and various rules thereunder. In general terms, “penny stock” is defined as any equity security that has a market price less than $5.00 per share, subject to certain exceptions. The rules provide that any equity security is considered to be a penny stock unless that security is registered and traded on a national securities exchange meeting specified criteria set by the SEC, issued by a registered investment company, and excluded from the definition on the basis of price (at least $5.00 per share), or based on the issuer’s net tangible assets or revenues. In the last case, the issuer’s net tangible assets must exceed $3,000,000 if in continuous operation for at least three years or $5,000,000 if in operation for less than three years or the issuer’s average revenues for each of the past three years must exceed $6,000,000.

Trading in shares of penny stock is subject to additional sales practice requirements for broker-dealers who sell penny stocks to persons other than established customers and accredited investors. Accredited investors, in general, include individuals with assets in excess of $1,000,000 or annual income exceeding $200,000 (or $300,000 together with their spouse), and certain institutional investors. For transactions covered by these rules, broker-dealers must make a special suitability determination for the purchase of the security and must have received the purchaser’s written consent to the transaction prior to the purchase. Additionally, for any transaction involving a penny stock, the rules require the delivery, prior to the first transaction, of a risk disclosure document relating to the penny stock. A broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative, and current quotations for the security. Finally, monthly statements must be sent disclosing recent price information for the penny stocks. These rules may restrict the ability of broker-dealers to trade or maintain a market in our common stock, to the extent it is penny stock, and may affect the ability of shareholders to sell their shares.

Recent Sale of Unregistered Securities

None.

Repurchase of Equity Securities

None.

Item 6. [Reserved]

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

FORWARD LOOKING STATEMENTS

We make certain forward-looking statements in this report. Statements concerning our future operations, prospects, strategies, financial condition, future economic performance (including growth and earnings), demand for our services, and other statements of our plans, beliefs, or expectations, including the statements contained under this caption as well as under captions elsewhere in this document, are forward-looking statements. In some cases, these statements are identifiable through the use of words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, “project”, “target”, “can”, “could”, “may”, “should”, “will”, “would”, and similar expressions. The forward-looking statements we make are not guarantees of future performance and are subject to various assumptions, risks, and other factors that could cause actual results to differ materially from those suggested by these forward-looking statements. These risks and uncertainties, together with the other risks described from time to time in reports and documents that we file with the SEC should be considered in evaluating forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by the forward-looking statements. Indeed, it is likely that some of our assumptions will prove to be incorrect. Our actual results and financial position will vary from those projected or implied in the forward-looking statements and the variances may be material. You are cautioned not to place undue reliance on such forward-looking statements, which reflect our view only as of the date of this report.

Important factors that could cause actual results to differ from those in the forward-looking statements include, without limitation, the following:

	●	the effect of political conditions, economic conditions, market conditions, and geopolitical events;

	●	legislative and regulatory changes that affect our business;

	●	the availability of funds and working capital; and

	●	the actions and initiatives of current and potential competitors.

Except as required by applicable laws, regulations, or rules, we do not undertake any responsibility to publicly release any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this report. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by any forward-looking statements.

The following discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes thereto as filed with the SEC and other financial information contained elsewhere in this report.

Except as otherwise indicated by the context, references in this report to “we”, “us”, “our”, “the Registrant”, “our Company”, or “the Company” are to China Health Industries Holdings, Inc., a Delaware corporation, China Health Industries Holdings Limited, a limited liability company incorporated under the laws of Hong Kong, its wholly owned subsidiary in China, Harbin Humankind Biology Technology Co. Limited (“Humankind”), and indirect wholly owned subsidiary, Heilongjiang Huimeijia Pharmaceutical Co., Ltd. (“HLJ Huimeijia”). Unless the context otherwise requires, all references to (i) the “PRC” and “China” are to the People’s Republic of China; (ii) “U.S. dollar,” “$” and “US$” are to United States dollars; (iii) “RMB” are to Renminbi Yuan of China; (iv) “Securities Act” are to the Securities Act of 1933, as amended; and (v) “Exchange Act” are to the Securities Exchange Act of 1934, as amended.

Business Overview

Our principal business operations are conducted through our wholly-owned subsidiaries, Humankind and HLJ Huimeijia.

We have developed the following products that are derived from hemp and obtained business license to manufacture and sell these products. We have begun to sell these products since May 2018. Hemp Oil, Hemp Protein Powder, Hemp Polypeptide and Collagen Peptide are sold through Humankind. Other products are sold through HLJ Huimeijia. The revenue of the Hemp Oil, Hemp Protein Powder and Hemp Polypeptide accounted for $nil and 89.88% of the total revenues for the fiscal year of 2022 and 2021, respectively.

Serial No.		Name
1		Hemp Oil
2		Hemp Protein Powder
3		Hemp Polypeptide
4		Collagen Peptide
5		Natural Hemp Essence Repair Lotion
6		Natural Hemp Revitalizing Essence
7		Natural Hemp Anit-aging Brightening Eye Cream
8		Natural Hemp Frozen Age Nourishing Cream

We sell our products directly to end customers through our own sales personnel as well as our sales agents, operating primarily in Anhui, Zhejiang, Shanghai, Jiangsu, Beijing and Gansu, where most of our revenues are generated. For the fiscal year 2022, we did not sell products to sales agents, because our sale activities were limited by the COVID-19 resurgence, and our productivity was limited due to enterprise Transformation. Although we do not currently sell our products online, we expect to do so in the future.

2023 Outlook

Overall, we anticipate our total revenues for the year ended June 30, 2023 to reach to $5.2 million, with growth in all categories of our product sales, including the anticipated revenue from Humankind for approximately $1.5 million, and from HLJ Huimeijia for approximately $3.7 million. The gross profit margin for the year ended June 30, 2023 is expected to be approximately 60%, and we estimate our overall net profit margin for the year ended June 30, 2023 to be approximately 20%. There is, however, no assurance that we will reach these projections.

The COVID-19 global pandemic has adversely affected our business in a short run. However, in the long run, we endeavor using our expertise to help humankind fight against the pandemic. We sell products such as Hemp Protein Powder and Hemp Polypeptide to help people improve their immune system. As the COVID-19 continues to spread and people’s awareness and knowledge of the virus continue to increase, consumers realized that strengthening their own immunity and resistance powers is among the most effective ways to fight against COVID-19, and consumers will pay more attention to strengthen the physical fitness, and therefore use more protein powder, protein peptides and other health foods and supplements. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the economy of China, U.S. and the rest of the world and, as such, the extent of the business disruption and the related financial impact cannot be reasonably estimated at this time.

Results of Operations

The following table summarizes the top lines of the results of our operations for the years ended June 30, 2022 and 2021, respectively:

	June 30, 2022			June 30, 2021			Variance			%
Revenues	$	267		$	6,492,720			(6,492,453	)		(100.0	)%
Humankind		-			6,475,966			(6,475,966	)		(100.0	)%
HLJ Huimeijia		267			16,754			(16,487	)		(98.4	)%
Cost of Goods Sold	$	1,748		$	2,850,729			(2,848,981	)		(99.9	)%
Humankind		-			2,754,413			(2,754,413	)		(100.0	)%
HLJ Huimeijia		1,748			96,316			(94,568	)		(98.2	)%
Gross Profit/(Loss)	$	(1,481	)	$	3,641,991			(3,643,472	)		(100.0	)%
Humankind		-			3,721,553			(3,721,553	)		(100.0	)%
HLJ Huimeijia		(1,481	)		(79,562	)		78,081			98.1	%

Revenue

Total revenues of the Company decreased by $6,492,453 or 100.0%, for the year ended June 30, 2022 as compared to the year ended June 30, 2021. The decrease in revenues was primarily due to a decrease of $6,475,966 or 100.0% in Humankind’s revenues for the year ended June 30, 2022 as compared to the year ended June 30, 2021.The decrease in Humankind’s sales revenues was primarily due to Humankind’s enterprise Transformation and COVID-19 resurgence. Humankind is using existing materials to research and develop new products. Humankind decided to transform the primary business to CBD extractive project, because the government intended to support the company research in CBD aspect. However, by the end of fiscal year 2022, the support guidelines had not been published. Although the research process is slow and unpredictable due to the zero-case policy and periodic quarantines caused by COVID-19 resurgence, we expect it to be completed by the end of calendar year of 2022 (“Transformation”). We do not currently sell our products online, but we expect to do so in the future.

Our total cost of sales decreased by $2,848,981 or 99.9% for the year ended June 30, 2022 as compared to the year ended June 30, 2021. The decrease in the overall cost of sales was attributable to a decrease of $2,754,413 or 100.0% in Humankind’s cost of sales in 2022 as compared to the year ended June 30, 2021. The decrease in Humankind’s sales revenues was primarily due to Humankind’s enterprise Transformation, also sales were not smooth because of factory shut down under COVID-19.

Our gross profit decreased by $3,643,472 from $3,641,991 for the year ended June 30, 2021 to gross loss $1,481 for the year ended June 30, 2022.

Sales by Product Line

The following table summarizes a breakdown of our sales by major product line for the years ended June 30, 2022 and 2021, respectively:

	June 30, 2022							June 30, 2021
	Quantity		Sales		%			Quantity		Sales		%
	(Unit)		US$		of			(Unit)		US$		of
Humankind
Propolis and Black Ant Capsule		-		-		-			-		-		-
Waterlilies Soft Capsule (Sailuozhi)		-		-		-			-		-		-
Hemp Oil		-	$	-		-			110,781	$	2,288,807		35.0	%
Collagen Peptide		-		-		-			51,632		640,779		9.9	%
Hemp Polypeptide		-		-		-			98,873		2,042,666		31.5	%
Hemp Protein Powder		-		-		-			121,245		1,503,714		23.2	%
HLJ Huimeijia		-		-		-							-
Natural Hemp Cosmetics		-		-		-							-
Muskiness Bone Strengthener Paste		223		18		6.7	%		108,496		10,016		0.2	%
ShangBiTongDing		-		-		-							-
Indometacin and Furazolidone Suppositories		383		32		12.1	%		20		16		-
Enema Glycerini		-		-		-			-		-		-
Ge Hong Beriberi Water		-		-		-			-		-		-
UmguentumAcidi Borici Camphoratum		-		-		-			-		-		-
Injury and Rheumatism Relieving Paste		1,852		152		56.9	%		26,838		3,375		0.1	%
Refining GouPi Cream		788		65		24.3	%		30,550		3,347		0.1	%
Natural Hemp supplies		-		-		-			-		-		-
Total			$	267		100.0	%			$	6,492,720		100.0	%

Operating Expenses

The following table summarizes our operating expenses for the years ended June 30, 2022 and 2021, respectively:

	June 30, 2022		June 30, 2021		Variance			%
Operating Expenses
Selling, general and administrative	$	934,927	$	1,168,385		(233,458	)		(20.0	)%
Depreciation and amortization		711,515		609,698		101,817			16.7	%
Total Operating Expenses	$	1,646,442	$	1,778,083		(131,641	)		(7.4	)%

Total operating expenses for the year ended June 30, 2022 declined by $131,641 or 7.4%, as compared to the corresponding period in 2021. The decrease in operating expenses was primarily attributable to a decrease of $233,458 or 20.0% in selling, general and administrative expenses. The decrease in selling, general and administrative expenses was mainly due to the decrease of revenue, the employees' salaries decreased, and the related expenses decreased accordingly.

Interest Income and Interest Expenses

Interest income was $157,860 for the year ended June 30, 2022, as compared to $137,485 for the year ended June 30, 2021. This increase of $20,375, or 14.8%, was primarily due to the increased deposits in the bank compared with the year ended June 30, 2021.

Interest expense was $nil for the year ended June 30, 2022, and for the year ended June 30, 2021.

Other Income

Other income was $1,139,746 expense for the year ended June 30, 2022, as compared to $20,972 for the year ended June 30, 2021. This increase of $1,118,774 or 5,334.6%, was primarily due to revenue earned by the transfer of one of Huimeijia’s production technique. This technique transfer would not affect future production of Huimeijia.

Income Taxes

Income taxes decreased by $727,527, or 99.6%, from $730,461 for the year ended June 30, 2021 to $2,934 for the year ended June 30, 2022. This decrease of income tax expense incurred in the fiscal year ended June 30, 2022 was primarily due to the decrease of net profits before income taxes.

Net Income (Loss) and Net Income per Share

Net loss after provision for income taxes decreased to $353,950, a decrease of $1,645,072 for the year ended June 30, 2022, as compared to net income of $1,291,122 for the year ended June 30, 2021. This decrease was mainly because of the COVID-19 resurgence in China and Humankind was temporarily out of production.

Net loss per share was $0.0054 for the year ended June 30, 2022 and net income per share was $0.0197 for the year ended June 30, 2021. This decrease was primarily a result of the above decrease in net income from the Company’s operations.

Liquidity and Capital Resources

We believe our current working capital position, together with our expected future cash flows from operations, loans from our major shareholder, will be adequate to fund our operations in the ordinary course of business, anticipated capital expenditures, debt payment requirements and other contractual obligations for at least the next twelve months. However, this belief is based upon many assumptions and is subject to numerous risks, and there can be no assurance that we will not require additional funding in the future.

The following table summarizes our cash and cash equivalents position, our working capital, and our cash flow activity as of the fiscal years ended June 30, 2022 and 2021:

	2022		2021
For the years ended June 30:
Cash and cash equivalent	$	44,789,999	$	44,346,744

Working capital	$	37,652,693	$	38,617,377

Inventories, net	$	521,229	$	761,639

For the years ended June 30:

Cash provided by (used in):

	2022		2021
Operating activities	$	2,115,726	$	5,556,694

Investing activities	$	-	$	(13,655	)

Financing activities	$	-	$	-

Cash and cash equivalents increased by $443,255 from $44,346,744 as of June 30, 2021 to $44,789,999 as of June 30, 2022.

Our working capital as of June 30, 2022 was $37,652,693, compared to working capital of $38,617,377 as of June 30, 2021. This decrease of $964,684 or 2.5% was primarily attributable to the decrease in accounts receivable in the amount of $2,337,300 and the decrease in amounts due to related parties in the amount of $1,320,000.

Net cash provided by operating activities was $2,115,726 for the year ended June 30, 2022, compared to $5,556,694 for the year ended June 30, 2021. The decrease of $3,440,968 in the net cash provided by operating activities was primarily attributable to a decrease of $1,645,072 in net income, $2,018,597 in amounts due to related parties, and $379,006 in accounts receivable, offset by increase of taxes payable in the amount of $233,264 and advance from customers in the amount of $330,983. Other items had no significant changes.

Net cash used in investing activities was $nil for the year ended June 30, 2022, compared to $13,655 for the year ended June 30, 2021, primarily due to the decrease of expenditure in construction in progress in the amount of $5,073 and purchase of property, plant and equipment in the amount of $8,582.

Net cash provided by financing activities was $nil for both years ended June 30, 2022 and 2021.

Other than as described in this report, we have no present agreements or commitments with respect to any material acquisitions of businesses, products, product rights or technologies or any other material capital expenditures. However, we will continue to evaluate acquisitions of, and/or investments in, products, technologies, capital equipment or improvements or companies that complement our business and may make such acquisitions and/or investments in the future. Accordingly, we may need to obtain additional sources of capital in the future to finance any such acquisitions and/or investments. We may not be able to obtain such financing on commercially reasonable terms, if at all. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our shareholders, in the case of equity financing.

Related Party Debts

We had related party debts of $6,759,761 as of June 30, 2022, as compared to $8,079,761 as of June 30, 2021, a decrease of $1,320,000 or 16.3%. The amount of related party debts mainly consists of a loan from Mr. Xin Sun, the CEO of the Company. The loan is unsecured and non-interest bearing and has no fixed terms of repayment. There was no written agreement for the loan. See Note 9.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that are currently material or reasonably likely to be material to our financial position or results of operations.

Critical Accounting Policies and Estimates

We regularly evaluate the accounting policies and estimates that we use to make budgetary and financial statement assumptions. A complete summary of these policies is included in Note 2 to our consolidated financial statements, “Significant Accounting Policies”, and is incorporated herein by reference. In general, management's estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

Not Applicable.

Item 8. Financial Statements and Supplementary Data.

The financial statements required by this item are set forth beginning on page F-1.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Table of Contents

Report of Independent Registered Public Accounting Firm (PCAOB Firm ID# 2769)		F-2

Consolidated Balance Sheets as of June 30, 2022 and 2021		F-4

Consolidated Statements of Operations and Comprehensive Income (Loss) For the Years Ended June 30, 2022 and 2021		F-5

Consolidated Statements of Equity For the Years Ended June 30, 2022 and 2021		F-7

Consolidated Statements of Cash Flows For the Years Ended June 30, 2022 and 2021		F-8

Notes to Consolidated Financial Statements		F-9 - F-26

F-1

Report of Independent Registered Public Accounting Firm

To:	The Board of Directors and Shareholders of
	China Health Industries Holdings, Inc.

Opinion of the Financial Statements

We have audited the accompanying consolidated balance sheets of China Health Industries Holdings, Inc. and its subsidiaries (the “Company”) as of June 30, 2022 and 2021, and the related consolidated statements of operations and comprehensive income, changes in shareholders’ equity and cash flows for each of the years in the two-year period ended June 30, 2022, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of June 30, 2022 and 2021 and the consolidated results of its operations and its cash flows for each of the years in the two-year period ended June 30, 2022, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Valuation of Inventory

Inventories consist of growing and processed plants and oils and are valued at the lower of cost or net realizable value. In evaluating whether inventories are stated at lower of cost or net realizable value, management considers such factors as inventories in hand, estimated time to sell such inventories and current market conditions. Write-offs for inventory obsolescence are recorded when, in the opinion of management, the value of specific inventory items has been impaired.

Our audit procedures to address the Company’s valuation of inventory included the following, among others. We updated to our understanding of the Company’s inventory process, observations of year end quantities, and the testing of the cultivation, manufacturing and processing costs allocated to the various stages of inventory during the year. We also tested the Company’s net realizable values across each inventory and the assumptions used.

F-2

Impairment of long-lived assets

The carrying value of long-lived assets are reviewed when facts and circumstances suggest that the assets may be impaired or that the amortization period may need to be changed. The Company considers internal and external factors relating to each asset, including cash flows, local market developments, industry trends and other publicly available information. If these factors and the projected undiscounted cash flows of the Company over the remaining amortization period indicate that the asset will not be recoverable, the carrying value will be adjusted to the fair market value

Our audit procedures relating to the Company’s assessment of impairment of long-lived assets included the following, among others. We evaluated the methodologies and tested the significant assumptions and underlying data used by the Company. Such testing included assessing the reasonableness of the undiscounted cash flow projections used by the Company in their assessment of impairment in comparison with historical data and the Company’s assumptions used for the projections.

/s/ Centurion ZD CPA & Co.
Centurion ZD CPA & Co.

We have served as the Company’s auditor since 2017.

Hong Kong, China

September 15, 2022

F-3

CHINA HEALTH INDUSTRIES HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Audited)

	June 30, 2022		June 30, 2021
ASSETS

Current assets
Cash and cash equivalents	$	44,789,999	$	44,346,744
Accounts receivable, net		9,567		2,346,867
Inventory		521,229		761,639
Other receivables, net		31,778		32,850
Advances to suppliers		214,915		218,307
Prepayments		30,004		24,466
Total current assets	$	45,597,492	$	47,730,873

Property, plants and equipment, net		3,158,021		3,629,905
Intangible assets, net		1,412,603		1,963,516
Construction in progress		579,402		560,910
Deferred tax assets		-		2,933
Prepayments – Non-Current		-		-
Total assets	$	50,747,518	$	53,888,137
LIABILITIES AND EQUITY

Current liabilities
Accounts payable and accrued expenses		334,972		406,821
Other payables		82,323		81,449
Advances from customers		472,307		150,504
Related party debts		6,759,761		8,079,761
Wages payable		162,431		218,602
Taxes payable		133,005		176,359
Total current liabilities	$	7,944,799	$	9,113,496

Equity
Common stock, ($0.0001 par value per share, 300,000,000 shares authorized, and 65,539,737 shares issued and outstanding as of June 30, 2022 and June 30, 2021, respectively)		6,554		6,554
Additional paid-in capital		521,987		521,987
Accumulated other comprehensive income		538,820		2,156,792
Statutory reserves		38,679		38,679
Retained earnings		41,696,679		42,050,629
Total stockholders’ equity	$	42,802,719	$	44,774,641
Total equity	$	42,802,719	$	44,774,641

Total liabilities and equity	$	50,747,518	$	53,888,137

The accompanying notes are an integral part of these consolidated financial statements.

F-4

CHINA HEALTH INDUSTRIES HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(Audited)

	For the Year Ended
	June 30, 2022			June 30, 2021

REVENUE	$	267		$	6,492,720

COST OF GOODS SOLD		1,748			2,850,729

GROSS PROFIT/(LOSS)		(1,481	)		3,641,991

OPERATING EXPENSES
Selling, general and administrative expenses		934,927			1,168,385
Depreciation and amortization expenses		711,515			609,698
Total operating expenses		1,646,442			1,778,083

(LOSS)/INCOME FROM OPERATIONS		(1,647,923	)		1,863,908

OTHER INCOME/(EXPENSES)
Interest income		157,860			137,485
Interest expense		-			-
Other income, net		1,139,746			20,972
Bank charges		(699	)		(782	)
Total other income, net		1,296,907			157,675

(LOSS)/INCOME BEFORE INCOME TAXES		(351,016	)		2,021,583

Provision for income taxes		(2,934	)		(730,461	)

NET (LOSS)/INCOME		(353,950	)		1,291,122

The accompanying notes are an integral part of these consolidated financial statements.

F-5

CHINA HEALTH INDUSTRIES HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(Audited) (CONTINUED)

	For the Year Ended
	June 30, 2022			June 30, 2021
Foreign currency translation adjustment		(1,617,972	)		3,815,533
COMPREHENSIVE (LOSS)/INCOME		(1,971,922	)	$	5,106,655

Net (loss)/income per share:

Net (loss)/income per share Basic & diluted		(0.0054	)	$	0.0197

Weighted average shares outstanding:
Basic & diluted		65,539,737			65,539,737

The accompanying notes are an integral part of these consolidated financial statements.

F-6

CHINA HEALTH INDUSTRIES HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Audited)

	Common Shares				Additional Paid-in		Retained			Statutory		Accumulated Other Comprehensive			Total Stockholders’			Non- controlling		Total
	Shares		Amount		Capital		Earnings			Reserve		Income (loss)			Equity			Interest		Equity

Balance, June 30, 2020		65,539,737	$	6,554	$	521,987		40,759,507			38,679		(1,658,741	)		39,667,986			-		39,667,986

Net income								1,291,122								1,291,122			-		1,291,122
Other comprehensive income - Translation adjustment													3,815,533			3,815,533			-		3,815,533

Balance, June 30, 2021		65,539,737	$	6,554	$	521,987		42,050,629			38,679		2,156,792			44,774,641			-		44,774,641

Net loss								(353,950	)							(353,950	)		-		(353,950	)

Other comprehensive loss - Translation adjustment													(1,617,972	)		(1,617,972	)		-		(1,617,972	)
Balance, June 30, 2022		65,539,737		6,554		521,987		41,696,679			38,679		538,820			42,802,719			-		42,802,719

The accompanying notes are an integral part of these consolidated financial statements.

F-7

CHINA HEALTH INDUSTRIES HOLDINGS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Audited)

	For the Year Ended
	June 30, 2022			June 30, 2021
Cash Flows from Operating Activities
Net (loss)/income attributable to China Health Industries Holdings	$	(353,950	)	$	1,291,122

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expenses		830,545			878,794
Provision for doubtful accounts		(9,556	)		(13,666	)
Deferred taxes gain		2,860			3,334
Changes in operating assets and liabilities:
Inventory		215,391			118,743
Accounts receivable		2,288,077			2,667,083
Other receivables		(114	)		2,383
Advance to suppliers and prepaid expenses		(11,024	)		26,980
Accounts payables and accrued expenses		(57,912	)		(36,554	)
Advance from customers and other payables		358,179			12,368
Amounts due to related parties		(1,057,059	)		961,538
Wages payable		(48,844	)		(81,300	)
Taxes payable		(40,867	)		(274,131	)
Net cash provided by operating activities	$	2,115,726		$	5,556,694

Cash Flows from Investing Activities
Withdraw of short term investment		-			-
Purchase of property, plant and equipment		-			(8,582	)
Expenditure in construction in progress		-			(5,073	)
Disposal of property, plant and equipment		-			-
Proceeds from short term investment		-			-
Proceeds from disposal of subsidiary		-			-
Net cash (used in)/provided by investing activities		-			(13,655	)

Cash Flows from Financing Activities
Proceed from related party debts		-			-
Payment of short term loans		-			-
Net cash (used in)/provided by financing activities		-			-
Effect of exchange rates change on cash and cash equivalents		(1,672,471	)		2,731,231

Net increase in cash and cash equivalents		443,255			8,274,270

Cash and cash equivalents, beginning of period		44,346,744			36,072,474
Cash and cash equivalents, end of period	$	44,789,999		$	44,346,744
Supplemental disclosure of cash flow information
Interest paid	$	-		$	-
Taxes paid	$	-		$	973,420
Non-cash activities:
Loan from related party for the construction of a facility	$	-		$	618,827

The accompanying notes are an integral part of these consolidated financial statements.

F-8

CHINA HEALTH INDUSTRIES HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1 - ORGANIZATION AND BUSINESS BACKGROUND

China Health Industries Holdings, Inc. (“China Health US”) was incorporated in the State of Arizona on July 11, 1996 and was the successor of the business known as Arizona Mist, Inc. which began in 1989. On May 9, 2005, it entered into a stock purchase agreement and Share Exchange (effecting a reverse merger) with Edmonds 6, Inc. (“Edmonds 6”), a Delaware corporation, and changed its name to Universal Fog, Inc. Pursuant to this agreement, Universal Fog, Inc. (which has been in continuous operation since 1996) became a wholly-owned subsidiary of Edmonds 6.

On December 31, 2008, China Health HK entered into a reverse merger with Universal Fog, Inc., a U.S. publicly traded shell company (the “Transaction”). China Health HK is the acquirer in the Transaction, and the Transaction has been treated as a recapitalization of China Health US. After the Transaction and a 20:1 reverse stock split, Mr. Xin Sun owned 61,203,088 shares of common stock, representing 98.3% of the 62,234,737 total outstanding shares of common stock of China Health US. On April 7, 2009, Mr. Sun transferred 28,200,000 shares of common stock to 296 individuals, leaving him with 33,003,088 shares of common stock of China Health US, or approximately 53.03% of the total outstanding shares of common stock. Universal Fog, Inc. changed its name to China Health Industries Holdings, Inc. on February 19, 2009.

On November 22, 2013, Humankind completed the acquisition of Heilongjiang Huimeijia Pharmaceutical Co., Ltd. (“HLJ Huimeijia”) for a total purchase price of $16,339,869 (RMB100,000,000). HLJ Huimeijia was founded on October 30, 2003, and is engaged in the manufacturing and distribution of tincture, ointments, rubber paste (including hormones), topical solution, suppositories, liniment (including traditional Chinese medicine extractions), enemas and oral liquids. HLJ Huimeijia’s predecessor is Heilongjiang Xue Du Pharmaceutical Co., Ltd., which has established its brand name in the market through its supply of high quality medical products. HLJ Huimeijia is categorized as a “high and new technology” enterprise by the Science Technology Department in Heilongjiang Province. HLJ Huimeijia has 21 products which have been approved by, and have received approval numbers issued by, the National Medical Products Administration (the “NMPA”). In addition, HLJ Huimeijia is the holder of one patent for utility models, five patents for external design and three trademarks in China, including the Chinese brand name of “Xue Du” which has an established reputation among customers in northeastern China.

F-9

On December 24, 2014, Humankind entered into a stock transfer agreement (the “Original Agreement”) with Xiuzheng Pharmaceutical Group Co., Ltd. a company incorporated under the laws of the PRC and located in Jilin province (“Xiuzheng Pharmacy” or the “Buyer”), Mr. Xin Sun, the CEO of the Company, and Huimeijia, 99% owned by Humankind and 1% owned by Mr. Xin Sun. Pursuant to the Original Agreement, Humankind and Mr. Xin Sun (the “Equity Holders”), would sell their respective equity interests in Huimeijia to Xiuzheng Pharmacy.

On February 9, 2015, the four parties entered into a supplementary agreement (the “Supplementary Agreement”) to modify the terms of the Original Agreement, pursuant to which the Equity Holders and Huimeijia (collectively the “Asset Transferors”) would sell only the 19 drug approval numbers (including the tablet, capsule, powder, mixture, oral liquid, syrup and oral solution under the 19 approval numbers; licenses including the original copies of Business License, Organization Code Certificate, Tax Registration Certificate, Drug Production Permit and GMP Certificate, and other documents and original copies related to the production and operation of the 19 drugs) (the “Assets”) to Xiuzheng Pharmacy. The Equity Holders would have retained their equity interests in Huimeijia, but would have pledged such equity interests to Xiuzheng Pharmacy until the Assets were transferred, at which time the cash consideration would have been paid by the Buyer. Total cash consideration would have been the same as under the Original Agreement, i.e., RMB 8,000,000 (approximately $1,306,186) to the Asset Transferors. In the event that the Assets had failed to be transferred to the Buyer due to the fault of the Asset Transferors, the paid consideration would have been returned to the Buyer with interest accrued. If the failure of the transfer of the Assets were a result of changes in government policy or force majeure, the paid cash consideration would have been returned to the Buyer but without any interest.

On October 12, 2016, the four parties agreed to rescind the Supplementary Agreement and entered into a new supplementary agreement (the “New Supplementary Agreement”), pursuant to which the four parties agreed to execute the transfer of the equity interests based on the Original Agreement and the Equity Holders agreed to sell their respective equity interests in Huimeijia to Xiuzheng Pharmacy. The transfer of 100% of the equity interests of Huimeijia to the Buyer was for total cash consideration of RMB 8,000,000 (approximately $1,306,186) (the “Purchase Price”) to the Equity Holders. 40% of the Purchase Price was due within 10 business days after the signing of the New Supplementary Agreement; 40% of the Purchase Price was due within 10 business days after the completion of the changes in business registration described in the Original Agreement and Xiuzheng Pharmacy obtaining documents evidencing its ownership on Huimeijia; 15% of the Purchase Price is due within 10 business days after the transfer of all of the Assets is approved by Heilongjiang FDA; and 5% of the Purchase Price is due within 10 business days after all of the Assets have been transferred to Xiuzheng Pharmacy or its designee and Humankind and Mr. Xin Sun have instructed Xiuzheng Pharmacy complete three-batches production of all forms of the drugs included in the Assets. As of the date of this report, 80% of the Purchase Price has been paid, the Company has completed changes in its business registration, and Xiuzheng Pharmacy has obtained a business license issued by the local State Administration of Industry and Commerce in Harbin (“Harbin SAIC”) to Huimeijia, in which the ownership of Huimeijia has been recorded as held by Xiuzheng Pharmacy, with Harbin SAIC and the legal representative (a person that is authorized to take most of the corporate actions on behalf of a company under the corporate laws in China) of Huimeijia has been appointed by the Buyer.

China Health US, China Health HK, Humankind and HLJ Huimeijia are collectively referred herein to as the “Company.”

As of June 30, 2022, the Company’s corporate structure was as follows:

F-10

Note 2 - SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles in the United States (“US GAAP”) and have been consistently applied in the preparation of the consolidated financial statements.

Principles of Consolidation

The accompanying consolidated financial statements include China Health US and its four subsidiary companies, including China Health HK, Humankind and HLJ Huimeijia. All significant intercompany balances and transactions have been eliminated in consolidation and combination.

On November 22, 2013, China Health US, through its wholly owned subsidiary Humankind, completed the acquisition of HLJ Huimeijia. HLJ Huimeijia and Humankind are under the common control of Mr. Xin Sun, the CEO of the Company before and after the date of transfer. Humankind’s accounting policy adopted the guidance in ASC 805-50-05-5 for the transfer of net assets between entities under common control to apply a method similar to the pooling-of-interests’ method. Under this method, the financial statements of Humankind shall report results of operations for the period in which the transfer occurs as though the transfer of net assets had occurred at the beginning of the period. Results of operations for that period will thus comprise both those of the previously separate entities combined from the beginning of the period to the date the transfer is completed and those of the combined operations from that date to the end of the period. Similarly, Humankind shall present the statements of financial position and other financial information as of the beginning of the period as though the assets and liabilities had been transferred at that date. Financial statements and financial information of Humankind presented for prior years also shall be retrospectively adjusted to furnish comparative information.

Segment Reporting

FASB ASC Topic 280, “Segment Reporting,” established standards for reporting information about operating segments on a basis consistent with the Company’s internal organizational structure as well as information about geographical areas, business segments and major customers in financial statements for details on the Company’s business segments. The Company has three reportable operating segments: Humankind, HLJ Huimeijia and Others. The segments are grouped based on the types of products provided.

Fair Value of Financial Instruments

The provisions of accounting guidance, FASB ASC Topic 820 that applies to the Company requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

Fair Value Measurements

FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” clarifies the definition of fair value for financial reporting, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements.

Various inputs are considered when determining the fair value of the Company’s debt. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below.

Level 1 – observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.).

Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments).

F-11

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. The Company had no financial assets or liabilities carried and measured on a recurring basis during the reporting periods.

The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment.

Foreign Currency Translation and Transaction

Humankind, Huimeijia and HLJ Huimeijia maintain their books and accounting records in PRC currency “Renminbi” (“RMB”), which has been determined as the functional currency. The functional currency of China Health HK is the Hong Kong Dollar (“HKD”).

Transactions denominated in currencies other than the functional currencies are recorded at the exchange rates prevailing on the date of the transactions, as quoted by the Federal Reserve Board. Foreign currency exchange gains and losses resulting from these transactions are included in operations.

Humankind, Huimeijia, HLJ Huimeijia and China Health Hong Kong’s financial statements are translated into the reporting currency, the United States Dollar (“USD”). Assets and liabilities of the above entities are translated at the prevailing exchange rate at each reporting period end date. Contributed capital accounts are translated using the historical rate of exchange when capital is injected. Income and expense accounts are translated at the average rate of exchange during the reporting period. Translation adjustments resulting from the translation of these financial statements are reflected as accumulated other comprehensive income in shareholders’ equity and non-controlling interests.

For the purpose of presenting these financial statements, the Company’s assets and liabilities with functional currency of HKD are expressed in USD at the exchange rate on the balance sheet date, which was 7.8472 and 7.7658 as of June 30, 2022 and June 30, 2021, respectively; stockholder’s equity accounts are translated at historical rates, and income and expense items are translated at the weighted average exchange rates during the year, which was 7.8049 and 7.7563 for the years ended June 30, 2022 and 2021, respectively. For Renminbi currency, the Company’s assets and liabilities are expressed in USD at the exchange rate on the balance sheet date, which was 6.6981 and 6.4566 as of June 30, 2022 and June 30, 2021, respectively; stockholder’s equity accounts are translated at historical rates, and income and expense items are translated at the weighted average exchange rates during the year, which was 6.4554 and 6.6221 for the years ended June 30, 2022 and 2021, respectively.

Statement of Cash Flows

In accordance with Statement FASB ASC Topic 230, “Statement of Cash Flows,” cash flow from the Company’s operations is calculated based upon the local currencies and translated to the reporting currency using an average foreign exchange rate for the reporting period. As a result, amounts related to assets and liabilities reported in the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and judgments on historical experience and on various other assumptions and information that are believed to be reasonable under the circumstances. Estimates and assumptions of future events and their effects cannot be perceived with certainty and, accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Significant estimates and assumptions by management include, among others; useful lives of long-lived assets and intangible assets, valuation of inventory, accounts receivable and notes receivable, impairment analysis of long-lived assets, construction in progress, intangible assets and deferred taxes. While the Company believes that the estimates and assumptions used in the preparation of the financial statements are appropriate, actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary.

F-12

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less at the time of purchase.

As of June 30, 2022, and 2021, the Company’s uninsured bank balance was mainly maintained at financial institutions located in the PRC and Hong Kong, totaled $44,789,999 and $44,346,744, respectively. The Company has no insured bank balance as of June 30, 2022 and 2021, respectively.

Accounts Receivable

Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company extends unsecured credit to its customers in the ordinary course of business but mitigates the associated risks by performing credit checks and actively pursuing past due accounts. An allowance for doubtful accounts is established and determined based on management’s assessment of known requirements, aging of receivables, payment and bad debt history, the customer’s current credit worthiness, changes in customer payment patterns and the economic environment. From November 1, 2013, the Company changed its credit policy by offering ninety (90) day payment terms for sales agents, whereas the payment terms for sales agents before November 1, 2013 were thirty (30) day. Due to COVID-19, the company extended its credit policy to 180 days this year. As of June 30, 2022 and 2021, the balances of accounts receivable were $9,567 and $2,346,867, respectively. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company evaluated the nature of all accounts receivable then provided allowance for doubtful accounts. As of June 30, 2022, and 2021, the balances of allowance for doubtful accounts were $48,769 and $60,394 respectively.

Advance to Suppliers

The Company periodically makes advances to certain vendors for purchases of raw materials, or service providers for services relating to construction plans for our plant, equipment and production lines for the GMP upgrading, and records these payments as advance to suppliers. The decrease in the amount of advance to suppliers is due to fluctuation of exchange rate. As a result, as of June 30, 2022, and 2021, advance to suppliers amounted to $214,915 and $218,307, respectively.

Inventory

Inventory consists of raw materials, work in progress and finished goods of manufactured products.

Inventory is stated at lower of cost or market and consists of materials, labor and overhead. HLJ Huimeijia uses the weighted average method for inventory valuation. The other entities of the Company use the first-in, first-out (“FIFO”) method for inventory valuation. Overhead costs included in finished goods include direct labor cost and other costs directly applicable to the manufacturing process. The Company evaluates inventory for excess, slow moving, and obsolete inventory as well as inventory the value of which is in excess of its net realizable value. This evaluation includes analysis of sales levels by product and projections of future demand. If future demand or market conditions are less favorable than the Company’s projections, a write-down of inventory may be required, and would be reflected in cost of goods sold in the period the revision is made. The inventory allowance with an amount of $nil and $nil were provided for the years ended June 30, 2022, and 2021, respectively.

F-13

Impairment of Long-Lived Assets

The Company’s long-lived assets and other assets are reviewed for impairment in accordance with the guidance of the FASB ASC Topic 360-10, “Property, Plant, and Equipment,” and FASB ASC Topic 205, “Presentation of Financial Statements.” The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of the asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on the Company’s reporting results and financial position. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. As of June 30, 2022, and 2021, the Company has not experienced impairment losses on its long-lived assets. However, there can be no assurances that demand for the Company’s products or services will continue, which could result in an impairment of long-lived assets in the future.

Property, Plant and Equipment

Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses. Maintenance, repairs and minor renewals are expensed as incurred, major renewals and improvements that extend the lives or increase the capacity of plant assets are capitalized.

When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in the results of operations in the reporting period of disposition.

Depreciation is calculated on a straight-line basis over the estimated useful life of the assets. The depreciable lives applied are:

Building, Warehouse and Improvements		20 to 30 years
Office Equipment		3 to 7 years
Vehicles		5 to15 years
Machinery and Equipment		7 to 15 years

Intangible Assets

The Company evaluates intangible assets in accordance with FASB ASC Topic 350, “Intangibles — Goodwill and Other.” Intangible assets deemed to have indefinite lives are not amortized, but are subject to annual impairment tests. If the assumptions and estimates used to allocate the purchase price are not correct, or if business conditions change, purchase price adjustments or future asset impairment charges could be required. The value of the Company’s intangible assets could be impacted by future adverse changes such as: (i) any future declines in the Company’s operating results, (ii) a decline in the valuation of technology, including the valuation of the Company’s common stock, (iii) a significant slowdown in the worldwide economy, or (iv) any failure to meet the performance projections included in the Company’s forecasts of future operating results. In accordance with FASB ASC Topic 350, the Company tests intangible assets for impairment on an annual basis or more frequently if the Company believes indicators of impairment exist. Impairment evaluations involve management estimates of asset useful lives and future cash flows. Significant judgment by management is required in the forecasts of future operating results that are used in the evaluations. It is possible, however, that the plans and estimates used may be incorrect. If the Company’s actual results, or the plans and estimates used in future impairment analysis, are lower than the original estimates used to assess the recoverability of these assets, we could incur additional impairment charges in a future period. Based on such evaluations, there were no impairments recorded for intangible assets for the years ended June 30, 2022 and 2021, respectively.

Construction in Progress

Construction in progress represents the costs incurred in connection with the construction of buildings or new additions to the Company’s plant facilities. Costs classified as construction in progress include all costs of obtaining the asset and bringing it to the location in the condition necessary for its intended use. No depreciation is provided for construction in progress until such time as the assets are completed and are placed into service.

F-14

The Company reviews the carrying value of construction in progress for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value of the assets, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of the assets. The factors considered by Management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this assessment, there were no impairments recorded for construction in progress, for the years ended June 30, 2022 and June 30, 2021, respectively. However, there can be no assurances that demand for the Company’s products or services will continue, which could result in an impairment of long-lived assets in the future.

Revenue Recognition

The Company recognizes revenue at the amount to which it expects to be entitled when control of the products or services is transferred to its customers based on any contract which has been identified. Control is generally transferred when the Company has a present right to payment and title and the significant risks and rewards of ownership of products or services are transferred to its customers while performance obligation are identified and completed. For most of the Company’s products net sales, control transfers when products are shipped and transaction price are determined. The majority of the Company’s revenue relates to the sale of inventory to customers, and revenue is recognized when control of the products or services is transferred to its customers that reflects the performance obligations are properly allocated and satisfied with transaction price determined. Given the nature of the Company’s business and the applicable rules guiding revenue recognition, the Company’s revenue recognition practices do not contain estimates that materially affect the results of operations. The Company records revenue at the discounted selling price and allows its customers to return products for exchange or credit subject to certain limitations. A provision for such returns is recorded based upon historical experience. There has been no provision recorded for returns based upon historical experience for the years ended June 30, 2022 and 2021, respectively.

Cost of Goods Sold

Cost of goods sold consists primarily of the costs of raw materials, freight charges, direct labor, depreciation of plants and machinery, warehousing and overhead costs associated with the manufacturing process and commission expenses.

Income Taxes

The Company adopts FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established for deferred tax assets if it is more likely than not that these items will either expire before the Company is able to realize the benefits or that future deductibility is uncertain.

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.

F-15

As a result of the implementation of FIN 48 (ASC 740-10), the Company undertook a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholders’ equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s financial statements.

The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from the Company’s estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.

Enterprise Income Tax

Under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC (the “EIT Law”), income tax is payable by enterprises at a rate of 25% of their taxable income.

Value Added Tax

The Provisional Regulations of the PRC Concerning Value Added Tax promulgated by the State Council came into effect on January 1, 1994 and revised on January 1, 2009. Under these regulations and the Implementing Rules of the Provisional Regulations of the PRC Concerning Value Added Tax, value added tax (“VAT”) is imposed on goods sold in, or imported into, the PRC and on processing, repair and replacement services provided within the PRC.

VAT payable in the PRC is charged on an aggregated basis at a rate of 13% or 16% (depending on the type of goods involved) on the full price collected for the goods sold or, in the case of taxable services provided, at a rate of 16% on the charges for the taxable services provided, but excluding, in respect of both goods and services, any amount paid in respect of VAT included in the price or charges, and less any deductible VAT already paid by the taxpayer on purchases of goods and services in the same financial year. As of June 30, 2022 and June 30, 2021, VAT payables were $29,835 and $34,697, respectively.

Sales-Related Taxes

Pursuant to the tax law and regulations of the PRC, the Company is obligated to pay 7% and 5% of the annual aggregate VAT paid by the Company as taxes for the purposes of maintaining and building cities and educational facilities, which fees are included as sales-related taxes. Sales-related taxes are recorded when sales revenue is recognized.

F-16

Concentrations of Business and Credit Risks

All of the Company’s manufacturing is located in the PRC. There can be no assurance that the Company will be able to successfully continue to manufacture its products and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. Moreover, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. These contingencies include general economic conditions, prices of raw materials, competition, governmental and political conditions, and changes in regulations. Since the Company is dependent on trade in the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company’s operations will be subject to the risks of restrictions on transfer of funds, domestic customs, changing taxation policies, foreign exchange restrictions, and political and governmental regulations. The Company operates in China, which may give rise to significant foreign currency risks from fluctuations and the degree of volatility of foreign exchange rates between U.S. dollars and the Chinese currency RMB. The results of operations denominated in foreign currency are translated at the average rate of exchange during the reporting periods.

Earnings Per Share

Basic earnings per common share is computed by dividing net earnings applicable to common shareholders by the weighted-average number of common shares outstanding during the period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. For the years ended June 30, 2022 and 2021, the Company had no potential dilutive common stock equivalents outstanding.

Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period.

FASB ASC Topic 260, “Earnings Per Share,” requires a reconciliation of the numerator and denominator of the basic and diluted earnings per share (EPS) computations.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments (ASU 2016-13). The main objective of the standard is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In issuing this standard, the FASB is responding to criticism that today’s guidance delays recognition of credit losses. The standard will replace today’s “incurred loss” approach with an “expected loss” model. The new model, referred to as the current expected credit loss (“CECL”) model, will apply to: (1) financial assets subject to credit losses and measured at amortized cost, and (2) certain off-balance sheet credit exposures. The standard is applicable to loans, accounts receivable, trade receivables, and other financial assets measured at amortized cost, loan commitments and certain other off-balance sheet credit exposures, debt securities (including those held-to-maturity) and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The CECL model does not apply to available-for-sale debt securities. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to what they do today, except that the credit losses will be recognized as allowances rather than reductions in the amortized cost of the securities. Accordingly, the new methodology will be utilized when assessing the Company’s financial instruments for impairment. As a result, entities will recognize improvements to estimated credit losses immediately in earnings rather than as interest income over time, as they do today. The ASU also simplifies the accounting model for purchased credit-impaired debt securities and loans. ASU 2016-13 also expands the disclosure requirements regarding an entity’s assumptions, models, and methods for estimating the allowance for loan and lease losses. ASU 2016-13 is effective for years beginning after December 15, 2019, including interim periods within those fiscal years under a modified retrospective approach. Early adoption is permitted for the periods beginning after December 15, 2018. The Company adopted the guidance from July 1, 2020. The Company finalized its analysis and determined that the adoption of this guidance has no material impact on the Company’s consolidated financial statements and its internal controls over financial reporting.

F-17

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13), which modifies the disclosure requirements on fair value measurements, including removing the requirement to disclose (1) the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, (2) the policy for timing of transfers between levels and (3) the valuation processes for Level 3 fair value measurements. ASU 2018-13 also added new disclosures including the requirement to disclose (a) the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and (b) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2019 and early adoption is permitted. This standard will only impact the disclosures pertaining to fair value measurements. The Company adopted the guidance from July 1, 2020. The Company finalized its analysis and determined that the adoption of this guidance has no material impact on the Company’s consolidated financial statements and its internal controls over financial reporting.

NOTE 3 - ASSETS SALE

On December 24, 2014, Humankind entered into a stock transfer agreement (the “Agreement”) with Xiuzheng Pharmaceutical Group Co., Ltd a company incorporated under the laws of the People’s Republic of China and located in Jilin province (“Xiuzheng Pharmacy” or the “Buyer”), and Mr. Xin Sun, the CEO of the Company, and Huimeijia, pursuant to which, Humankind and Mr. Xin Sun (the “Equity Holders”), shall sell their respective equity interests in Huimeijia to Xiuzheng Pharmacy. The transfer of the 100% equity interests of Huimeijia to the Buyer was for a total cash consideration of RMB 8,000,000 (approximately $1,306,186) to the Equity Holders.

On February 9, 2015, the four parties entered into a supplementary agreement (the “Supplementary Agreement”) to modify the terms of the Agreement, pursuant to which, the Equity Holders and Huimeijia (collectively the “Assets Transferors”) shall only sell the 19 drug approval numbers (including the tablet, capsule, powder, mixture, oral liquid, syrup and oral solution under the 19 approval numbers; licenses including the original copies of Business License, Organization Code Certificate, Tax Registration Certificate, Drug Production Permit and GMP Certificate, and other documents and original copies related to the production and operation of the 19 drugs) (the “Assets”) to Xiuzheng Pharmacy. The Equity Holders will retain the equity interests in Huimeijia, but will have the equity interests pledged to Xiuzheng Pharmacy until the Assets are transferred, at which time all the cash consideration shall be paid by the Buyer. The total cash consideration remains to be the same as under the Agreement, i.e., RMB 8,000,000 (approximately $1,306,186) to the Assets Transferors. In the event that the Assets are failed to be transferred to the Buyer due to the fault of the Assets Transferors, the paid consideration shall be returned to the Buyer with interests accrued. If the failure of the transfer of the Assets is a result of the government policy changes or force majeure, the paid cash consideration shall be returned to the Buyer but without any interests.

As of June 30, 2016, the transfer of the Assets had not been completed because the assets transfer crossed different provinces which resulted in a complicated interaction among the local administrations of Heilongjiang Province, where Huimeijia is located and Jilin Province, where the transferee is located.

F-18

On October 12, 2016, the four parties agreed to rescind the Supplementary Agreement and entered into a new supplementary agreement (the “New Supplementary Agreement”), pursuant to which the four parties agreed to execute the transfer of the equity interests based on the Original Agreement and the Equity Holders agreed to sell their respective equity interests in Huimeijia to Xiuzheng Pharmacy. The transfer of 100% of the equity interests of Huimeijia to the Buyer was for a total cash consideration of RMB 8,000,000 (approximately $1,306,186) (the “Purchase Price”) to the Equity Holders. 40% of the Purchase Price was due within 10 business days after the signing of the New Supplementary Agreement; 40% of the Purchase Price was due within 10 business days after the completion of the changes in business registration described in the Original Agreement and Xiuzheng Pharmacy obtaining documents evidencing its ownership on Huimeijia; 15% of the Purchase Price is due within 10 business days after the transfer of all of the Assets is approved by Heilongjiang FDA; and 5% of the Purchase Price is due within 10 business days after all of the Assets have been transferred to Xiuzheng Pharmacy or its designee and Humankind and Mr. Xin Sun have instructed Xiuzheng Pharmacy to complete three-batches production of all forms of the drugs included in the Assets. As of the date of this report, 80% of the Purchase Price has been paid, the Company has completed changes in its business registration, and Xiuzheng Pharmacy has obtained a business license issued by the local State Administration of Industry and Commerce in Harbin (“Harbin SAIC”) to Huimeijia, in which the ownership of Huimeijia has been recorded as held by Xiuzheng Pharmacy, with Harbin SAIC and the legal representative (a person that is authorized to take most of the corporate actions on behalf of a company under the corporate laws in China) of Huimeijia has been appointed by the Buyer.

NOTE 4 - ACCOUNTS RECEIVABLE

The Company’s accounts receivable amounted to $9,567 and $2,346,867 net of allowance for doubtful accounts amounting to $48,769 and $60,394 as of June 30, 2022 and 2021, respectively.

NOTE 5 - INVENTORIES

Inventory consists of following:

	June 30, 2022		June 30, 2021
Raw Materials	$	213,055	$	251,989
Supplies and Packing Materials		90,303		93,452
Work-in-Progress		82,412		273,924
Finished Goods		135,459		142,274
Total	$	521,229	$	761,639

The finished goods produced for wholesale are sold out and cannot be refilled because of the lockdown of factory plant. In addition, the finished goods produced for retail cannot be sold because of the lockdown of the retail store. The inventory allowance with an amount of $nil and $nil were provided for the years ended June 30, 2022 and 2021, respectively.

F-19

NOTE 6 - CONSTRUCTION IN PROGRESS

Construction in progress consisted of the following:

	June 30, 2022		June 30, 2021
Plant - HLJ Huimeijia	$	579,402	$	560,910
Total	$	579,402	$	560,910

On April 6, 2012, HLJ Huimeijia entered into an agreement with a contractor for construction of the HLJ Huimeijia plant. The estimated total cost of construction was approximately $1.86 million (RMB 12,800,000). As of June 30, 2022, 77.9% of construction has been completed, $1,448,567 (RMB9,702,644) has been recorded as costs of construction in progress and construction in progress at an amount of $949,040 (RMB6,356,767) has been completed and converted into property, plant and equipment.

NOTE 7 - PROPERTY, PLANTS AND EQUIPMENT

Property, plants and equipment consisted of the following:

	June 30, 2022			June 30, 2021
Building, Warehouses and Improvements	$	3,946,492		$	4,094,105
Machinery and Equipment		1,832,446			1,900,986
Office Equipment		78,360			81,291
Vehicles		217,808			225,955
Others		962,667			998,674
Less Accumulated Depreciation		(3,879,752	)		(3,671,106	)
Total	$	3,158,021		$	3,629,905

Depreciation expense was $344,919 and $393,168 for the years ended June 30, 2022 and 2021, respectively. Depreciation expense charged to operations was $344,919 and $124,073 for the years ended June 30, 2022 and 2021, respectively. Depreciation expense charged to cost of goods sold was $nil and $269,095 for the years ended June 30, 2022 and 2021, respectively.

F-20

NOTE 8 - INTANGIBLE ASSETS

The following is a summary of intangible assets:

	June 30, 2022			June 30, 2021
Land Use Rights – Humankind	$	946,237		$	981,630
Health Supplement Product Patents – Humankind		4,478,882			4,646,408
Pharmaceutical Patents - HLJ Huimeijia		390,285			404,883
Land Use Rights - HLJ Huimeijia		647,211			671,419
Less: Accumulated Amortization		(5,050,012	)		(4,740,824	)
Intangible Assets, net, Held for Continuing Operations	$	1,412,603		$	1,963,516

There is no private land ownership in PRC.. Enterprises and individuals can pay the government a fee to obtain the right to use a piece of land for commercial purposes or residential purposes for an initial period of 50 years or 70 years, respectively. The land use right can be sold, purchased, and exchanged in the market. The successor owner of the land use right will have the right to use the land for the time remaining on the initial period. The patent has amortized life of 10 years.

Amortization expense charged to operations was $485,625 and $485,625 for the years ended June 30, 2022 and 2021, respectively.

F-21

NOTE 9 - RELATED PARTY DEBTS

Related party debts, which represent temporary short-term loans from Mr. Xin Sun and Mr. Kai Sun consisted of the following:

	June 30, 2022		June 30, 2021
Mr. Xin Sun	$	6,724,850	$	8,043,544
Mr. Kai Sun		34,911		36,217
Related Party Debts, Held for Continuing Operations	$	6,759,761	$	8,079,761

These loans are unsecured and non-interest bearing and have no fixed terms of repayment; therefore, they are deemed payable on demand. Mr. Kai Sun, a director of Humankind, is a PRC citizen and a family member of Mr. Xin Sun, the CEO of the Company.

NOTE 10 - INCOME TAXES

(a) Corporate income taxes

China Health US was incorporated in the State of Arizona on July 11, 1996. After the Company had acquired the business of China Health HK through the acquisition of all the share capital of China Health HK under a share exchange agreement dated December 31, 2008, it became a holding company and did not conduct any substantial operations or business of its own in the State of Delaware and in the U.S.

The Company also does not provide for U.S. taxes or foreign withholding taxes on undistributed earnings from its non-U.S. subsidiaries, either owned directly or indirectly, because it was elected to indefinitely reinvest such earnings outside the U.S to support non-U.S. liquidity needs to fund operations and growth of its foreign subsidiaries and acquisitions.

United States

China Health US had no taxable income for U.S. corporate income tax purposes for the years ended June 30, 2022 and 2021, respectively. As of June 30, 2022 and 2021, China Health US had $1,793,042 and $1,569,209 in net operating loss carry forwards available to offset future taxable income, respectively. The federal corporate net operating loss carryover is expired in 20 taxable years following the taxable year of the loss. If not utilized, the federal net operating loss for the fiscal years 2022 and 2021 in an amount of $223,833 and $187,462, respectively, will begin to expire in the years 2041 and 2040, respectively. Management believes that it is more likely than not that the benefits from these accumulated net operating losses will not be realized in the future due to the Company’s operating history and the continued losses of its U.S. operation. Accordingly, the Company has provided a full valuation allowance on the deferred tax assets under its U.S. entity.

Hong Kong

China Health Industries Holdings Limited (“China Health HK”) was incorporated in Hong Kong on July 20, 2007 and is subject to Hong Kong profits taxation on its business activities conducted in Hong Kong and income sourced in Hong Kong. As of June 30, 2022, and 2021, China Health Hong Kong had $11,030 and $10,588 in net operating loss carry forwards available to offset future taxable income, respectively. Net operating losses of Hong Kong can generally be carried forward indefinitely. The Company believes that it is more likely than not that these accumulated net operating losses will not be utilized in the future due to the fact that the Company does not have and probably will not have any business operations in HK. Therefore, the Company had provided full valuation allowance for the deferred tax assets arising from the losses in Hong Kong during the years ended June 30, 2022, and 2021, amounting $441 and $489, respectively. Accordingly, there is no net deferred tax assets under this entity.

F-22

People’s Republic of China

Under the EIT Law, the standard EIT rate is 25%. The PRC subsidiaries of the Company are subject to PRC income taxes on an entity basis on income arising in or derived from the tax jurisdiction in which they operate.

The provision for income taxes consisted of the following for the years ended June 30, 2022 and 2021:

As of June 30, 2022, and 2021, taxes payable consists of:

	June 30, 2022		June 30, 2021
Income tax payable	$	23,839	$	28,895
Value-added tax payable		29,835		34,697
Other taxes payable		79,331		112,767
Total	$	133,005	$	176,359

A reconciliation between the Company’s actual provision for income taxes and the provision at the statutory rate is as follows:

	June 30, 2022			June 30, 2021
Pre-tax book income	$	(351,016	)	$	2,021,583
Federal statutory rate		21	%		21	%
Income tax computed at U.S. federal statutory rate		(73,714	)		424,532
Non-deductible staff welfare		-			-
Foreign rate differential		(7,874	)		392,435
Change in valuation allowance		84,522			(86,506	)
Total provision for income taxes	$	2,934		$	730,461

The Company’s effective tax rate was 0.8% and 36.1% for the years ended June 30, 2022 and 2021, respectively.

F-23

The provision for income taxes on income consists of the following for the years ended June 30, 2022 and 2021:

Provision for income taxes consisted of:

	For the Years Ended
	June 30,
	2022		2021
Current provision:
Domestic	$	-	$	-
Foreign		-		727,588
Total current provision		-		727,588
Deferred provision:
Domestic		-		-
Foreign		2,934		2,873
Total deferred provision		2,934		2,873
Total provision for income taxes	$	2,934	$	730,461

Significant components of deferred tax assets were as follows:

	June 30, 2022			June 30, 2021
Deferred tax assets
Net operating loss carry forward	$	1,096,936		$	1,018,253
Allowance for doubtful accounts		(12,192	)		(15,100	)
Valuation allowance		(1,084,744	)		(1,000,220	)
Deferred tax assets, net	$	-		$	2,933

(b) Uncertain tax positions

There were no unrecognized tax benefits as of June 30, 2022 and 2021, respectively. Management does not anticipate any potential future adjustments in the next twelve months which would result in a material change to its tax positions. There was no interests and penalties arising from its tax payments for the years ended June 30, 2022.

F-24

NOTE 11 - EARNINGS PER SHARE

FASB ASC Topic 260, Earnings Per Share, requires a reconciliation of the numerator and denominator of the basic and diluted earnings per share (EPS) computations.

For the years ended June 30, 2022, and 2021, the Company does not have potential dilutive shares. The following table sets forth the computation of basic and diluted net income per share:

	For the Years Ended
	June 30,			June 30,
	2022			2021
Net income/(loss)	$	(353,950	)	$	1,291,122

Net income/(loss) per share:

Net income (loss) per share Basic & diluted	$	(0.0054	)	$	0.0197

Weighted average shares outstanding:
Basic & diluted		65,539,737			65,539,737

NOTE 12 - COMMITMENTS AND CONTINGENCIES

The Company’s assets are located in the PRC and revenues are derived from operations in the PRC.

In terms of industry regulations and policies, the economy of the PRC has been transitioning from a planned economy to market oriented economy. Although in recent years the Chinese government has implemented measures emphasizing the utilization of market forces for economic reforms, the reduction of state ownership of productive assets and the establishment of sound corporate governance in business enterprises, a substantial portion of productive assets in the PRC is still owned by the Chinese government. For example, there is no private land ownership in PRC and all land is leased by government to business entities or individuals through the government’s granting of Land Use Rights. The granting process is typically based on government policies at the time of granting and can be lengthy and complex. This process may adversely affect the Company’s future manufacturing expansions. The Chinese government also exercises significant control over the PRC’s economic growth through the allocation of resources and providing preferential treatment to particular industries or companies. Uncertainties may arise with changing of governmental policies and measures.

The Company faces a number of risks and challenges not typically associated with companies in North America and Western Europe, since its assets exist solely in the PRC, and its revenues are derived from its operations therein. The PRC is a developing country with an early stage market economic system, overshadowed by the state. Its political and economic systems are very different from the more developed countries and are in a state of change. The PRC also faces many social, economic and political challenges that may produce major shocks, instabilities and even crises, in both its domestic arena and in its relationships with other countries, including the United States. Such shocks, instabilities and crises may in turn significantly and negatively affect the Company’s performance.

The Company had no rental commitment as of June 30, 2022.

NOTE 13 - MAJOR SUPPLIERS AND CUSTOMERS

For the year ended June 30, 2022, the Company had no suppliers due to its being temporarily out of production. For the year ended June 30, 2021, the Company had three suppliers that in aggregate accounted for approximately 78% of the Company’s purchases, with each supplier accounting for 40%, 22% and 16%, respectively.

For the year ended June 30, 2022, the Company had no customers due to the enterprise Transformation and the COVID-19 resurgence. For the year ended June 30, 2021, the Company had six customers that in aggregate accounted for 91% of the Company’s total sales, with each customer accounting for 23%, 18%, 16%, 13%, 12%, and 9%, respectively.

F-25

NOTE 14 - SEGMENT REPORTING

The Company was organized into three main business segments based on the types of products being provided to customers: HLJ Huimeijia, Humankind and others. Each of the three operating segments referenced above has separate and distinct general ledgers. The chief operating decision maker (“CODM”) receives financial information, including revenue, gross margin, operating income, and net income produced from the various general ledger systems to make decisions about allocating resources and assessing performance; however, the principal measure of segment profitability or loss used by the CODM is net income or loss by segment.

The following tables present summary information by segment for the years ended June 30, 2022 and 2021, respectively:

				For the Year Ended June 30, 2022														For the Year Ended June 30, 2021
	HLJ									Consolidated			HLJ								Consolidated
	Huimeijia			Humankind			Others			operations			Huimeijia			Humankind		Others			operations
Revenues	$	267		$	-		$	-		$	267		$	16,754		$	6,475,966	$	-		$	6,492,720
Cost of revenues		1,748			-			-			1,748			96,316			2,754,413		-			2,850,729
Gross profit (loss)		(1,481	)		-			-			(1,481	)		(79,562	)		3,721,553		-			3,641,991
Interest income		322			157,536			2			157,860			9			137,468		8			137,485
Interest expense		-			-			-			-			-			-		-			-
Depreciation and amortization		60,962			650,553			-			711,515			62,239			547,459		-			609,698
Income tax		-			2,934			-			2,934			-			730,461		-			730,461
Net income (loss)		509,990			(637,666	)		(226,274	)		(353,950	)		(386,910	)		1,865,983		(187,951	)		1,291,122
Total capital expenditures		-			-			-			-			5,074			8,582		-			13,656
Total assets	$	2,994,826		$	47,724,803		$	27,889		$	50,747,518		$	3,453,342		$	50,347,870	$	86,925		$	53,888,137

NOTE 15 - SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined that there are no additional items required to disclose.

F-26

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain a set of disclosure controls and procedures designed to ensure that information required to be disclosed by us in our reports filed under the Securities Exchange Act, is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that this information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Based upon their evaluation as of the end of the periods covered by this report, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective to satisfy the objectives, due to the material weakness in our internal control over financial reporting discussed below.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control system was designed to provide reasonable assurance to our management and our sole board member regarding the preparation and fair presentation of published financial statements.

Our management assessed the effectiveness of our internal control over financial reporting as of June 30, 2022. In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013 in Internal Control—Integrated Framework. Our management has implemented and tested our internal control over financial reporting based on these criteria and did not identify any significant deficiencies and material weaknesses as of June 30, 2022. However, based on the fact that we do not have any full-time accounting personnel who have U.S. GAAP experience, our management has considered this as a material weakness and determined that as of June 30, 2022, the internal control over financial reporting was not effective.

In an effort to remedy this material weakness in the future, we intend to do the following:

	●	Develop a comprehensive training and development plan, for our finance, accounting and internal audit personnel, including our Chief Financial Officer, Financial Manager, and others, in the principles and rules of U.S. GAAP, SEC reporting requirements and the application thereof.

	●	Design and implement a program to provide ongoing company-wide training regarding the Company’s internal controls, with particular emphasis on our finance and accounting staff.

	●	Implement an internal review process over financial reporting to review all recent accounting pronouncements and to verify that the accounting treatment identified in such report have been fully implemented and confirmed by our internal control department. In the future, we will continue to improve our ongoing review and supervision of our internal control over financial reporting.

	●	Hire an individual that possesses the requisite U.S. GAAP experience and education.

Despite the material weakness reported above, our management believes that our consolidated financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

This report does not include an attestation report of our registered accounting firm regarding internal control over financial reporting. The management’s report was not subject to attestation by our registered public accounting firm because we are a smaller reporting company.

Changes in Internal Control over Financial Reporting

No changes in our internal control over financial reporting have come to management’s attention during our last fiscal year that have materially affected, or are likely to materially affect, our internal control over financial reporting.

Limitations on Controls

Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

Item 9B. Other Information.

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

None.

Part III

Item 10. Directors, Executive Officers and Corporate Governance.

The following table sets forth information regarding our sole board member and executive officer. Our sole director holds office until the election and qualification of his successor.

Name	Age	Position

Xin Sun	56	Chairman (sole director), Chief Executive Officer, Chief Financial Officer and Treasurer

Biography

Mr. Xin Sun, age 56, has been serving as our Chairman of Board of Directors, Chief Executive Officer and Chief Financial Officer since 2009. From 1988 to 1991, he was the Production Manager at Ha Yao Group Sanchine Medicine Joint-Stock Company Ltd. From 1991 to 1994, he was the District Director for the Northeast District of China for Pfizer Pharmaceuticals Limited. Thereafter, he spent one year as the Director of Marketing for Ha Yao Group Sanchine Medicine Joint-Stock Company Ltd. From 1996 to 2002, he was the Chief Executive Officer of a company he founded, Heilongjiang Bijie Chemical Industry Co., Ltd., which is no longer in existence. From 2003 to the present, he has been the President and Chief Executive Officer of Humankind. Mr. Sun is also President and General Manager of Huimeijia. Mr. Xin Sun attended Jia Mu Si Medical College with a major in Pharmacy from 1984 to 1988. He obtained his Masters of Business Administration from Renmin University of China in 2004. Mr. Sun attended the Doctor of Business Administration program in Business Institute of Pennsylvania since September 2018 and received a doctor’s degree in 2019.

As a result of his professional experience, Mr. Xin Sun is well known in the pharmaceutical field in Harbin, PRC. While he was studying at Renmin University, Mr. Xin Sun developed many contacts in the pharmaceutical field, many of which later became district agents and other employees in Humankind’s distribution system.

Our sole director, Mr. Xin Sun, does not hold any directorships in other reporting companies and does not qualify as an “independent director” under the Rules of NASDAQ, Marketplace Rule 4200(a)(15).

To our knowledge, during the last ten years, none of our directors and executive officers (including those of our subsidiaries) have:

(a)

had a bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time.

(b)

been convicted in a criminal proceeding or been subject to a pending criminal proceeding, excluding traffic violations and other minor offenses.

(c)

been subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities.

(d)

been found by a court of competent jurisdiction (in a civil action), the SEC, or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

Director Qualifications

Directors are responsible for overseeing the Company’s business consistent with their fiduciary duty to the shareholders. This significant responsibility requires highly-skilled individuals with various qualities, attributes and professional experience. Our sole director believes that there are general requirements for service on the Board that are applicable to all directors and that there are other skills and experience that should be represented on the Board as a whole but not necessarily by each director. The existing board member considers the qualifications of director and director candidates individually and in the broader context of the Board’s overall composition and the Company’s current and future needs.

Qualifications for All Directors

In its assessment of each potential candidate, including those recommended by the shareholders, the Board will consider the nominee’s judgment, integrity, experience, independence, understanding of the Company’s business or other related industries and such other factors it determines are pertinent in light of the current needs of the Board.

The Board also takes into account the ability of a director to devote the time and effort necessary to fulfill his or her responsibilities to the Company.

The Board requires that each director be a recognized person of high integrity with a proven record of success in his or her field. Each director must demonstrate innovative thinking, familiarity with and respect for corporate governance requirements and practices, an appreciation of multiple cultures and a commitment to sustainability and to dealing responsibly with social issues. In addition to the qualifications required of all directors, the Board conducts interviews of potential director candidates to assess intangible qualities including the individual’s ability to ask difficult questions and, simultaneously, to work collegially. The Board does not have a specific diversity policy, but considers diversity of race, ethnicity, gender, age, cultural background and professional experiences in evaluating candidates for Board membership. Diversity is important because a variety of points of view contribute to a more effective decision-making process.

Qualifications, Attributes, Skills and Experience to be Represented on the Board as a Whole

The Board has identified particular qualifications, attributes, skills and experiences that should be represented on the Board as a whole, in light of the Company’s current needs and its business priorities. The Board believes that it should include some directors with a high level of financial literacy and some directors who possess relevant business experiences as a chief executive officer, president or similar position at a company. Marketing is the core focus of our business and the Company seeks to develop and deploy innovative and effective marketing and technology. Therefore, the Board believes that marketing and technology experience should be represented on the Board.

Presently, Mr. Xin Sun is the sole director of the Company. Mr. Xin Sun possesses many of the skills and experiences needed for our business. He has experience in the pharmaceutical industry, having previously been the District Director for the Northeast District of China for Pfizer Pharmaceuticals Limited from 1991 to 1994. He has also been the Director of Marketing for Ha Yao Group Sanchine Medicine Joint-Stock Company Ltd., where he acquired strong marketing experience. From 1996 to 2002, Mr. Xin Sun was the chief executive officer of a company he founded, Heilongjiang Bijie Chemical Industry Co., Ltd., and from 2003 to the present, he has been the president and chief executive officer of Humankind.

The Board plans to eventually increase its membership to include directors with skills and experiences complementary to Mr. Xin Sun’s background.

Board Leadership Structure and Role in Risk Oversight

Mr. Xin Sun is the Company’s Chairman and Chief Executive Officer. The Board’s role in the risk oversight of the Company includes, among other things:

appointing, retaining and overseeing the work of the independent auditors, including resolving disagreements between the management and the independent auditors relating to financial reporting;

approving all auditing and non-auditing services permitted to be performed by the independent auditors;

reviewing annually the independence and quality control procedures of the independent auditors;

reviewing and approving all proposed related party transactions;

discussing the annual audited financial statements with the management; and

meeting separately with the independent auditors to discuss critical accounting policies, management letters, recommendations on internal controls, the auditor’s engagement letter and independence letter and other material written communications between the independent auditors and the management.

Compliance with Section 16(a) of Exchange Act

Section 16(a) of the Exchange Act requires our executive officers and directors and persons who own more than ten percent of a registered class of our equity securities to file with the SEC initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of our common stock and other equity securities, on Form 3, 4 and 5 respectively. Executive officers, directors and greater than ten percent shareholders are required by the SEC regulations to furnish the Company with copies of all Section 16(a) reports they file.

Based solely on our review of the copies of such reports, we believe that, with respect to the fiscal year ended June 30, 2022, there is no triggering event for the filing of any report under Section 16(a) by our sole officer and director, or by any of the persons known to us to own more than ten percent of our common stock.

Meetings of Our Board of Directors

The Board held no meetings; however, the Board had resolved matters in written consent one time during the fiscal year ended June 30, 2022.

Board Committees

Audit Committee. We intend to establish an audit committee of the Board which will consist of soon-to-be-nominated independent directors. The audit committee’s duties will be to recommend to the Board the engagement of independent auditors to audit our financial statements and to review our accounting and auditing principles. The audit committee will review the scope, timing and fees for the annual audit and the results of audit examinations performed by the internal auditors and independent public accountants, including their recommendations to improve the system of accounting and internal controls. The audit committee will at all times be composed exclusively of directors who are, in the opinion of the Board, free from any relationship which would interfere with the exercise of independent judgment as a committee member and who possess an understanding of financial statements and generally accepted accounting principles.

Audit Committee Financial Expert. The Board currently acts as our audit committee. Since we are still a developing company, the Board is still in the process of finding an “audit committee financial expert” as defined in Regulation S-K and directors that are “independent” as that term is used in Section 10A of the Exchange Act.

Compensation Committee. We intend to establish a compensation committee of the Board. The compensation committee will review and approve our salary and benefits policies, including compensation of executive officers.

Code of Ethics

We currently do not have a Code of Ethics because we presently only have one director and one officer. We plan to adopt a Code of Ethics when the size of the Board and management increases.

Director Compensation

We did not compensate our director for the fiscal year ended June 30, 2022. Going forward, however, we intend to implement a market-based director compensation program.

Limitations on Liability

Under Delaware law, a corporation may indemnify its officers, directors, employees and agents under certain circumstances, including indemnification of such persons against liability under the Securities Act. Those circumstances include that an officer, director, employee or agent may be indemnified if the person acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was unlawful.

Article Seven of our Articles of Incorporation provides that no director shall be personally liable to the Company or the shareholders for monetary damages for any breach of fiduciary duty by such person in his or her capacity as a director. Notwithstanding the foregoing sentence, a director shall be liable to the extent provided by applicable law, (i) for breach of his or her duty of loyalty to the Company or the shareholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) pursuant to Section 174 of the Delaware General Corporation law, or (iv) for any transaction from which he or she derived an improper personal benefit. No amendment to or repeal of this provision shall apply to or have any effect on the liability or alleged liability of any director of the Company for or with respect to any acts or omissions of such director occurring prior to such amendment.

We are also permitted to apply for insurance on behalf of any director, officer, employee or other agent for liability arising out of his or her actions, whether or not the Delaware General Corporation Law would permit indemnification.

Indemnification against Public Policy

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling an issuer pursuant to the foregoing provisions, the opinion of the SEC is that such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than by a director, officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The effect of indemnification may be to limit the rights of the Company and the shareholders (through shareholders’ derivative suits on behalf of the Company) to recover monetary damages and expenses against a director for breach of fiduciary duty.

Directors and Officers of Humankind

The following table sets forth certain information as of June 30, 2022 concerning the directors and executive officers of Humankind:

Directors and Executive Officers	Position/Title	Age
Xin Sun	Chairman, Chief Financial Officer, Treasurer	56
Baosen Ma	President, Secretary, Director	54
Kai Sun	Director	51

The following is a summary of the biographical information of those directors and officers of Humankind whose biographical information does not appear above:

Xin Sun, Chairman, Chief Financial Officer, Treasurer

Mr. Sun’s biography is discussed above under Item 10. Directors, Executive Officers and Corporate Governance and incorporated herein by reference.

Baosen Ma, President, Secretary and Director

Mr. Baosen Ma graduated from China University of Political Science and Law with a major in Financial Accounting. From 1987 to 1992, he was an accountant with Harbin Keluola Solar Power Co., Ltd. Thereafter, from 1992 to 1996, he was Vice General Manager and Sales Manager for Shanghai Dahua Solar Battery Co., Ltd. From 1996 to 2004, he was the East China Manager for the Ha Yao Group Sanchine Medicine Joint-Stock Ltd. In January 2004, Mr. Ma was appointed President, Secretary and Director of Humankind.

Kai Sun, Director

Mr. Kai Sun graduated from Mu Dan Jiang University with a major in Economics. From 1993 to 1995, he was Vice Director of Mu Dan Jiang Engine Factory. Thereafter, from 1995 to 1998, he was a Director at Mu Dan Jiang Engine Factory. From 1998 to 2004, he was an Administration Director for Mu Dan Jiang Lysine Co., Ltd. Since 2004, he has been the Administration Director at Humankind. Mr. Kai Sun is the younger brother of Mr. Xin Sun, the Company’s Chairman, Chief Financial Officer, Treasurer and sole director. In January 2004, Mr. Kai Sun was appointed a director of Humankind.

Item 11. Executive Compensation.

The following Summary Compensation Table sets forth, for the years indicated, all cash compensation paid, distributed or accrued for services, including salary and bonus amounts, rendered in all capacities by our Chief Executive Officer and all other executive officers who received or are entitled to receive remuneration in excess of $100,000 during the stated periods. Mr. Xin Sun, our Chief Executive Officer and sole director, receives no additional compensation for the services he provides in his capacity as director.

SUMMARY COMPENSATION TABLE

(all figures in US Dollars)

Non-Equity

Non-qualified

Incentive

Deferred

All

Stock

Option

Plan

Compensation

Other

Salary

Bonus

Awards

Compensation

Earnings

Compensation

Total

Name and Principal Position

Year

($)

Xin Sun, Chief Executive Officer,

2022

9,016

N/A

9,016

Chief Financial Officer

2021

31,327

N/A

31,327

Employment Agreements

We have no employment agreement with our sole principal executive officer, Mr. Xin Sun.

Equity Compensation Plan Information

The following table sets forth information regarding grants of awards and outstanding equity awards to Named Executive Officer during the year ended June 30, 2022:

Grants of Plan-Based Awards

Estimated future payouts
under non-equity incentive
plan awards

Estimated future payouts
under equity incentive plan
awards

All other stock awards: Number of shares of stock or

All other option awards: Number of securities underlying

Exercise or base price of option

Grant date fair value of stock and

Name

Grant
date

Threshold($)

Target($)

Maximum($)

Threshold(#)

Target(#)

Maximum(#)

units
(#)

options
(#)

awards
($/Sh)

option
awards

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

Xin Sun, Chief Executive Officer, Chief Financial Officer

Outstanding Equity Awards at Fiscal Year-End

Option awards

Stock awards

Name

Number of securities underlying unexercised options(#) exercisable

Number of securities underlying unexercised options(#) unexercisable

Equity incentive plan awards: number of securities underlying unexercised unearned options(#)

Option exercise price($)

Option expiration date

Number of shares or units of stock that have not vested(#)

Market value of shares or units of stock that have not vested(#)

Equity incentive plan awards: number of unearned shares, units or other rights that have not vested(#)

Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested($)

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

Xin Sun, Chief Executive Officer, Chief Financial Officer

Option Exercises and Stock Vested

Option awards

Stock awards

Name

Number of shares acquired on exercise (#)

Value realized on exercise ($)

Number of shares acquired on vesting (#)

Value realized on vesting ($)

(a)

(b)

(c)

(d)

(e)

Xin Sun, Chief Executive Officer, Chief Financial Officer

Director’s and Officer’s Liability Insurance

We currently do not have insurance insuring directors and officers against liability; however, we are in the process of investigating the availability of such insurance.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The following table sets forth certain information with respect to the beneficial ownership of our voting securities by (i) any person or group owning more than five percent of any class of voting securities, (ii) our director, (iii) our chief executive officer and president and (iv) all executive officers and directors as a group as of September 15, 2022.

The address of the beneficial owner listed below is Harbin Humankind Biology Technology Co. Limited, 3199-1 Longxiang Road, Songbei District, Harbin, Heilongjiang Province, PRC.

		Amount and Nature of
Title of Class	Name	Beneficial Owner		Percent of Class ⁽¹⁾

Common Stock	Xin Sun, Chairman, Chief Executive Officer, Chief Financial Officer and Treasurer		20,507,188		31.3	%

Common Stock	All officers and directors as a group (1 person)		20,507,188		31.3	%

⁽¹⁾

Based on 65,539,737 total issued and outstanding shares of the Company as of September 15, 2022. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Shares of common stock subject to options or warrants currently exercisable or convertible, or exercisable or convertible within 60 days of September 15, 2022 are deemed outstanding for computing the percentage of the person holding such option or warrant but are not deemed outstanding for computing the percentage of any other person.

Mr. Xin Sun has the sole power to vote and dispose all shares of common stock listed opposite his name. Mr. Sun did not and does not own any options or convertible securities.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

The Company received temporary short-term loans from its majority owner and our sole director and principal executive officer, Mr. Xin Sun, a PRC citizen. These loans are unsecured and non-interest bearing, and have no fixed terms of repayment; therefore, they are deemed payable on demand. Cash flows classified as due to majority owner are classified as cash flows from financing activities.

The amounts due to related parties are used to support the normal business operation of the Company, the related cash flows are classified as operating activities. The total amounts due to Mr. Sun were $6,724,850 and $8,043,544 as of June 30, 2022 and June 30, 2021, respectively.

There were no interested imputed on the loans for the fiscal years 2022 and 2021, respectively.

Item 14. Principal Accountant Fees and Services.

We were billed by CENTURION ZD CPA & CO., our independent public accountants for the following professional services it performed for us during the fiscal year ended June 30, 2022 and 2021, as set forth in the table below:

			Audit-
	Audit		Related		Tax		Other
	Fees		Fees		Fees		Fees
2022	$	140,000		-		-		-

2021	$	140,000		-		-		-

Audit Fees — This category includes the audit of our annual financial statements and services that are normally provided by the independent auditors in connection with engagements for those fiscal years.

Audit-Related Fees — This category consists of assurance and related services by the independent auditors that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under “Audit Fees”.

Tax Fees — This category consists of professional services rendered by the Company’s independent registered public accounting firm for tax compliance and tax advice. The services for the fees disclosed under this category include tax return preparation and technical tax advice.

All Other Fees — This category consists of fees for other miscellaneous items.

Pre-Approval Policies and Procedures

All of the services rendered to us by our independent registered public accountants were pre-approved by the Board.

PART IV

Item 15. Exhibits and Financial Statement Schedules

Exhibit		Filed
Index	Description of Document	Herewith	Incorporated by Reference To:

3.1	Articles of Incorporation.		Exhibit 3.1 of the Company’s Registration Statement on Form 10-SB filed with the SEC on December 1, 2004.

3.2	By-laws.		Exhibits 3.2 of the Company’s Registration Statement on Form 10-SB filed with the SEC on December 1, 2004.

3.3	Certificate of Amendment, dated May 11, 2005.		Exhibits 3.3 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

3.4	Certificate of Amendment, dated November 12, 2008.		Exhibit 3.4 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

3.5	Certificate of Amendment, dated February 11, 2009.		Exhibit 3.5 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

4.1	Specimen of Common Stock Certificate		Exhibit 4.1 of the Company’s Annual Report on Form 10-K filed with the SEC on September 29, 2014.

4.2	Description of Securities Registered Pursuant to Section 12 of the Exchange Act.	X

10.1	English Translation of Land Use Agreement, dated June 7, 2004, between Harbin Humankind Biology Technology Co. Limited and Harbin City, Daochu District, Songbei Township, Jinxin Village.		Exhibit 10.3 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

10.2	English Translation of Cooperative Agreement, dated September 17, 2008, between Harbin Humankind Biology Technology Co. Limited and the Commercial Bureau of Qing’an County.		Exhibit 10.5 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

10.3	English Translation of Land Purchase Agreement, dated July 7, 2009, between Harbin Humankind Biology Technology Co. Limited and Harbin Songbei District Construction and Development Management Committee.		Exhibit 10.6 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

10.4	English Translation of Technology Transfer Agreement, dated October 12, 2007, between Harbin Humankind Biology Technology Co. Limited and Beijing Jindelikang Bio- Technology Co., Ltd.		Exhibit 10.7 of the Company’s Annual Report on Form 10-K/A filed with the SEC on November 16, 2010.

10.5	English Translation of Health Food Technology Transfer Agreement, dated January 18, 2013 by and between Harbin Humankind Biology Technology Co., Limited and Guangzhou Aoda Biology Beauty Healthy Technology Co., Ltd.	Exhibit 10.22 of the Company’s Annual Report on Form 10-K filed with the SEC on October 15, 2013.

10.6	English Translation of Stock Transfer Agreement, dated April 10, 2013, by and between Stockholder of Heilongjiang Huimeijia Pharmaceuticals Co., Ltd, Liyuan Sun and Harbin Humankind Biology Technology Co., Limited. and its addendum dated June 18, 2013.	Exhibit 10.23 of the Company’s Annual Report on Form 10-K filed with the SEC on October 15, 2013.

10.7	English Translation of Stock Transfer Agreement, dated April 10, 2013, by and between Stockholder of Heilongjiang Huimeijia Pharmaceuticals Co., Ltd, Wenbin Zhang and Harbin Humankind Biology Technology Co., Limited. and its addendum dated June 18, 2013.	Exhibit 10.24 of the Company’s Annual Report on Form 10-K filed with the SEC on October 15, 2013.

10.8	English Translation of Stock Transfer Agreement dated December 24, 2014, by and among Harbin Humankind Biology Technology Co., Limited., Xin Sun, Harbin Huimeijia Medicine Company, and Xiuzheng Pharmaceutical Group Co., Ltd.	Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on December 31, 2014.

10.9	English Translation of the Supplementary Agreement dated February 9, 2015, by and among Harbin Humankind Biology Technology Co., Limited., Xin Sun, Harbin Huimeijia Medicine Company, and Xiuzheng Pharmaceutical Group Co., Ltd.	Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed with the SEC on February 13, 2015.

10.10	China Health Industries Holdings, Inc. 2015 Equity Incentive Plan, effective as of March 27, 2015	Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on April 2, 2015.

10.11	Form of the Restricted Stock Award Agreement	Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on April 2, 2015.

21.1	List of Subsidiaries.		Exhibit 21.1 of the Company’s Annual Report on Form 10-K filed with the SEC on September 28, 2018.

23.1	Consent of the Independent Publicly Registered Accountants	x

31.1	Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	x

31.2	Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	x

32.1	Certification pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.	x

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema Document.

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CHINA HEALTH INDUSTRIES HOLDINGS, INC.

	By:	/s/ Xin Sun
Date: September 15, 2022	Name:	Xin Sun
	Title:	Chief Executive Officer (principal executive officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By:	/s/ Xin Sun
Name:	Xin Sun
Title:	Chief Executive Officer (principal executive officer),
	Chief Financial Officer (principal financial officer and principal accounting officer) and sole director

Date: September 15, 2022

EX-4.2 2 f10k2022ex4-2_chinahealth.htm DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE EXCHANGE ACT

Exhibit 4.2

DESCRIPTION OF SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE

SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

As of June 30, 2022, China Health Industries Holdings, Inc. (the “Company,” “we,” “us,” and “our” or “CHHE”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which is our common stock, par value $0.0001 per share (the “common stock”).

We are incorporated in the State of Delaware. The rights of our shareholders are generally covered by Delaware law and our certificate of incorporation and by-laws. The terms of our common stock are therefore subject to Delaware law, including the Delaware General Corporation Law. The following is a summary of the material terms of our common stock. This summary does not purport to be exhaustive and is qualified in its entirety by reference to our certificate of incorporation, bylaws, to the applicable provisions of Delaware law.

As of September 15, 2022, there were 65,539,737 shares of our common stock issued and outstanding, held by approximately 502 shareholders of record.

Our common stock is currently traded on the OTC Markets QB Tier under the symbol “CHHE.”

Authorized Shares of Common Stock. We currently have authorized 100,000,000 shares of common stock.

Voting. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the shareholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election.

Dividends. The holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.

Liquidation. In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities.

Rights and Preferences. The holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock.

Fully Paid and Nonassessable. All of our issued and outstanding shares of common stock are fully paid and nonassessable.

Direct Transfer LLC, 1981 Murray Holladay Road, Suite 100, Salt Lake City, UT 84117, is the registrar and transfer agent of our common stock.

Delaware Anti-Takeover Provisions

We are subject to Section 203 of the Delaware General Corporation Law, which prohibits a publicly-held Delaware corporation from engaging in a “business combination,” except under certain circumstances, with an “interested shareholder” for a period of three years following the date such person became an “interested shareholder” unless:

●

before such person became an interested shareholder, the board of directors of the corporation approved either the business combination or the transaction that resulted in the interested shareholder becoming an interested shareholder;

●

upon the consummation of the transaction that resulted in the interested shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares held by directors who also are officers of the corporation and shares held by employee stock plans; or

●

at or following the time such person became an interested shareholder, the business combination is approved by the board of directors of the corporation authorized at a meeting of shareholders by the affirmative vote of the holders of two-thirds (2/3) of the outstanding voting stock of the corporation which is not owned by the interested shareholder.

For purposes of Section 203, the term “interested shareholder” generally is defined as a person who, together with affiliates and associates, owns, or, within the three years prior to the determination of interested shareholder status, owned, 15% or more of a corporation’s outstanding voting stock. The term “business combination” includes mergers, asset or stock sales and other similar transactions resulting in a financial benefit to an interested shareholder. Section 203 makes it more difficult for an “interested shareholder” to effect various business combinations with a corporation for a three-year period. The existence of this provision would be expected to have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by shareholders. Presently, we have not opted out of this provision.

EX-23.1 3 f10k2022ex23-1_chinahealth.htm CONSENT OF THE INDEPENDENT PUBLICLY REGISTERED ACCOUNTANTS

Exhibit 23.1

中正達會計師事務所有限公司

Centurion ZD CPA & Co.

Certified Public Accountants (Practising)

Unit 1304, 13/F., Two Harbourfront, 22 Tak Fung Street, Hunghom, Hong Kong

香港紅磡德豐街22號海濱廣場二期13樓1304室

Tel : (852) 2126 2388 Fax: (852) 2122 9078

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S¬8 (File No. 333-214487) of China Health Industries Holdings, Inc. of our report dated September 15, 2022, relating to the consolidated financial statements which appears in this annual report on Form 10-K for the fiscal year ended June 30, 2022 filed with the Securities and Exchange Commission.

/s/ Centurion ZD CPA & Co.
Hong Kong, China
September 15, 2022

EX-31.1 4 f10k2022ex31-1_chinahealth.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Xin Sun, certify that:

1.	I have reviewed this Form 10-K of China Health Industries Holdings, Inc.;

Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

3.	Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: September 15, 2022	/s/ Xin Sun
	Xin Sun
	Chief Executive Officer (principal executive officer)

EX-31.2 5 f10k2022ex31-2_chinahealth.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Xin Sun, certify that:

1.	I have reviewed this Form 10-K of China Health Industries Holdings, Inc.;

3.	Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: September 15, 2022	/s/ Xin Sun
	Xin Sun
	Chief Financial Officer (principal financial officer and principal accounting officer)

EX-32.1 6 f10k2022ex32-1_chinahealth.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of China Health Industries Holdings, Inc. (the “Company”) on Form 10-K for the year ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Xin Sun, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: September 15, 2022	/s/ Xin Sun
	Xin Sun
	Chief Executive Officer and Chief Financial Officer
	(principal executive officer, principal financial officer, and principal accounting officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

GRAPHIC 7 img_001.jpg GRAPHIC begin 644 img_001.jpg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

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Jun. 30, 2022	Sep. 15, 2022	Dec. 31, 2021
Document Information Line Items
Entity Registrant Name	CHINA HEALTH INDUSTRIES HOLDINGS, INC.
Document Type	10-K
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		65,539,737
Entity Public Float			$ 5,436,329
Amendment Flag	false
Entity Central Index Key	0001309057
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-51060
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-0827216
Entity Address, Address Line One	3199-1 Longxiang Road
Entity Address, Address Line Two	Songbei District
Entity Address, City or Town	Harbin City
Entity Address, Country	CN
Entity Address, Postal Zip Code	150028
Entity Interactive Data Current	Yes
Auditor Firm ID	2769
Auditor Name	Centurion ZD CPA & Co.
Auditor Location	Hong Kong, China
City Area Code	86-451-
Local Phone Number	88100688

XML 16 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Audited) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Current assets
Cash and cash equivalents	$ 44,789,999	$ 44,346,744
Accounts receivable, net	9,567	2,346,867
Inventory	521,229	761,639
Other receivables, net	31,778	32,850
Advances to suppliers	214,915	218,307
Prepayments	30,004	24,466
Total current assets	45,597,492	47,730,873
Property, plants and equipment, net	3,158,021	3,629,905
Intangible assets, net	1,412,603	1,963,516
Construction in progress	579,402	560,910
Deferred tax assets		2,933
Prepayments – Non-Current
Total assets	50,747,518	53,888,137
Current liabilities
Accounts payable and accrued expenses	334,972	406,821
Other payables	82,323	81,449
Advances from customers	472,307	150,504
Related party debts	6,759,761	8,079,761
Wages payable	162,431	218,602
Taxes payable	133,005	176,359
Total current liabilities	7,944,799	9,113,496
Equity
Common stock, ($0.0001 par value per share, 300,000,000 shares authorized, and 65,539,737 shares issued and outstanding as of June 30, 2022 and June 30, 2021, respectively)	6,554	6,554
Additional paid-in capital	521,987	521,987
Accumulated other comprehensive income	538,820	2,156,792
Statutory reserves	38,679	38,679
Retained earnings	41,696,679	42,050,629
Total stockholders’ equity	42,802,719	44,774,641
Total equity	42,802,719	44,774,641
Total liabilities and equity	$ 50,747,518	$ 53,888,137

XML 17 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Audited) (Parentheticals) - $ / shares	Jun. 30, 2022	Jun. 30, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	65,539,737	65,539,737
Common stock, shares outstanding	65,539,737	65,539,737

XML 18 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Income (Audited) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
REVENUE	$ 267	$ 6,492,720
COST OF GOODS SOLD	1,748	2,850,729
GROSS PROFIT/(LOSS)	(1,481)	3,641,991
OPERATING EXPENSES
Selling, general and administrative expenses	934,927	1,168,385
Depreciation and amortization expenses	711,515	609,698
Total operating expenses	1,646,442	1,778,083
(LOSS)/INCOME FROM OPERATIONS	(1,647,923)	1,863,908
OTHER INCOME/(EXPENSES)
Interest income	157,860	137,485
Interest expense
Other income, net	1,139,746	20,972
Bank charges	(699)	(782)
Total other income, net	1,296,907	157,675
(LOSS)/INCOME BEFORE INCOME TAXES	(351,016)	2,021,583
Provision for income taxes	(2,934)	(730,461)
NET (LOSS)/INCOME	(353,950)	1,291,122
Foreign currency translation adjustment	(1,617,972)	3,815,533
COMPREHENSIVE (LOSS)/INCOME	$ (1,971,922)	$ 5,106,655
Net (loss)/income per share:
Net (loss)/income per share Basic & diluted (in Dollars per share)	$ (0.0054)	$ 0.0197
Weighted average shares outstanding:
Basic & diluted (in Shares)	65,539,737	65,539,737

XML 19 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Income (Audited) (Parentheticals) - $ / shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net (loss)/income per share Basic & diluted (in Dollars per share)	$ (0.0054)	$ 0.0197
Basic & diluted (in Shares)	65,539,737	65,539,737

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

XML 20 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders’ Equity (Audited) - USD ($)	Common Shares	Additional Paid-in Capital	Retained Earnings	Statutory Reserve	Accumulated Other Comprehensive Income (loss)	Total Stockholders’ Equity	Total
Balance at Jun. 30, 2020	$ 6,554	$ 521,987	$ 40,759,507	$ 38,679	$ (1,658,741)	$ 39,667,986	$ 39,667,986
Balance (in Shares) at Jun. 30, 2020	65,539,737
Net income (loss)			1,291,122			1,291,122	1,291,122
Other comprehensive income (loss) - Translation adjustment					3,815,533	3,815,533	3,815,533
Balance at Jun. 30, 2021	$ 6,554	521,987	42,050,629	38,679	2,156,792	44,774,641	44,774,641
Balance (in Shares) at Jun. 30, 2021	65,539,737
Net income (loss)			(353,950)			(353,950)	(353,950)
Other comprehensive income (loss) - Translation adjustment					(1,617,972)	(1,617,972)	(1,617,972)
Balance at Jun. 30, 2022	$ 6,554	$ 521,987	$ 41,696,679	$ 38,679	$ 538,820	$ 42,802,719	$ 42,802,719
Balance (in Shares) at Jun. 30, 2022	65,539,737

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 21 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Audited) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flows from Operating Activities
Net (loss)/income attributable to China Health Industries Holdings	$ (353,950)	$ 1,291,122
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expenses	830,545	878,794
Provision for doubtful accounts	(9,556)	(13,666)
Deferred taxes gain	2,860	3,334
Changes in operating assets and liabilities:
Inventory	215,391	118,743
Accounts receivable	2,288,077	2,667,083
Other receivables	(114)	2,383
Advance to suppliers and prepaid expenses	(11,024)	26,980
Accounts payables and accrued expenses	(57,912)	(36,554)
Advance from customers and other payables	358,179	12,368
Amounts due to related parties	(1,057,059)	961,538
Wages payable	(48,844)	(81,300)
Taxes payable	(40,867)	(274,131)
Net cash provided by operating activities	2,115,726	5,556,694
Cash Flows from Investing Activities
Withdraw of short term investment
Purchase of property, plant and equipment		(8,582)
Expenditure in construction in progress		(5,073)
Disposal of property, plant and equipment
Proceeds from short term investment
Proceeds from disposal of subsidiary
Net cash (used in)/provided by investing activities		(13,655)
Cash Flows from Financing Activities
Proceed from related party debts
Payment of short term loans
Net cash (used in)/provided by financing activities
Effect of exchange rates change on cash and cash equivalents	(1,672,471)	2,731,231
Net increase in cash and cash equivalents	443,255	8,274,270
Cash and cash equivalents, beginning of period	44,346,744	36,072,474
Cash and cash equivalents, end of period	44,789,999	44,346,744
Supplemental disclosure of cash flow information
Interest paid
Taxes paid		973,420
Non-cash activities:
Loan from related party for the construction of a facility		$ 618,827

XML 22 R8.htm IDEA: XBRL DOCUMENT

Organization and Business Background

12 Months Ended

Jun. 30, 2022

Organization and Business Background [Abstract]

ORGANIZATION AND BUSINESS BACKGROUND

Note 1 - ORGANIZATION AND BUSINESS BACKGROUND

China Health Industries Holdings, Inc. (“China Health US”) was incorporated in the State of Arizona on July 11, 1996 and was the successor of the business known as Arizona Mist, Inc. which began in 1989. On May 9, 2005, it entered into a stock purchase agreement and Share Exchange (effecting a reverse merger) with Edmonds 6, Inc. (“Edmonds 6”), a Delaware corporation, and changed its name to Universal Fog, Inc. Pursuant to this agreement, Universal Fog, Inc. (which has been in continuous operation since 1996) became a wholly-owned subsidiary of Edmonds 6.

On December 31, 2008, China Health HK entered into a reverse merger with Universal Fog, Inc., a U.S. publicly traded shell company (the “Transaction”). China Health HK is the acquirer in the Transaction, and the Transaction has been treated as a recapitalization of China Health US. After the Transaction and a 20:1 reverse stock split, Mr. Xin Sun owned 61,203,088 shares of common stock, representing 98.3% of the 62,234,737 total outstanding shares of common stock of China Health US. On April 7, 2009, Mr. Sun transferred 28,200,000 shares of common stock to 296 individuals, leaving him with 33,003,088 shares of common stock of China Health US, or approximately 53.03% of the total outstanding shares of common stock. Universal Fog, Inc. changed its name to China Health Industries Holdings, Inc. on February 19, 2009.

On November 22, 2013, Humankind completed the acquisition of Heilongjiang Huimeijia Pharmaceutical Co., Ltd. (“HLJ Huimeijia”) for a total purchase price of $16,339,869 (RMB100,000,000). HLJ Huimeijia was founded on October 30, 2003, and is engaged in the manufacturing and distribution of tincture, ointments, rubber paste (including hormones), topical solution, suppositories, liniment (including traditional Chinese medicine extractions), enemas and oral liquids. HLJ Huimeijia’s predecessor is Heilongjiang Xue Du Pharmaceutical Co., Ltd., which has established its brand name in the market through its supply of high quality medical products. HLJ Huimeijia is categorized as a “high and new technology” enterprise by the Science Technology Department in Heilongjiang Province. HLJ Huimeijia has 21 products which have been approved by, and have received approval numbers issued by, the National Medical Products Administration (the “NMPA”). In addition, HLJ Huimeijia is the holder of one patent for utility models, five patents for external design and three trademarks in China, including the Chinese brand name of “Xue Du” which has an established reputation among customers in northeastern China.

China Health US, China Health HK, Humankind and HLJ Huimeijia are collectively referred herein to as the “Company.”

As of June 30, 2022, the Company’s corporate structure was as follows:

XML 23 R9.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

12 Months Ended

Jun. 30, 2022

Organization and Business Background [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

Note 2 - SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Principles of Consolidation

Segment Reporting

Fair Value of Financial Instruments

Fair Value Measurements

Level 1 – observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets.

Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.).

Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments).

Foreign Currency Translation and Transaction

Statement of Cash Flows

Use of Estimates and Assumptions

Cash and Cash Equivalents

Accounts Receivable

Advance to Suppliers

Inventory

Inventory consists of raw materials, work in progress and finished goods of manufactured products.

Impairment of Long-Lived Assets

Property, Plant and Equipment

Depreciation is calculated on a straight-line basis over the estimated useful life of the assets. The depreciable lives applied are:

Building, Warehouse and Improvements		20 to 30 years
Office Equipment		3 to 7 years
Vehicles		5 to15 years
Machinery and Equipment		7 to 15 years

Intangible Assets

Construction in Progress

Revenue Recognition

Cost of Goods Sold

Income Taxes

Enterprise Income Tax

Value Added Tax

Sales-Related Taxes

Concentrations of Business and Credit Risks

Earnings Per Share

FASB ASC Topic 260, “Earnings Per Share,” requires a reconciliation of the numerator and denominator of the basic and diluted earnings per share (EPS) computations.

Recent Accounting Pronouncements

XML 24 R10.htm IDEA: XBRL DOCUMENT

Assets Sale

12 Months Ended

Jun. 30, 2022

Discontinued Operations and Disposal Groups [Abstract]

ASSETS SALE

NOTE 3 - ASSETS SALE

On October 12, 2016, the four parties agreed to rescind the Supplementary Agreement and entered into a new supplementary agreement (the “New Supplementary Agreement”), pursuant to which the four parties agreed to execute the transfer of the equity interests based on the Original Agreement and the Equity Holders agreed to sell their respective equity interests in Huimeijia to Xiuzheng Pharmacy. The transfer of 100% of the equity interests of Huimeijia to the Buyer was for a total cash consideration of RMB 8,000,000 (approximately $1,306,186) (the “Purchase Price”) to the Equity Holders. 40% of the Purchase Price was due within 10 business days after the signing of the New Supplementary Agreement; 40% of the Purchase Price was due within 10 business days after the completion of the changes in business registration described in the Original Agreement and Xiuzheng Pharmacy obtaining documents evidencing its ownership on Huimeijia; 15% of the Purchase Price is due within 10 business days after the transfer of all of the Assets is approved by Heilongjiang FDA; and 5% of the Purchase Price is due within 10 business days after all of the Assets have been transferred to Xiuzheng Pharmacy or its designee and Humankind and Mr. Xin Sun have instructed Xiuzheng Pharmacy to complete three-batches production of all forms of the drugs included in the Assets. As of the date of this report, 80% of the Purchase Price has been paid, the Company has completed changes in its business registration, and Xiuzheng Pharmacy has obtained a business license issued by the local State Administration of Industry and Commerce in Harbin (“Harbin SAIC”) to Huimeijia, in which the ownership of Huimeijia has been recorded as held by Xiuzheng Pharmacy, with Harbin SAIC and the legal representative (a person that is authorized to take most of the corporate actions on behalf of a company under the corporate laws in China) of Huimeijia has been appointed by the Buyer.

XML 25 R11.htm IDEA: XBRL DOCUMENT

Accounts Receivable

12 Months Ended

Jun. 30, 2022

Accounts Receivable [Abstract]

ACCOUNTS RECEIVABLE

NOTE 4 - ACCOUNTS RECEIVABLE

The Company’s accounts receivable amounted to $9,567 and $2,346,867 net of allowance for doubtful accounts amounting to $48,769 and $60,394 as of June 30, 2022 and 2021, respectively.

XML 26 R12.htm IDEA: XBRL DOCUMENT

Inventories

12 Months Ended

Jun. 30, 2022

Inventories [Abstract]

INVENTORIES

NOTE 5 - INVENTORIES

Inventory consists of following:

	June 30, 2022		June 30, 2021
Raw Materials	$	213,055	$	251,989
Supplies and Packing Materials		90,303		93,452
Work-in-Progress		82,412		273,924
Finished Goods		135,459		142,274
Total	$	521,229	$	761,639

XML 27 R13.htm IDEA: XBRL DOCUMENT

Construction in Progress

12 Months Ended

Jun. 30, 2022

Construction In Progress Disclosure Abstract

CONSTRUCTION IN PROGRESS

NOTE 6 - CONSTRUCTION IN PROGRESS

Construction in progress consisted of the following:

	June 30, 2022		June 30, 2021
Plant - HLJ Huimeijia	$	579,402	$	560,910
Total	$	579,402	$	560,910

XML 28 R14.htm IDEA: XBRL DOCUMENT

Property, Plants and Equipment

12 Months Ended

Jun. 30, 2022

Property, Plants and Equipment [Abstract]

PROPERTY, PLANTS AND EQUIPMENT

NOTE 7 - PROPERTY, PLANTS AND EQUIPMENT

Property, plants and equipment consisted of the following:

	June 30, 2022			June 30, 2021
Building, Warehouses and Improvements	$	3,946,492		$	4,094,105
Machinery and Equipment		1,832,446			1,900,986
Office Equipment		78,360			81,291
Vehicles		217,808			225,955
Others		962,667			998,674
Less Accumulated Depreciation		(3,879,752	)		(3,671,106	)
Total	$	3,158,021		$	3,629,905

XML 29 R15.htm IDEA: XBRL DOCUMENT

Intangible Assets

12 Months Ended

Jun. 30, 2022

Intangible Assets [Abstract]

INTANGIBLE ASSETS

NOTE 8 - INTANGIBLE ASSETS

The following is a summary of intangible assets:

	June 30, 2022			June 30, 2021
Land Use Rights – Humankind	$	946,237		$	981,630
Health Supplement Product Patents – Humankind		4,478,882			4,646,408
Pharmaceutical Patents - HLJ Huimeijia		390,285			404,883
Land Use Rights - HLJ Huimeijia		647,211			671,419
Less: Accumulated Amortization		(5,050,012	)		(4,740,824	)
Intangible Assets, net, Held for Continuing Operations	$	1,412,603		$	1,963,516

Amortization expense charged to operations was $485,625 and $485,625 for the years ended June 30, 2022 and 2021, respectively.

XML 30 R16.htm IDEA: XBRL DOCUMENT

Related Party Debts

12 Months Ended

Jun. 30, 2022

RELATED PARTY DEBTS

NOTE 9 - RELATED PARTY DEBTS

Related party debts, which represent temporary short-term loans from Mr. Xin Sun and Mr. Kai Sun consisted of the following:

	June 30, 2022		June 30, 2021
Mr. Xin Sun	$	6,724,850	$	8,043,544
Mr. Kai Sun		34,911		36,217
Related Party Debts, Held for Continuing Operations	$	6,759,761	$	8,079,761

XML 31 R17.htm IDEA: XBRL DOCUMENT

Income Taxes

12 Months Ended

Jun. 30, 2022

Income Taxes [Abstract]

INCOME TAXES

NOTE 10 - INCOME TAXES

(a) Corporate income taxes

United States

Hong Kong

People’s Republic of China

The provision for income taxes consisted of the following for the years ended June 30, 2022 and 2021:

As of June 30, 2022, and 2021, taxes payable consists of:

	June 30, 2022		June 30, 2021
Income tax payable	$	23,839	$	28,895
Value-added tax payable		29,835		34,697
Other taxes payable		79,331		112,767
Total	$	133,005	$	176,359

A reconciliation between the Company’s actual provision for income taxes and the provision at the statutory rate is as follows:

	June 30, 2022			June 30, 2021
Pre-tax book income	$	(351,016	)	$	2,021,583
Federal statutory rate		21	%		21	%
Income tax computed at U.S. federal statutory rate		(73,714	)		424,532
Non-deductible staff welfare		-			-
Foreign rate differential		(7,874	)		392,435
Change in valuation allowance		84,522			(86,506	)
Total provision for income taxes	$	2,934		$	730,461

The Company’s effective tax rate was 0.8% and 36.1% for the years ended June 30, 2022 and 2021, respectively.

The provision for income taxes on income consists of the following for the years ended June 30, 2022 and 2021:

Provision for income taxes consisted of:

	For the Years Ended
	June 30,
	2022		2021
Current provision:
Domestic	$	-	$	-
Foreign		-		727,588
Total current provision		-		727,588
Deferred provision:
Domestic		-		-
Foreign		2,934		2,873
Total deferred provision		2,934		2,873
Total provision for income taxes	$	2,934	$	730,461

Significant components of deferred tax assets were as follows:

	June 30, 2022			June 30, 2021
Deferred tax assets
Net operating loss carry forward	$	1,096,936		$	1,018,253
Allowance for doubtful accounts		(12,192	)		(15,100	)
Valuation allowance		(1,084,744	)		(1,000,220	)
Deferred tax assets, net	$	-		$	2,933

(b) Uncertain tax positions

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 32 R18.htm IDEA: XBRL DOCUMENT

Earnings Per Share

12 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

EARNINGS PER SHARE

NOTE 11 - EARNINGS PER SHARE

FASB ASC Topic 260, Earnings Per Share, requires a reconciliation of the numerator and denominator of the basic and diluted earnings per share (EPS) computations.

For the years ended June 30, 2022, and 2021, the Company does not have potential dilutive shares. The following table sets forth the computation of basic and diluted net income per share:

	For the Years Ended
	June 30,			June 30,
	2022			2021
Net income/(loss)	$	(353,950	)	$	1,291,122

Net income/(loss) per share:

Net income (loss) per share Basic & diluted	$	(0.0054	)	$	0.0197

Weighted average shares outstanding:
Basic & diluted		65,539,737			65,539,737

XML 33 R19.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

12 Months Ended

Jun. 30, 2022

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 12 - COMMITMENTS AND CONTINGENCIES

The Company’s assets are located in the PRC and revenues are derived from operations in the PRC.

The Company had no rental commitment as of June 30, 2022.

XML 34 R20.htm IDEA: XBRL DOCUMENT

Major Suppliers and Customers

12 Months Ended

Jun. 30, 2022

Major Suppliers and Customers [Abstract]

MAJOR SUPPLIERS AND CUSTOMERS

NOTE 13 - MAJOR SUPPLIERS AND CUSTOMERS

XML 35 R21.htm IDEA: XBRL DOCUMENT

Segment Reporting

12 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

SEGMENT REPORTING

NOTE 14 - SEGMENT REPORTING

The following tables present summary information by segment for the years ended June 30, 2022 and 2021, respectively:

				For the Year Ended June 30, 2022														For the Year Ended June 30, 2021
	HLJ									Consolidated			HLJ								Consolidated
	Huimeijia			Humankind			Others			operations			Huimeijia			Humankind		Others			operations
Revenues	$	267		$	-		$	-		$	267		$	16,754		$	6,475,966	$	-		$	6,492,720
Cost of revenues		1,748			-			-			1,748			96,316			2,754,413		-			2,850,729
Gross profit (loss)		(1,481	)		-			-			(1,481	)		(79,562	)		3,721,553		-			3,641,991
Interest income		322			157,536			2			157,860			9			137,468		8			137,485
Interest expense		-			-			-			-			-			-		-			-
Depreciation and amortization		60,962			650,553			-			711,515			62,239			547,459		-			609,698
Income tax		-			2,934			-			2,934			-			730,461		-			730,461
Net income (loss)		509,990			(637,666	)		(226,274	)		(353,950	)		(386,910	)		1,865,983		(187,951	)		1,291,122
Total capital expenditures		-			-			-			-			5,074			8,582		-			13,656
Total assets	$	2,994,826		$	47,724,803		$	27,889		$	50,747,518		$	3,453,342		$	50,347,870	$	86,925		$	53,888,137

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

XML 36 R22.htm IDEA: XBRL DOCUMENT

Subsequent Events

12 Months Ended

Jun. 30, 2022

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 15 - SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined that there are no additional items required to disclose.

XML 37 R23.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)	12 Months Ended
Accounting Policies, by Policy (Policies)	Jun. 30, 2022
Organization and Business Background [Abstract]
Basis of Presentation	Basis of Presentation This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles in the United States (“US GAAP”) and have been consistently applied in the preparation of the consolidated financial statements.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include China Health US and its four subsidiary companies, including China Health HK, Humankind and HLJ Huimeijia. All significant intercompany balances and transactions have been eliminated in consolidation and combination. On November 22, 2013, China Health US, through its wholly owned subsidiary Humankind, completed the acquisition of HLJ Huimeijia. HLJ Huimeijia and Humankind are under the common control of Mr. Xin Sun, the CEO of the Company before and after the date of transfer. Humankind’s accounting policy adopted the guidance in ASC 805-50-05-5 for the transfer of net assets between entities under common control to apply a method similar to the pooling-of-interests’ method. Under this method, the financial statements of Humankind shall report results of operations for the period in which the transfer occurs as though the transfer of net assets had occurred at the beginning of the period. Results of operations for that period will thus comprise both those of the previously separate entities combined from the beginning of the period to the date the transfer is completed and those of the combined operations from that date to the end of the period. Similarly, Humankind shall present the statements of financial position and other financial information as of the beginning of the period as though the assets and liabilities had been transferred at that date. Financial statements and financial information of Humankind presented for prior years also shall be retrospectively adjusted to furnish comparative information.
Segment Reporting	Segment Reporting FASB ASC Topic 280, “Segment Reporting,” established standards for reporting information about operating segments on a basis consistent with the Company’s internal organizational structure as well as information about geographical areas, business segments and major customers in financial statements for details on the Company’s business segments. The Company has three reportable operating segments: Humankind, HLJ Huimeijia and Others. The segments are grouped based on the types of products provided.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The provisions of accounting guidance, FASB ASC Topic 820 that applies to the Company requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.
Fair Value Measurements	Fair Value Measurements FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” clarifies the definition of fair value for financial reporting, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements. Various inputs are considered when determining the fair value of the Company’s debt. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below. Level 1 – observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets. Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.). Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments). The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. The Company had no financial assets or liabilities carried and measured on a recurring basis during the reporting periods. The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment.
Foreign Currency Translation and Transaction	Foreign Currency Translation and Transaction Humankind, Huimeijia and HLJ Huimeijia maintain their books and accounting records in PRC currency “Renminbi” (“RMB”), which has been determined as the functional currency. The functional currency of China Health HK is the Hong Kong Dollar (“HKD”). Transactions denominated in currencies other than the functional currencies are recorded at the exchange rates prevailing on the date of the transactions, as quoted by the Federal Reserve Board. Foreign currency exchange gains and losses resulting from these transactions are included in operations. Humankind, Huimeijia, HLJ Huimeijia and China Health Hong Kong’s financial statements are translated into the reporting currency, the United States Dollar (“USD”). Assets and liabilities of the above entities are translated at the prevailing exchange rate at each reporting period end date. Contributed capital accounts are translated using the historical rate of exchange when capital is injected. Income and expense accounts are translated at the average rate of exchange during the reporting period. Translation adjustments resulting from the translation of these financial statements are reflected as accumulated other comprehensive income in shareholders’ equity and non-controlling interests. For the purpose of presenting these financial statements, the Company’s assets and liabilities with functional currency of HKD are expressed in USD at the exchange rate on the balance sheet date, which was 7.8472 and 7.7658 as of June 30, 2022 and June 30, 2021, respectively; stockholder’s equity accounts are translated at historical rates, and income and expense items are translated at the weighted average exchange rates during the year, which was 7.8049 and 7.7563 for the years ended June 30, 2022 and 2021, respectively. For Renminbi currency, the Company’s assets and liabilities are expressed in USD at the exchange rate on the balance sheet date, which was 6.6981 and 6.4566 as of June 30, 2022 and June 30, 2021, respectively; stockholder’s equity accounts are translated at historical rates, and income and expense items are translated at the weighted average exchange rates during the year, which was 6.4554 and 6.6221 for the years ended June 30, 2022 and 2021, respectively.
Statement of Cash Flows	Statement of Cash Flows In accordance with Statement FASB ASC Topic 230, “Statement of Cash Flows,” cash flow from the Company’s operations is calculated based upon the local currencies and translated to the reporting currency using an average foreign exchange rate for the reporting period. As a result, amounts related to assets and liabilities reported in the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet.
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and judgments on historical experience and on various other assumptions and information that are believed to be reasonable under the circumstances. Estimates and assumptions of future events and their effects cannot be perceived with certainty and, accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Significant estimates and assumptions by management include, among others; useful lives of long-lived assets and intangible assets, valuation of inventory, accounts receivable and notes receivable, impairment analysis of long-lived assets, construction in progress, intangible assets and deferred taxes. While the Company believes that the estimates and assumptions used in the preparation of the financial statements are appropriate, actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less at the time of purchase. As of June 30, 2022, and 2021, the Company’s uninsured bank balance was mainly maintained at financial institutions located in the PRC and Hong Kong, totaled $44,789,999 and $44,346,744, respectively. The Company has no insured bank balance as of June 30, 2022 and 2021, respectively.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company extends unsecured credit to its customers in the ordinary course of business but mitigates the associated risks by performing credit checks and actively pursuing past due accounts. An allowance for doubtful accounts is established and determined based on management’s assessment of known requirements, aging of receivables, payment and bad debt history, the customer’s current credit worthiness, changes in customer payment patterns and the economic environment. From November 1, 2013, the Company changed its credit policy by offering ninety (90) day payment terms for sales agents, whereas the payment terms for sales agents before November 1, 2013 were thirty (30) day. Due to COVID-19, the company extended its credit policy to 180 days this year. As of June 30, 2022 and 2021, the balances of accounts receivable were $9,567 and $2,346,867, respectively. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company evaluated the nature of all accounts receivable then provided allowance for doubtful accounts. As of June 30, 2022, and 2021, the balances of allowance for doubtful accounts were $48,769 and $60,394 respectively.
Advance to Suppliers	Advance to Suppliers The Company periodically makes advances to certain vendors for purchases of raw materials, or service providers for services relating to construction plans for our plant, equipment and production lines for the GMP upgrading, and records these payments as advance to suppliers. The decrease in the amount of advance to suppliers is due to fluctuation of exchange rate. As a result, as of June 30, 2022, and 2021, advance to suppliers amounted to $214,915 and $218,307, respectively.
Inventory	Inventory Inventory consists of raw materials, work in progress and finished goods of manufactured products. Inventory is stated at lower of cost or market and consists of materials, labor and overhead. HLJ Huimeijia uses the weighted average method for inventory valuation. The other entities of the Company use the first-in, first-out (“FIFO”) method for inventory valuation. Overhead costs included in finished goods include direct labor cost and other costs directly applicable to the manufacturing process. The Company evaluates inventory for excess, slow moving, and obsolete inventory as well as inventory the value of which is in excess of its net realizable value. This evaluation includes analysis of sales levels by product and projections of future demand. If future demand or market conditions are less favorable than the Company’s projections, a write-down of inventory may be required, and would be reflected in cost of goods sold in the period the revision is made. The inventory allowance with an amount of $nil and $nil were provided for the years ended June 30, 2022, and 2021, respectively.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company’s long-lived assets and other assets are reviewed for impairment in accordance with the guidance of the FASB ASC Topic 360-10, “Property, Plant, and Equipment,” and FASB ASC Topic 205, “Presentation of Financial Statements.” The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of the asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on the Company’s reporting results and financial position. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. As of June 30, 2022, and 2021, the Company has not experienced impairment losses on its long-lived assets. However, there can be no assurances that demand for the Company’s products or services will continue, which could result in an impairment of long-lived assets in the future.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses. Maintenance, repairs and minor renewals are expensed as incurred, major renewals and improvements that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in the results of operations in the reporting period of disposition. Depreciation is calculated on a straight-line basis over the estimated useful life of the assets.
Intangible Assets	Intangible Assets The Company evaluates intangible assets in accordance with FASB ASC Topic 350, “Intangibles — Goodwill and Other.” Intangible assets deemed to have indefinite lives are not amortized, but are subject to annual impairment tests. If the assumptions and estimates used to allocate the purchase price are not correct, or if business conditions change, purchase price adjustments or future asset impairment charges could be required. The value of the Company’s intangible assets could be impacted by future adverse changes such as: (i) any future declines in the Company’s operating results, (ii) a decline in the valuation of technology, including the valuation of the Company’s common stock, (iii) a significant slowdown in the worldwide economy, or (iv) any failure to meet the performance projections included in the Company’s forecasts of future operating results. In accordance with FASB ASC Topic 350, the Company tests intangible assets for impairment on an annual basis or more frequently if the Company believes indicators of impairment exist. Impairment evaluations involve management estimates of asset useful lives and future cash flows. Significant judgment by management is required in the forecasts of future operating results that are used in the evaluations. It is possible, however, that the plans and estimates used may be incorrect. If the Company’s actual results, or the plans and estimates used in future impairment analysis, are lower than the original estimates used to assess the recoverability of these assets, we could incur additional impairment charges in a future period. Based on such evaluations, there were no impairments recorded for intangible assets for the years ended June 30, 2022 and 2021, respectively.
Construction in Progress	Construction in Progress Construction in progress represents the costs incurred in connection with the construction of buildings or new additions to the Company’s plant facilities. Costs classified as construction in progress include all costs of obtaining the asset and bringing it to the location in the condition necessary for its intended use. No depreciation is provided for construction in progress until such time as the assets are completed and are placed into service. The Company reviews the carrying value of construction in progress for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value of the assets, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of the assets. The factors considered by Management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this assessment, there were no impairments recorded for construction in progress, for the years ended June 30, 2022 and June 30, 2021, respectively. However, there can be no assurances that demand for the Company’s products or services will continue, which could result in an impairment of long-lived assets in the future.
Revenue Recognition	Revenue Recognition The Company recognizes revenue at the amount to which it expects to be entitled when control of the products or services is transferred to its customers based on any contract which has been identified. Control is generally transferred when the Company has a present right to payment and title and the significant risks and rewards of ownership of products or services are transferred to its customers while performance obligation are identified and completed. For most of the Company’s products net sales, control transfers when products are shipped and transaction price are determined. The majority of the Company’s revenue relates to the sale of inventory to customers, and revenue is recognized when control of the products or services is transferred to its customers that reflects the performance obligations are properly allocated and satisfied with transaction price determined. Given the nature of the Company’s business and the applicable rules guiding revenue recognition, the Company’s revenue recognition practices do not contain estimates that materially affect the results of operations. The Company records revenue at the discounted selling price and allows its customers to return products for exchange or credit subject to certain limitations. A provision for such returns is recorded based upon historical experience. There has been no provision recorded for returns based upon historical experience for the years ended June 30, 2022 and 2021, respectively.
Cost of Goods Sold	Cost of Goods Sold Cost of goods sold consists primarily of the costs of raw materials, freight charges, direct labor, depreciation of plants and machinery, warehousing and overhead costs associated with the manufacturing process and commission expenses.
Income Taxes	Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established for deferred tax assets if it is more likely than not that these items will either expire before the Company is able to realize the benefits or that future deductibility is uncertain. Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition. As a result of the implementation of FIN 48 (ASC 740-10), the Company undertook a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholders’ equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s financial statements. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from the Company’s estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.
Enterprise Income Tax	Enterprise Income Tax Under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC (the “EIT Law”), income tax is payable by enterprises at a rate of 25% of their taxable income.
Value Added Tax	Value Added Tax The Provisional Regulations of the PRC Concerning Value Added Tax promulgated by the State Council came into effect on January 1, 1994 and revised on January 1, 2009. Under these regulations and the Implementing Rules of the Provisional Regulations of the PRC Concerning Value Added Tax, value added tax (“VAT”) is imposed on goods sold in, or imported into, the PRC and on processing, repair and replacement services provided within the PRC. VAT payable in the PRC is charged on an aggregated basis at a rate of 13% or 16% (depending on the type of goods involved) on the full price collected for the goods sold or, in the case of taxable services provided, at a rate of 16% on the charges for the taxable services provided, but excluding, in respect of both goods and services, any amount paid in respect of VAT included in the price or charges, and less any deductible VAT already paid by the taxpayer on purchases of goods and services in the same financial year. As of June 30, 2022 and June 30, 2021, VAT payables were $29,835 and $34,697, respectively.
Sales-Related Taxes	Sales-Related Taxes Pursuant to the tax law and regulations of the PRC, the Company is obligated to pay 7% and 5% of the annual aggregate VAT paid by the Company as taxes for the purposes of maintaining and building cities and educational facilities, which fees are included as sales-related taxes. Sales-related taxes are recorded when sales revenue is recognized.
Concentrations of Business and Credit Risks	Concentrations of Business and Credit Risks All of the Company’s manufacturing is located in the PRC. There can be no assurance that the Company will be able to successfully continue to manufacture its products and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. Moreover, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. These contingencies include general economic conditions, prices of raw materials, competition, governmental and political conditions, and changes in regulations. Since the Company is dependent on trade in the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company’s operations will be subject to the risks of restrictions on transfer of funds, domestic customs, changing taxation policies, foreign exchange restrictions, and political and governmental regulations. The Company operates in China, which may give rise to significant foreign currency risks from fluctuations and the degree of volatility of foreign exchange rates between U.S. dollars and the Chinese currency RMB. The results of operations denominated in foreign currency are translated at the average rate of exchange during the reporting periods.
Earnings Per Share	Earnings Per Share Basic earnings per common share is computed by dividing net earnings applicable to common shareholders by the weighted-average number of common shares outstanding during the period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. For the years ended June 30, 2022 and 2021, the Company had no potential dilutive common stock equivalents outstanding. Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period. FASB ASC Topic 260, “Earnings Per Share,” requires a reconciliation of the numerator and denominator of the basic and diluted earnings per share (EPS) computations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments (ASU 2016-13). The main objective of the standard is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In issuing this standard, the FASB is responding to criticism that today’s guidance delays recognition of credit losses. The standard will replace today’s “incurred loss” approach with an “expected loss” model. The new model, referred to as the current expected credit loss (“CECL”) model, will apply to: (1) financial assets subject to credit losses and measured at amortized cost, and (2) certain off-balance sheet credit exposures. The standard is applicable to loans, accounts receivable, trade receivables, and other financial assets measured at amortized cost, loan commitments and certain other off-balance sheet credit exposures, debt securities (including those held-to-maturity) and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The CECL model does not apply to available-for-sale debt securities. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to what they do today, except that the credit losses will be recognized as allowances rather than reductions in the amortized cost of the securities. Accordingly, the new methodology will be utilized when assessing the Company’s financial instruments for impairment. As a result, entities will recognize improvements to estimated credit losses immediately in earnings rather than as interest income over time, as they do today. The ASU also simplifies the accounting model for purchased credit-impaired debt securities and loans. ASU 2016-13 also expands the disclosure requirements regarding an entity’s assumptions, models, and methods for estimating the allowance for loan and lease losses. ASU 2016-13 is effective for years beginning after December 15, 2019, including interim periods within those fiscal years under a modified retrospective approach. Early adoption is permitted for the periods beginning after December 15, 2018. The Company adopted the guidance from July 1, 2020. The Company finalized its analysis and determined that the adoption of this guidance has no material impact on the Company’s consolidated financial statements and its internal controls over financial reporting. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13), which modifies the disclosure requirements on fair value measurements, including removing the requirement to disclose (1) the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, (2) the policy for timing of transfers between levels and (3) the valuation processes for Level 3 fair value measurements. ASU 2018-13 also added new disclosures including the requirement to disclose (a) the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and (b) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2019 and early adoption is permitted. This standard will only impact the disclosures pertaining to fair value measurements. The Company adopted the guidance from July 1, 2020. The Company finalized its analysis and determined that the adoption of this guidance has no material impact on the Company’s consolidated financial statements and its internal controls over financial reporting.

XML 38 R24.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

12 Months Ended

Jun. 30, 2022

Organization and Business Background [Abstract]

Schedule of straight-line basis over the estimated useful life of the assets

Building, Warehouse and Improvements		20 to 30 years
Office Equipment		3 to 7 years
Vehicles		5 to15 years
Machinery and Equipment		7 to 15 years

XML 39 R25.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

12 Months Ended

Jun. 30, 2022

Inventories [Abstract]

Schedule of inventory

	June 30, 2022		June 30, 2021
Raw Materials	$	213,055	$	251,989
Supplies and Packing Materials		90,303		93,452
Work-in-Progress		82,412		273,924
Finished Goods		135,459		142,274
Total	$	521,229	$	761,639

XML 40 R26.htm IDEA: XBRL DOCUMENT

Construction in Progress (Tables)

12 Months Ended

Jun. 30, 2022

Construction In Progress Disclosure Abstract

Schedule of construction in progress

	June 30, 2022		June 30, 2021
Plant - HLJ Huimeijia	$	579,402	$	560,910
Total	$	579,402	$	560,910

XML 41 R27.htm IDEA: XBRL DOCUMENT

Property, Plants and Equipment (Tables)

12 Months Ended

Jun. 30, 2022

Property, Plants and Equipment [Abstract]

Schedule of property, plants and equipment

	June 30, 2022			June 30, 2021
Building, Warehouses and Improvements	$	3,946,492		$	4,094,105
Machinery and Equipment		1,832,446			1,900,986
Office Equipment		78,360			81,291
Vehicles		217,808			225,955
Others		962,667			998,674
Less Accumulated Depreciation		(3,879,752	)		(3,671,106	)
Total	$	3,158,021		$	3,629,905

XML 42 R28.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

12 Months Ended

Jun. 30, 2022

Intangible Assets [Abstract]

Schedule of intangible assets

	June 30, 2022			June 30, 2021
Land Use Rights – Humankind	$	946,237		$	981,630
Health Supplement Product Patents – Humankind		4,478,882			4,646,408
Pharmaceutical Patents - HLJ Huimeijia		390,285			404,883
Land Use Rights - HLJ Huimeijia		647,211			671,419
Less: Accumulated Amortization		(5,050,012	)		(4,740,824	)
Intangible Assets, net, Held for Continuing Operations	$	1,412,603		$	1,963,516

XML 43 R29.htm IDEA: XBRL DOCUMENT

Related Party Debts (Tables)

12 Months Ended

Jun. 30, 2022

Schedule of related party debts

	June 30, 2022		June 30, 2021
Mr. Xin Sun	$	6,724,850	$	8,043,544
Mr. Kai Sun		34,911		36,217
Related Party Debts, Held for Continuing Operations	$	6,759,761	$	8,079,761

XML 44 R30.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

12 Months Ended

Jun. 30, 2022

Income Taxes [Abstract]

Schedule of taxes payable

	June 30, 2022		June 30, 2021
Income tax payable	$	23,839	$	28,895
Value-added tax payable		29,835		34,697
Other taxes payable		79,331		112,767
Total	$	133,005	$	176,359

Schedule of provision for income taxes and the provision at the statutory rate

	June 30, 2022			June 30, 2021
Pre-tax book income	$	(351,016	)	$	2,021,583
Federal statutory rate		21	%		21	%
Income tax computed at U.S. federal statutory rate		(73,714	)		424,532
Non-deductible staff welfare		-			-
Foreign rate differential		(7,874	)		392,435
Change in valuation allowance		84,522			(86,506	)
Total provision for income taxes	$	2,934		$	730,461

Schedule of provision for income taxes

	For the Years Ended
	June 30,
	2022		2021
Current provision:
Domestic	$	-	$	-
Foreign		-		727,588
Total current provision		-		727,588
Deferred provision:
Domestic		-		-
Foreign		2,934		2,873
Total deferred provision		2,934		2,873
Total provision for income taxes	$	2,934	$	730,461

Schedule of components of deferred tax assets

	June 30, 2022			June 30, 2021
Deferred tax assets
Net operating loss carry forward	$	1,096,936		$	1,018,253
Allowance for doubtful accounts		(12,192	)		(15,100	)
Valuation allowance		(1,084,744	)		(1,000,220	)
Deferred tax assets, net	$	-		$	2,933

XML 45 R31.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Tables)

12 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Schedule of basic and diluted net income per share

	For the Years Ended
	June 30,			June 30,
	2022			2021
Net income/(loss)	$	(353,950	)	$	1,291,122

Net income/(loss) per share:

Net income (loss) per share Basic & diluted	$	(0.0054	)	$	0.0197

Weighted average shares outstanding:
Basic & diluted		65,539,737			65,539,737

XML 46 R32.htm IDEA: XBRL DOCUMENT

Segment Reporting (Tables)

12 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Schedule of information by segment

				For the Year Ended June 30, 2022														For the Year Ended June 30, 2021
	HLJ									Consolidated			HLJ								Consolidated
	Huimeijia			Humankind			Others			operations			Huimeijia			Humankind		Others			operations
Revenues	$	267		$	-		$	-		$	267		$	16,754		$	6,475,966	$	-		$	6,492,720
Cost of revenues		1,748			-			-			1,748			96,316			2,754,413		-			2,850,729
Gross profit (loss)		(1,481	)		-			-			(1,481	)		(79,562	)		3,721,553		-			3,641,991
Interest income		322			157,536			2			157,860			9			137,468		8			137,485
Interest expense		-			-			-			-			-			-		-			-
Depreciation and amortization		60,962			650,553			-			711,515			62,239			547,459		-			609,698
Income tax		-			2,934			-			2,934			-			730,461		-			730,461
Net income (loss)		509,990			(637,666	)		(226,274	)		(353,950	)		(386,910	)		1,865,983		(187,951	)		1,291,122
Total capital expenditures		-			-			-			-			5,074			8,582		-			13,656
Total assets	$	2,994,826		$	47,724,803		$	27,889		$	50,747,518		$	3,453,342		$	50,347,870	$	86,925		$	53,888,137

XML 47 R33.htm IDEA: XBRL DOCUMENT

Organization and Business Background (Details)					1 Months Ended
Organization and Business Background (Details)	Oct. 12, 2016 USD ($)	Oct. 12, 2016 CNY (¥)	Feb. 09, 2015 USD ($)	Feb. 09, 2015 CNY (¥)	Nov. 22, 2013 USD ($)	Nov. 22, 2013 CNY (¥)	Dec. 31, 2008	Aug. 20, 2007 USD ($)	Dec. 24, 2014	Apr. 07, 2009 shares	Oct. 14, 2008
Mr. Xin Sun [Member]
Organization and Business Background (Details) [Line Items]
Majority ownership, percentage											1.00%
Supplementary Agreement [Member]
Organization and Business Background (Details) [Line Items]
Total cash consideration			$ 1,306,186	¥ 8,000,000
Percentage of purchase price paid	80.00%	80.00%
New Supplementary Agreement [Member]
Organization and Business Background (Details) [Line Items]
Total cash consideration	$ 1,306,186	¥ 8,000,000
Purchase price, description	40% of the Purchase Price was due within 10 business days after the signing of the New Supplementary Agreement; 40% of the Purchase Price was due within 10 business days after the completion of the changes in business registration described in the Original Agreement and Xiuzheng Pharmacy obtaining documents evidencing its ownership on Huimeijia; 15% of the Purchase Price is due within 10 business days after the transfer of all of the Assets is approved by Heilongjiang FDA; and 5% of the Purchase Price is due within 10 business days after all of the Assets have been transferred to Xiuzheng Pharmacy or its designee and Humankind and Mr. Xin Sun have instructed Xiuzheng Pharmacy complete three-batches production of all forms of the drugs included in the Assets.	40% of the Purchase Price was due within 10 business days after the signing of the New Supplementary Agreement; 40% of the Purchase Price was due within 10 business days after the completion of the changes in business registration described in the Original Agreement and Xiuzheng Pharmacy obtaining documents evidencing its ownership on Huimeijia; 15% of the Purchase Price is due within 10 business days after the transfer of all of the Assets is approved by Heilongjiang FDA; and 5% of the Purchase Price is due within 10 business days after all of the Assets have been transferred to Xiuzheng Pharmacy or its designee and Humankind and Mr. Xin Sun have instructed Xiuzheng Pharmacy complete three-batches production of all forms of the drugs included in the Assets.
Harbin Humankind Biology Technology Co., Limited [Member]
Organization and Business Background (Details) [Line Items]
Total purchase price \| $								$ 60,408
China Health Industries Holdings Limited [Member]
Organization and Business Background (Details) [Line Items]
Transaction and subsequent reverse stock split							After the Transaction and a 20:1 reverse stock split, Mr. Xin Sun owned 61,203,088 shares of common stock, representing 98.3% of the 62,234,737 total outstanding shares of common stock of China Health US.
Heilongjiang Huimeijia Pharmaceutical Co., Ltd. [Member]
Organization and Business Background (Details) [Line Items]
Total purchase price					$ 16,339,869	¥ 100,000,000
Equity Interests Huimeijia [Member]
Organization and Business Background (Details) [Line Items]
Equity interests, percentage									100.00%
Equity Interests Huimeijia [Member] \| New Supplementary Agreement [Member]
Organization and Business Background (Details) [Line Items]
Equity interests, percentage	100.00%	100.00%
Mr. Xin Sun [Member] \| China Health Industries Holdings Limited [Member]
Organization and Business Background (Details) [Line Items]
Number of shares transferred (in Shares)										28,200,000
Number of individuals										296
Number of shares held (in Shares)										33,003,088
Percentage of shares held										53.03%
Business Combination [Member] \| Mr. Xin Sun [Member]
Organization and Business Background (Details) [Line Items]
Ownership percentage									1.00%
Business Combination [Member] \| Harbin Humankind Biology Technology Co., Limited [Member]
Organization and Business Background (Details) [Line Items]
Ownership percentage								100.00%	99.00%
Business Combination [Member] \| Harbin Huimeijia Medicine Company [Member]
Organization and Business Background (Details) [Line Items]
Ownership percentage											99.00%

XML 48 R34.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) - USD ($)	12 Months Ended
Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Significant Accounting Policies (Details) [Line Items]
Foreign currency translation, description	For the purpose of presenting these financial statements, the Company’s assets and liabilities with functional currency of HKD are expressed in USD at the exchange rate on the balance sheet date, which was 7.8472 and 7.7658 as of June 30, 2022 and June 30, 2021, respectively; stockholder’s equity accounts are translated at historical rates, and income and expense items are translated at the weighted average exchange rates during the year, which was 7.8049 and 7.7563 for the years ended June 30, 2022 and 2021, respectively.
Uninsured bank balances	$ 44,789,999	$ 44,346,744
Accounts receivable	9,567	2,346,867
Allowance for doubtful accounts	48,769	60,394
Advance to suppliers	214,915	218,307
Inventory net of allowances
Percentage of enterprises rate	25.00%
Income tax services rate percentage	16.00%
Value added tax payables	$ 29,835	$ 34,697
Minimum [Member]
Significant Accounting Policies (Details) [Line Items]
VAT payable, percentage	13.00%
Annual aggregate, percentage	5.00%
Maximum [Member]
Significant Accounting Policies (Details) [Line Items]
VAT payable, percentage	16.00%
Annual aggregate, percentage	7.00%

XML 49 R35.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets	12 Months Ended
	Jun. 30, 2022
Building, Warehouse and Improvements [Member] \| Minimum [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets [Line Items]
Estimated useful life	20 years
Building, Warehouse and Improvements [Member] \| Maximum [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets [Line Items]
Estimated useful life	30 years
Office Equipment [Member] \| Minimum [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets [Line Items]
Estimated useful life	3 years
Office Equipment [Member] \| Maximum [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets [Line Items]
Estimated useful life	7 years
Vehicles [Member] \| Minimum [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets [Line Items]
Estimated useful life	5 years
Vehicles [Member] \| Maximum [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets [Line Items]
Estimated useful life	15 years
Machinery and Equipment [Member] \| Minimum [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets [Line Items]
Estimated useful life	7 years
Machinery and Equipment [Member] \| Maximum [Member]
Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets [Line Items]
Estimated useful life	15 years

XML 50 R36.htm IDEA: XBRL DOCUMENT

Assets Sale (Details)					1 Months Ended
Assets Sale (Details)	Oct. 12, 2016 USD ($)	Oct. 12, 2016 CNY (¥)	Feb. 09, 2015 USD ($)	Feb. 09, 2015 CNY (¥)	Dec. 24, 2014 USD ($)	Dec. 24, 2014 CNY (¥)
Assets Sale (Details) [Line Items]
Total cash consideration					$ 1,306,186	¥ 8,000,000
Equity Interests Huimeijia [Member]
Assets Sale (Details) [Line Items]
Equity interests, percentage					100.00%	100.00%
Supplementary Agreement [Member]
Assets Sale (Details) [Line Items]
Total cash consideration			$ 1,306,186	¥ 8,000,000
Agreement terms, description			the four parties entered into a supplementary agreement (the “Supplementary Agreement”) to modify the terms of the Agreement, pursuant to which, the Equity Holders and Huimeijia (collectively the “Assets Transferors”) shall only sell the 19 drug approval numbers (including the tablet, capsule, powder, mixture, oral liquid, syrup and oral solution under the 19 approval numbers; licenses including the original copies of Business License, Organization Code Certificate, Tax Registration Certificate, Drug Production Permit and GMP Certificate, and other documents and original copies related to the production and operation of the 19 drugs) (the “Assets”) to Xiuzheng Pharmacy.	the four parties entered into a supplementary agreement (the “Supplementary Agreement”) to modify the terms of the Agreement, pursuant to which, the Equity Holders and Huimeijia (collectively the “Assets Transferors”) shall only sell the 19 drug approval numbers (including the tablet, capsule, powder, mixture, oral liquid, syrup and oral solution under the 19 approval numbers; licenses including the original copies of Business License, Organization Code Certificate, Tax Registration Certificate, Drug Production Permit and GMP Certificate, and other documents and original copies related to the production and operation of the 19 drugs) (the “Assets”) to Xiuzheng Pharmacy.
New Supplementary Agreement [Member]
Assets Sale (Details) [Line Items]
Total cash consideration	$ 1,306,186	¥ 8,000,000
Purchase Price, description	40% of the Purchase Price was due within 10 business days after the signing of the New Supplementary Agreement; 40% of the Purchase Price was due within 10 business days after the completion of the changes in business registration described in the Original Agreement and Xiuzheng Pharmacy obtaining documents evidencing its ownership on Huimeijia; 15% of the Purchase Price is due within 10 business days after the transfer of all of the Assets is approved by Heilongjiang FDA; and 5% of the Purchase Price is due within 10 business days after all of the Assets have been transferred to Xiuzheng Pharmacy or its designee and Humankind and Mr. Xin Sun have instructed Xiuzheng Pharmacy to complete three-batches production of all forms of the drugs included in the Assets. As of the date of this report, 80% of the Purchase Price has been paid, the Company has completed changes in its business registration, and Xiuzheng Pharmacy has obtained a business license issued by the local State Administration of Industry and Commerce in Harbin (“Harbin SAIC”) to Huimeijia, in which the ownership of Huimeijia has been recorded as held by Xiuzheng Pharmacy, with Harbin SAIC and the legal representative (a person that is authorized to take most of the corporate actions on behalf of a company under the corporate laws in China) of Huimeijia has been appointed by the Buyer.	40% of the Purchase Price was due within 10 business days after the signing of the New Supplementary Agreement; 40% of the Purchase Price was due within 10 business days after the completion of the changes in business registration described in the Original Agreement and Xiuzheng Pharmacy obtaining documents evidencing its ownership on Huimeijia; 15% of the Purchase Price is due within 10 business days after the transfer of all of the Assets is approved by Heilongjiang FDA; and 5% of the Purchase Price is due within 10 business days after all of the Assets have been transferred to Xiuzheng Pharmacy or its designee and Humankind and Mr. Xin Sun have instructed Xiuzheng Pharmacy to complete three-batches production of all forms of the drugs included in the Assets. As of the date of this report, 80% of the Purchase Price has been paid, the Company has completed changes in its business registration, and Xiuzheng Pharmacy has obtained a business license issued by the local State Administration of Industry and Commerce in Harbin (“Harbin SAIC”) to Huimeijia, in which the ownership of Huimeijia has been recorded as held by Xiuzheng Pharmacy, with Harbin SAIC and the legal representative (a person that is authorized to take most of the corporate actions on behalf of a company under the corporate laws in China) of Huimeijia has been appointed by the Buyer.
New Supplementary Agreement [Member] \| Equity Interests Huimeijia [Member]
Assets Sale (Details) [Line Items]
Equity interests, percentage	100.00%	100.00%

XML 51 R37.htm IDEA: XBRL DOCUMENT

Accounts Receivable (Details) - Accounts Receivable [Member] - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Accounts Receivable (Details) [Line Items]
Accounts receivable	$ 9,567	$ 2,346,867
Net of allowance for doubtful accounts	$ 48,769	$ 60,394

XML 52 R38.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Inventories [Abstract]
Inventory allowance

XML 53 R39.htm IDEA: XBRL DOCUMENT

Inventories (Details) - Schedule of inventory - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Inventory Abstract
Raw Materials	$ 213,055	$ 251,989
Supplies and Packing Materials	90,303	93,452
Work-in-Progress	82,412	273,924
Finished Goods	135,459	142,274
Total	$ 521,229	$ 761,639

XML 54 R40.htm IDEA: XBRL DOCUMENT

Construction in Progress (Details)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 CNY (¥)	Apr. 06, 2012 USD ($)	Apr. 06, 2012 CNY (¥)
Construction In Progress Disclosure Abstract
Estimated total cost of construction			$ 1,860,000	¥ 12,800,000
Construction in progress, percentage	77.90%	77.90%
Cost of construction in progress	$ 1,448,567	¥ 9,702,644
Construction in progress	$ 949,040	¥ 6,356,767

XML 55 R41.htm IDEA: XBRL DOCUMENT

Construction in Progress (Details) - Schedule of construction in progress - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Construction in Progress (Details) - Schedule of construction in progress [Line Items]
Total	$ 579,402	$ 560,910
Plant - HLJ Huimeijia [Member]
Construction in Progress (Details) - Schedule of construction in progress [Line Items]
Total	$ 579,402	$ 560,910

XML 56 R42.htm IDEA: XBRL DOCUMENT

Property, Plants and Equipment (Details) - USD ($)	12 Months Ended
Property, Plants and Equipment (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Property, Plants and Equipment (Textual)
Depreciation expense	$ 344,919	$ 393,168
Depreciation expense charged to operations	344,919	124,073
Depreciation expense charged to cost of goods sold		$ 269,095

XML 57 R43.htm IDEA: XBRL DOCUMENT

Property, Plants and Equipment (Details) - Schedule of property, plants and equipment - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
Less Accumulated Depreciation	$ (3,879,752)	$ (3,671,106)
Total	3,158,021	3,629,905
Building, Warehouses and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plants and equipment, Gross	3,946,492	4,094,105
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plants and equipment, Gross	1,832,446	1,900,986
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plants and equipment, Gross	78,360	81,291
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plants and equipment, Gross	217,808	225,955
Others [Member]
Property, Plant and Equipment [Line Items]
Property, plants and equipment, Gross	$ 962,667	$ 998,674

XML 58 R44.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details) - USD ($)	12 Months Ended
Intangible Assets (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Intangible Assets (Details) [Line Items]
Intangible asset, useful life	10 years
Amortization expense (in Dollars)	$ 485,625	$ 485,625
Commercial Purpose [Member]
Intangible Assets (Details) [Line Items]
Intangible asset, useful life	50 years
Residential Purpose [Member]
Intangible Assets (Details) [Line Items]
Intangible asset, useful life	70 years

XML 59 R45.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details) - Schedule of intangible assets - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Less: Accumulated Amortization	$ (5,050,012)	$ (4,740,824)
Intangible Assets, net, Held for Continuing Operations	1,412,603	1,963,516
Land Use Rights [Member] \| Humankind [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	946,237	981,630
Land Use Rights [Member] \| HLJ Huimeijia [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	647,211	671,419
Health Supplement Product Patents [Member] \| Humankind [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	4,478,882	4,646,408
Pharmaceutical Patents [Member] \| HLJ Huimeijia [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 390,285	$ 404,883

XML 60 R46.htm IDEA: XBRL DOCUMENT

Related Party Debts (Details) - Schedule of related party debts - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Related Party Transaction [Line Items]
Related Party Debts, Held for Continuing Operations	$ 6,759,761	$ 8,079,761
Mr. Xin Sun [Member]
Related Party Transaction [Line Items]
Related Party Debts, Held for Continuing Operations	6,724,850	8,043,544
Mr. Kai Sun [Member]
Related Party Transaction [Line Items]
Related Party Debts, Held for Continuing Operations	$ 34,911	$ 36,217

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

+ Details

XML 61 R47.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
United States [Member]
Income Taxes (Details) [Line Items]
Operating loss carry forwards	$ 1,793,042	$ 1,569,209
Operating loss carryover is expired term	20 years
Federal net operating loss, description	If not utilized, the federal net operating loss for the fiscal years 2022 and 2021 in an amount of $223,833 and $187,462, respectively, will begin to expire in the years 2041 and 2040, respectively.
China Health HK [Member]
Income Taxes (Details) [Line Items]
Operating loss carry forwards	$ 11,030	10,588
Valuation allowance for the deferred tax assets	$ 441	$ 489
People’s Republic of China [Member]
Income Taxes (Details) [Line Items]
Standard EIT rate under EIT law		25.00%
Effective tax rate	0.80%	36.10%

XML 62 R48.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - Schedule of taxes payable - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Schedule of taxes payable [Abstract]
Income tax payable	$ 23,839	$ 28,895
Value-added tax payable	29,835	34,697
Other taxes payable	79,331	112,767
Total	$ 133,005	$ 176,359

XML 63 R49.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - Schedule of provision for income taxes and the provision at the statutory rate - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Schedule of Provision For Income Taxes And The Provision at The Statutory Rate [Abstract]
Pre-tax book income	$ (351,016)	$ 2,021,583
Federal statutory rate	21.00%	21.00%
Income tax computed at U.S. federal statutory rate	$ (73,714)	$ 424,532
Non-deductible staff welfare
Foreign rate differential	(7,874)	392,435
Change in valuation allowance	84,522	(86,506)
Total provision for income taxes	$ 2,934	$ 730,461

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

XML 64 R50.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - Schedule of provision for income taxes - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Current provision:
Domestic
Foreign		727,588
Total current provision		727,588
Deferred provision:
Domestic
Foreign	2,934	2,873
Total deferred provision	2,934	2,873
Total provision for income taxes	$ 2,934	$ 730,461

XML 65 R51.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - Schedule of components of deferred tax assets - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Deferred tax assets
Net operating loss carry forward	$ 1,096,936	$ 1,018,253
Allowance for doubtful accounts	(12,192)	(15,100)
Valuation allowance	(1,084,744)	(1,000,220)
Deferred tax assets, net		$ 2,933

XML 66 R52.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Details) - Schedule of basic and diluted net income per share - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Basic And Diluted Net Income Per Share [Abstract]
Net income/(loss)	$ (353,950)	$ 1,291,122
Net income/(loss) per share:
Net income (loss) per share Basic & diluted	$ (0.0054)	$ 0.0197
Weighted average shares outstanding:
Basic & diluted	65,539,737	65,539,737

- Definition

Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(14))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 67 R53.htm IDEA: XBRL DOCUMENT

Major Suppliers and Customers (Details)	12 Months Ended
Major Suppliers and Customers (Details)	Jun. 30, 2021
Major Suppliers and Customers (Details) [Line Items]
Number of suppliers	3
Concentration risk, percentage	91.00%
Number of customers	6
Purchase [Member]
Major Suppliers and Customers (Details) [Line Items]
Concentration risk, percentage	78.00%
Supplier One [Member] \| Purchase [Member]
Major Suppliers and Customers (Details) [Line Items]
Concentration risk, percentage	40.00%
Supplier Two [Member] \| Purchase [Member]
Major Suppliers and Customers (Details) [Line Items]
Concentration risk, percentage	22.00%
Supplier Three [Member] \| Purchase [Member]
Major Suppliers and Customers (Details) [Line Items]
Concentration risk, percentage	16.00%
Customer One [Member] \| Total sales [Member]
Major Suppliers and Customers (Details) [Line Items]
Concentration risk, percentage	23.00%
Customer Two [Member] \| Total sales [Member]
Major Suppliers and Customers (Details) [Line Items]
Concentration risk, percentage	18.00%
Customer Three [Member] \| Total sales [Member]
Major Suppliers and Customers (Details) [Line Items]
Concentration risk, percentage	16.00%
Customer Four [Member] \| Total sales [Member]
Major Suppliers and Customers (Details) [Line Items]
Concentration risk, percentage	13.00%
Customer Five [Member] \| Total sales [Member]
Major Suppliers and Customers (Details) [Line Items]
Concentration risk, percentage	12.00%
Customer Six [Member] \| Total sales [Member]
Major Suppliers and Customers (Details) [Line Items]
Concentration risk, percentage	9.00%

XML 68 R54.htm IDEA: XBRL DOCUMENT

Segment Reporting (Details)	12 Months Ended
Segment Reporting (Details)	Jun. 30, 2022
Segment Reporting [Abstract]
Number of business segments	3
Number of operating segments	3

XML 69 R55.htm IDEA: XBRL DOCUMENT

Segment Reporting (Details) - Schedule of information by segment - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
HLJ Huimeijia [Member]
Segment Reporting Information [Line Items]
Revenues	$ 267	$ 16,754
Cost of revenues	1,748	96,316
Gross profit (loss)	(1,481)	(79,562)
Interest income	322	9
Interest expense
Depreciation and amortization	60,962	62,239
Income tax
Net income (loss)	509,990	(386,910)
Total capital expenditures		5,074
Total assets	2,994,826	3,453,342
Humankind [Member]
Segment Reporting Information [Line Items]
Revenues		6,475,966
Cost of revenues		2,754,413
Gross profit (loss)		3,721,553
Interest income	157,536	137,468
Interest expense
Depreciation and amortization	650,553	547,459
Income tax	2,934	730,461
Net income (loss)	(637,666)	1,865,983
Total capital expenditures		8,582
Total assets	47,724,803	50,347,870
Others [Member]
Segment Reporting Information [Line Items]
Revenues
Cost of revenues
Gross profit (loss)
Interest income	2	8
Interest expense
Depreciation and amortization
Income tax
Net income (loss)	(226,274)	(187,951)
Total capital expenditures
Total assets	27,889	86,925
Consolidated operations [Member]
Segment Reporting Information [Line Items]
Revenues	267	6,492,720
Cost of revenues	1,748	2,850,729
Gross profit (loss)	(1,481)	3,641,991
Interest income	157,860	137,485
Interest expense
Depreciation and amortization	711,515	609,698
Income tax	2,934	730,461
Net income (loss)	(353,950)	1,291,122
Total capital expenditures		13,656
Total assets	$ 50,747,518	$ 53,888,137

Note 1 - ORGANIZATION AND BUSINESS BACKGROUND China Health Industries Holdings, Inc. (“China Health US”) was incorporated in the State of Arizona on July 11, 1996 and was the successor of the business known as Arizona Mist, Inc. which began in 1989. On May 9, 2005, it entered into a stock purchase agreement and Share Exchange (effecting a reverse merger) with Edmonds 6, Inc. (“Edmonds 6”), a Delaware corporation, and changed its name to Universal Fog, Inc. Pursuant to this agreement, Universal Fog, Inc. (which has been in continuous operation since 1996) became a wholly-owned subsidiary of Edmonds 6. China Health Industries Holdings Limited (“China Health HK”) was incorporated on July 20, 2007 in Hong Kong under the Companies Ordinance as a limited liability company. China Health HK was formed for the purpose of seeking and consummating a merger or acquisition with a business entity organized as a private corporation, partnership, or sole proprietorship as defined by FASB ACS Topic 915 (“Development Stage Entities”). Harbin Humankind Biology Technology Co., Limited (“Humankind”) was incorporated in Harbin City, Heilongjiang Province, the People’s Republic of China (the “PRC”) on December 14, 2003, as a limited liability company under the Company Law of the PRC. Humankind is engaged in the manufacturing and sale of health products. On August 20, 2007, the sole shareholder of China Health HK entered into a share purchase agreement (the “Share Purchase Agreement”) with the owners of Humankind. Pursuant to the Share Purchase Agreement, China Health HK purchased 100% of the ownership in Humankind for a cash consideration of $60,408 (the “Share Purchase”). Subsequent to the completion of the Share Purchase, Humankind became a wholly-owned subsidiary of China Health HK. The Share Purchase was accounted for as a “reverse merger” since the owner of Humankind owned a majority of the outstanding shares of China Health HK’s common stock immediately following the execution of the Share Purchase Agreement, it was deemed to be the accounting acquirer in the reverse merger. Consequently, the assets and liabilities and the historical operations that have been reflected in the financial statements for periods prior to the Share Purchase are those of Humankind and have been recorded at the historical cost basis. After completion of the Share Purchase, China Health HK’s consolidated financial statements include the assets and liabilities of both China Health HK and Humankind, the historical operations of Humankind, and the operations of China Health HK and its subsidiaries from the closing date of the Share Purchase. On October 14, 2008, Humankind set up a 99% owned subsidiary, Harbin Huimeijia Medicine Company (“Huimeijia”), with its primary business being manufacturing and distributing medicine. Mr. Xin Sun, the Company’s majority owner, owns 1% of Huimeijia. Huimeijia is consolidated in the consolidated financial statements of China Health HK. On December 31, 2008, China Health HK entered into a reverse merger with Universal Fog, Inc., a U.S. publicly traded shell company (the “Transaction”). China Health HK is the acquirer in the Transaction, and the Transaction has been treated as a recapitalization of China Health US. After the Transaction and a 20:1 reverse stock split, Mr. Xin Sun owned 61,203,088 shares of common stock, representing 98.3% of the 62,234,737 total outstanding shares of common stock of China Health US. On April 7, 2009, Mr. Sun transferred 28,200,000 shares of common stock to 296 individuals, leaving him with 33,003,088 shares of common stock of China Health US, or approximately 53.03% of the total outstanding shares of common stock. Universal Fog, Inc. changed its name to China Health Industries Holdings, Inc. on February 19, 2009. On November 22, 2013, Humankind completed the acquisition of Heilongjiang Huimeijia Pharmaceutical Co., Ltd. (“HLJ Huimeijia”) for a total purchase price of $16,339,869 (RMB100,000,000). HLJ Huimeijia was founded on October 30, 2003, and is engaged in the manufacturing and distribution of tincture, ointments, rubber paste (including hormones), topical solution, suppositories, liniment (including traditional Chinese medicine extractions), enemas and oral liquids. HLJ Huimeijia’s predecessor is Heilongjiang Xue Du Pharmaceutical Co., Ltd., which has established its brand name in the market through its supply of high quality medical products. HLJ Huimeijia is categorized as a “high and new technology” enterprise by the Science Technology Department in Heilongjiang Province. HLJ Huimeijia has 21 products which have been approved by, and have received approval numbers issued by, the National Medical Products Administration (the “NMPA”). In addition, HLJ Huimeijia is the holder of one patent for utility models, five patents for external design and three trademarks in China, including the Chinese brand name of “Xue Du” which has an established reputation among customers in northeastern China. On December 24, 2014, Humankind entered into a stock transfer agreement (the “Original Agreement”) with Xiuzheng Pharmaceutical Group Co., Ltd. a company incorporated under the laws of the PRC and located in Jilin province (“Xiuzheng Pharmacy” or the “Buyer”), Mr. Xin Sun, the CEO of the Company, and Huimeijia, 99% owned by Humankind and 1% owned by Mr. Xin Sun. Pursuant to the Original Agreement, Humankind and Mr. Xin Sun (the “Equity Holders”), would sell their respective equity interests in Huimeijia to Xiuzheng Pharmacy. On February 9, 2015, the four parties entered into a supplementary agreement (the “Supplementary Agreement”) to modify the terms of the Original Agreement, pursuant to which the Equity Holders and Huimeijia (collectively the “Asset Transferors”) would sell only the 19 drug approval numbers (including the tablet, capsule, powder, mixture, oral liquid, syrup and oral solution under the 19 approval numbers; licenses including the original copies of Business License, Organization Code Certificate, Tax Registration Certificate, Drug Production Permit and GMP Certificate, and other documents and original copies related to the production and operation of the 19 drugs) (the “Assets”) to Xiuzheng Pharmacy. The Equity Holders would have retained their equity interests in Huimeijia, but would have pledged such equity interests to Xiuzheng Pharmacy until the Assets were transferred, at which time the cash consideration would have been paid by the Buyer. Total cash consideration would have been the same as under the Original Agreement, i.e., RMB 8,000,000 (approximately $1,306,186) to the Asset Transferors. In the event that the Assets had failed to be transferred to the Buyer due to the fault of the Asset Transferors, the paid consideration would have been returned to the Buyer with interest accrued. If the failure of the transfer of the Assets were a result of changes in government policy or force majeure, the paid cash consideration would have been returned to the Buyer but without any interest. On October 12, 2016, the four parties agreed to rescind the Supplementary Agreement and entered into a new supplementary agreement (the “New Supplementary Agreement”), pursuant to which the four parties agreed to execute the transfer of the equity interests based on the Original Agreement and the Equity Holders agreed to sell their respective equity interests in Huimeijia to Xiuzheng Pharmacy. The transfer of 100% of the equity interests of Huimeijia to the Buyer was for total cash consideration of RMB 8,000,000 (approximately $1,306,186) (the “Purchase Price”) to the Equity Holders. 40% of the Purchase Price was due within 10 business days after the signing of the New Supplementary Agreement; 40% of the Purchase Price was due within 10 business days after the completion of the changes in business registration described in the Original Agreement and Xiuzheng Pharmacy obtaining documents evidencing its ownership on Huimeijia; 15% of the Purchase Price is due within 10 business days after the transfer of all of the Assets is approved by Heilongjiang FDA; and 5% of the Purchase Price is due within 10 business days after all of the Assets have been transferred to Xiuzheng Pharmacy or its designee and Humankind and Mr. Xin Sun have instructed Xiuzheng Pharmacy complete three-batches production of all forms of the drugs included in the Assets. As of the date of this report, 80% of the Purchase Price has been paid, the Company has completed changes in its business registration, and Xiuzheng Pharmacy has obtained a business license issued by the local State Administration of Industry and Commerce in Harbin (“Harbin SAIC”) to Huimeijia, in which the ownership of Huimeijia has been recorded as held by Xiuzheng Pharmacy, with Harbin SAIC and the legal representative (a person that is authorized to take most of the corporate actions on behalf of a company under the corporate laws in China) of Huimeijia has been appointed by the Buyer. China Health US, China Health HK, Humankind and HLJ Huimeijia are collectively referred herein to as the “Company.” As of June 30, 2022, the Company’s corporate structure was as follows:

60408

0.99

0.01

After the Transaction and a 20:1 reverse stock split, Mr. Xin Sun owned 61,203,088 shares of common stock, representing 98.3% of the 62,234,737 total outstanding shares of common stock of China Health US.

28200000 296 33003088 0.5303

8000000 1306186 40% of the Purchase Price was due within 10 business days after the signing of the New Supplementary Agreement; 40% of the Purchase Price was due within 10 business days after the completion of the changes in business registration described in the Original Agreement and Xiuzheng Pharmacy obtaining documents evidencing its ownership on Huimeijia; 15% of the Purchase Price is due within 10 business days after the transfer of all of the Assets is approved by Heilongjiang FDA; and 5% of the Purchase Price is due within 10 business days after all of the Assets have been transferred to Xiuzheng Pharmacy or its designee and Humankind and Mr. Xin Sun have instructed Xiuzheng Pharmacy complete three-batches production of all forms of the drugs included in the Assets. 0.80

Basis of Presentation This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles in the United States (“US GAAP”) and have been consistently applied in the preparation of the consolidated financial statements.

Principles of Consolidation The accompanying consolidated financial statements include China Health US and its four subsidiary companies, including China Health HK, Humankind and HLJ Huimeijia. All significant intercompany balances and transactions have been eliminated in consolidation and combination. On November 22, 2013, China Health US, through its wholly owned subsidiary Humankind, completed the acquisition of HLJ Huimeijia. HLJ Huimeijia and Humankind are under the common control of Mr. Xin Sun, the CEO of the Company before and after the date of transfer. Humankind’s accounting policy adopted the guidance in ASC 805-50-05-5 for the transfer of net assets between entities under common control to apply a method similar to the pooling-of-interests’ method. Under this method, the financial statements of Humankind shall report results of operations for the period in which the transfer occurs as though the transfer of net assets had occurred at the beginning of the period. Results of operations for that period will thus comprise both those of the previously separate entities combined from the beginning of the period to the date the transfer is completed and those of the combined operations from that date to the end of the period. Similarly, Humankind shall present the statements of financial position and other financial information as of the beginning of the period as though the assets and liabilities had been transferred at that date. Financial statements and financial information of Humankind presented for prior years also shall be retrospectively adjusted to furnish comparative information.

Segment Reporting FASB ASC Topic 280, “Segment Reporting,” established standards for reporting information about operating segments on a basis consistent with the Company’s internal organizational structure as well as information about geographical areas, business segments and major customers in financial statements for details on the Company’s business segments. The Company has three reportable operating segments: Humankind, HLJ Huimeijia and Others. The segments are grouped based on the types of products provided.

Fair Value of Financial Instruments The provisions of accounting guidance, FASB ASC Topic 820 that applies to the Company requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

Fair Value Measurements FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” clarifies the definition of fair value for financial reporting, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements. Various inputs are considered when determining the fair value of the Company’s debt. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below. Level 1 – observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets. Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.). Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments). The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. The Company had no financial assets or liabilities carried and measured on a recurring basis during the reporting periods. The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment.

Foreign Currency Translation and Transaction Humankind, Huimeijia and HLJ Huimeijia maintain their books and accounting records in PRC currency “Renminbi” (“RMB”), which has been determined as the functional currency. The functional currency of China Health HK is the Hong Kong Dollar (“HKD”). Transactions denominated in currencies other than the functional currencies are recorded at the exchange rates prevailing on the date of the transactions, as quoted by the Federal Reserve Board. Foreign currency exchange gains and losses resulting from these transactions are included in operations. Humankind, Huimeijia, HLJ Huimeijia and China Health Hong Kong’s financial statements are translated into the reporting currency, the United States Dollar (“USD”). Assets and liabilities of the above entities are translated at the prevailing exchange rate at each reporting period end date. Contributed capital accounts are translated using the historical rate of exchange when capital is injected. Income and expense accounts are translated at the average rate of exchange during the reporting period. Translation adjustments resulting from the translation of these financial statements are reflected as accumulated other comprehensive income in shareholders’ equity and non-controlling interests. For the purpose of presenting these financial statements, the Company’s assets and liabilities with functional currency of HKD are expressed in USD at the exchange rate on the balance sheet date, which was 7.8472 and 7.7658 as of June 30, 2022 and June 30, 2021, respectively; stockholder’s equity accounts are translated at historical rates, and income and expense items are translated at the weighted average exchange rates during the year, which was 7.8049 and 7.7563 for the years ended June 30, 2022 and 2021, respectively. For Renminbi currency, the Company’s assets and liabilities are expressed in USD at the exchange rate on the balance sheet date, which was 6.6981 and 6.4566 as of June 30, 2022 and June 30, 2021, respectively; stockholder’s equity accounts are translated at historical rates, and income and expense items are translated at the weighted average exchange rates during the year, which was 6.4554 and 6.6221 for the years ended June 30, 2022 and 2021, respectively.

Statement of Cash Flows In accordance with Statement FASB ASC Topic 230, “Statement of Cash Flows,” cash flow from the Company’s operations is calculated based upon the local currencies and translated to the reporting currency using an average foreign exchange rate for the reporting period. As a result, amounts related to assets and liabilities reported in the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet.

Use of Estimates and Assumptions The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and judgments on historical experience and on various other assumptions and information that are believed to be reasonable under the circumstances. Estimates and assumptions of future events and their effects cannot be perceived with certainty and, accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment changes. Significant estimates and assumptions by management include, among others; useful lives of long-lived assets and intangible assets, valuation of inventory, accounts receivable and notes receivable, impairment analysis of long-lived assets, construction in progress, intangible assets and deferred taxes. While the Company believes that the estimates and assumptions used in the preparation of the financial statements are appropriate, actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary.

Cash and Cash Equivalents Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less at the time of purchase. As of June 30, 2022, and 2021, the Company’s uninsured bank balance was mainly maintained at financial institutions located in the PRC and Hong Kong, totaled $44,789,999 and $44,346,744, respectively. The Company has no insured bank balance as of June 30, 2022 and 2021, respectively.

44789999

44346744

Accounts Receivable Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company extends unsecured credit to its customers in the ordinary course of business but mitigates the associated risks by performing credit checks and actively pursuing past due accounts. An allowance for doubtful accounts is established and determined based on management’s assessment of known requirements, aging of receivables, payment and bad debt history, the customer’s current credit worthiness, changes in customer payment patterns and the economic environment. From November 1, 2013, the Company changed its credit policy by offering ninety (90) day payment terms for sales agents, whereas the payment terms for sales agents before November 1, 2013 were thirty (30) day. Due to COVID-19, the company extended its credit policy to 180 days this year. As of June 30, 2022 and 2021, the balances of accounts receivable were $9,567 and $2,346,867, respectively. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company evaluated the nature of all accounts receivable then provided allowance for doubtful accounts. As of June 30, 2022, and 2021, the balances of allowance for doubtful accounts were $48,769 and $60,394 respectively.

Advance to Suppliers The Company periodically makes advances to certain vendors for purchases of raw materials, or service providers for services relating to construction plans for our plant, equipment and production lines for the GMP upgrading, and records these payments as advance to suppliers. The decrease in the amount of advance to suppliers is due to fluctuation of exchange rate. As a result, as of June 30, 2022, and 2021, advance to suppliers amounted to $214,915 and $218,307, respectively. 214915 218307

Inventory Inventory consists of raw materials, work in progress and finished goods of manufactured products. Inventory is stated at lower of cost or market and consists of materials, labor and overhead. HLJ Huimeijia uses the weighted average method for inventory valuation. The other entities of the Company use the first-in, first-out (“FIFO”) method for inventory valuation. Overhead costs included in finished goods include direct labor cost and other costs directly applicable to the manufacturing process. The Company evaluates inventory for excess, slow moving, and obsolete inventory as well as inventory the value of which is in excess of its net realizable value. This evaluation includes analysis of sales levels by product and projections of future demand. If future demand or market conditions are less favorable than the Company’s projections, a write-down of inventory may be required, and would be reflected in cost of goods sold in the period the revision is made. The inventory allowance with an amount of $nil and $nil were provided for the years ended June 30, 2022, and 2021, respectively.

Impairment of Long-Lived Assets The Company’s long-lived assets and other assets are reviewed for impairment in accordance with the guidance of the FASB ASC Topic 360-10, “Property, Plant, and Equipment,” and FASB ASC Topic 205, “Presentation of Financial Statements.” The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of the asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on the Company’s reporting results and financial position. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. As of June 30, 2022, and 2021, the Company has not experienced impairment losses on its long-lived assets. However, there can be no assurances that demand for the Company’s products or services will continue, which could result in an impairment of long-lived assets in the future.

Property, Plant and Equipment Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses. Maintenance, repairs and minor renewals are expensed as incurred, major renewals and improvements that extend the lives or increase the capacity of plant assets are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in the results of operations in the reporting period of disposition. Depreciation is calculated on a straight-line basis over the estimated useful life of the assets.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Building, Warehouse and Improvements</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: right">20 to 30 years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Office Equipment</td><td> </td> <td style="text-align: right">3 to 7 years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vehicles</td><td> </td> <td style="text-align: right">5 to15 years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Machinery and Equipment</td><td> </td> <td style="text-align: right">7 to 15 years</td></tr> </table>

Intangible Assets The Company evaluates intangible assets in accordance with FASB ASC Topic 350, “Intangibles — Goodwill and Other.” Intangible assets deemed to have indefinite lives are not amortized, but are subject to annual impairment tests. If the assumptions and estimates used to allocate the purchase price are not correct, or if business conditions change, purchase price adjustments or future asset impairment charges could be required. The value of the Company’s intangible assets could be impacted by future adverse changes such as: (i) any future declines in the Company’s operating results, (ii) a decline in the valuation of technology, including the valuation of the Company’s common stock, (iii) a significant slowdown in the worldwide economy, or (iv) any failure to meet the performance projections included in the Company’s forecasts of future operating results. In accordance with FASB ASC Topic 350, the Company tests intangible assets for impairment on an annual basis or more frequently if the Company believes indicators of impairment exist. Impairment evaluations involve management estimates of asset useful lives and future cash flows. Significant judgment by management is required in the forecasts of future operating results that are used in the evaluations. It is possible, however, that the plans and estimates used may be incorrect. If the Company’s actual results, or the plans and estimates used in future impairment analysis, are lower than the original estimates used to assess the recoverability of these assets, we could incur additional impairment charges in a future period. Based on such evaluations, there were no impairments recorded for intangible assets for the years ended June 30, 2022 and 2021, respectively.

Construction in Progress Construction in progress represents the costs incurred in connection with the construction of buildings or new additions to the Company’s plant facilities. Costs classified as construction in progress include all costs of obtaining the asset and bringing it to the location in the condition necessary for its intended use. No depreciation is provided for construction in progress until such time as the assets are completed and are placed into service. The Company reviews the carrying value of construction in progress for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value of the assets, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of the assets. The factors considered by Management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors. Based on this assessment, there were no impairments recorded for construction in progress, for the years ended June 30, 2022 and June 30, 2021, respectively. However, there can be no assurances that demand for the Company’s products or services will continue, which could result in an impairment of long-lived assets in the future.

Revenue Recognition The Company recognizes revenue at the amount to which it expects to be entitled when control of the products or services is transferred to its customers based on any contract which has been identified. Control is generally transferred when the Company has a present right to payment and title and the significant risks and rewards of ownership of products or services are transferred to its customers while performance obligation are identified and completed. For most of the Company’s products net sales, control transfers when products are shipped and transaction price are determined. The majority of the Company’s revenue relates to the sale of inventory to customers, and revenue is recognized when control of the products or services is transferred to its customers that reflects the performance obligations are properly allocated and satisfied with transaction price determined. Given the nature of the Company’s business and the applicable rules guiding revenue recognition, the Company’s revenue recognition practices do not contain estimates that materially affect the results of operations. The Company records revenue at the discounted selling price and allows its customers to return products for exchange or credit subject to certain limitations. A provision for such returns is recorded based upon historical experience. There has been no provision recorded for returns based upon historical experience for the years ended June 30, 2022 and 2021, respectively.

Cost of Goods Sold Cost of goods sold consists primarily of the costs of raw materials, freight charges, direct labor, depreciation of plants and machinery, warehousing and overhead costs associated with the manufacturing process and commission expenses.

Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established for deferred tax assets if it is more likely than not that these items will either expire before the Company is able to realize the benefits or that future deductibility is uncertain.Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition. As a result of the implementation of FIN 48 (ASC 740-10), the Company undertook a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by FIN 48 (ASC 740-10). The Company recognized no material adjustments to liabilities or shareholders’ equity as a result of the implementation. The adoption of FIN 48 did not have a material impact on the Company’s financial statements. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from the Company’s estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.

Enterprise Income Tax Under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC (the “EIT Law”), income tax is payable by enterprises at a rate of 25% of their taxable income. 0.25 Value Added Tax The Provisional Regulations of the PRC Concerning Value Added Tax promulgated by the State Council came into effect on January 1, 1994 and revised on January 1, 2009. Under these regulations and the Implementing Rules of the Provisional Regulations of the PRC Concerning Value Added Tax, value added tax (“VAT”) is imposed on goods sold in, or imported into, the PRC and on processing, repair and replacement services provided within the PRC. VAT payable in the PRC is charged on an aggregated basis at a rate of 13% or 16% (depending on the type of goods involved) on the full price collected for the goods sold or, in the case of taxable services provided, at a rate of 16% on the charges for the taxable services provided, but excluding, in respect of both goods and services, any amount paid in respect of VAT included in the price or charges, and less any deductible VAT already paid by the taxpayer on purchases of goods and services in the same financial year. As of June 30, 2022 and June 30, 2021, VAT payables were $29,835 and $34,697, respectively. 0.13 0.16 0.16 29835 34697 Sales-Related Taxes Pursuant to the tax law and regulations of the PRC, the Company is obligated to pay 7% and 5% of the annual aggregate VAT paid by the Company as taxes for the purposes of maintaining and building cities and educational facilities, which fees are included as sales-related taxes. Sales-related taxes are recorded when sales revenue is recognized. 0.07 0.05

Concentrations of Business and Credit Risks All of the Company’s manufacturing is located in the PRC. There can be no assurance that the Company will be able to successfully continue to manufacture its products and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. Moreover, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. These contingencies include general economic conditions, prices of raw materials, competition, governmental and political conditions, and changes in regulations. Since the Company is dependent on trade in the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company’s operations will be subject to the risks of restrictions on transfer of funds, domestic customs, changing taxation policies, foreign exchange restrictions, and political and governmental regulations. The Company operates in China, which may give rise to significant foreign currency risks from fluctuations and the degree of volatility of foreign exchange rates between U.S. dollars and the Chinese currency RMB. The results of operations denominated in foreign currency are translated at the average rate of exchange during the reporting periods.

Earnings Per Share Basic earnings per common share is computed by dividing net earnings applicable to common shareholders by the weighted-average number of common shares outstanding during the period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. For the years ended June 30, 2022 and 2021, the Company had no potential dilutive common stock equivalents outstanding. Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period. FASB ASC Topic 260, “Earnings Per Share,” requires a reconciliation of the numerator and denominator of the basic and diluted earnings per share (EPS) computations.

Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments (ASU 2016-13). The main objective of the standard is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In issuing this standard, the FASB is responding to criticism that today’s guidance delays recognition of credit losses. The standard will replace today’s “incurred loss” approach with an “expected loss” model. The new model, referred to as the current expected credit loss (“CECL”) model, will apply to: (1) financial assets subject to credit losses and measured at amortized cost, and (2) certain off-balance sheet credit exposures. The standard is applicable to loans, accounts receivable, trade receivables, and other financial assets measured at amortized cost, loan commitments and certain other off-balance sheet credit exposures, debt securities (including those held-to-maturity) and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The CECL model does not apply to available-for-sale debt securities. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to what they do today, except that the credit losses will be recognized as allowances rather than reductions in the amortized cost of the securities. Accordingly, the new methodology will be utilized when assessing the Company’s financial instruments for impairment. As a result, entities will recognize improvements to estimated credit losses immediately in earnings rather than as interest income over time, as they do today. The ASU also simplifies the accounting model for purchased credit-impaired debt securities and loans. ASU 2016-13 also expands the disclosure requirements regarding an entity’s assumptions, models, and methods for estimating the allowance for loan and lease losses. ASU 2016-13 is effective for years beginning after December 15, 2019, including interim periods within those fiscal years under a modified retrospective approach. Early adoption is permitted for the periods beginning after December 15, 2018. The Company adopted the guidance from July 1, 2020. The Company finalized its analysis and determined that the adoption of this guidance has no material impact on the Company’s consolidated financial statements and its internal controls over financial reporting. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13), which modifies the disclosure requirements on fair value measurements, including removing the requirement to disclose (1) the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, (2) the policy for timing of transfers between levels and (3) the valuation processes for Level 3 fair value measurements. ASU 2018-13 also added new disclosures including the requirement to disclose (a) the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and (b) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2019 and early adoption is permitted. This standard will only impact the disclosures pertaining to fair value measurements. The Company adopted the guidance from July 1, 2020. The Company finalized its analysis and determined that the adoption of this guidance has no material impact on the Company’s consolidated financial statements and its internal controls over financial reporting.

NOTE 3 - ASSETS SALE On December 24, 2014, Humankind entered into a stock transfer agreement (the “Agreement”) with Xiuzheng Pharmaceutical Group Co., Ltd a company incorporated under the laws of the People’s Republic of China and located in Jilin province (“Xiuzheng Pharmacy” or the “Buyer”), and Mr. Xin Sun, the CEO of the Company, and Huimeijia, pursuant to which, Humankind and Mr. Xin Sun (the “Equity Holders”), shall sell their respective equity interests in Huimeijia to Xiuzheng Pharmacy. The transfer of the 100% equity interests of Huimeijia to the Buyer was for a total cash consideration of RMB 8,000,000 (approximately $1,306,186) to the Equity Holders. On February 9, 2015, the four parties entered into a supplementary agreement (the “Supplementary Agreement”) to modify the terms of the Agreement, pursuant to which, the Equity Holders and Huimeijia (collectively the “Assets Transferors”) shall only sell the 19 drug approval numbers (including the tablet, capsule, powder, mixture, oral liquid, syrup and oral solution under the 19 approval numbers; licenses including the original copies of Business License, Organization Code Certificate, Tax Registration Certificate, Drug Production Permit and GMP Certificate, and other documents and original copies related to the production and operation of the 19 drugs) (the “Assets”) to Xiuzheng Pharmacy. The Equity Holders will retain the equity interests in Huimeijia, but will have the equity interests pledged to Xiuzheng Pharmacy until the Assets are transferred, at which time all the cash consideration shall be paid by the Buyer. The total cash consideration remains to be the same as under the Agreement, i.e., RMB 8,000,000 (approximately $1,306,186) to the Assets Transferors. In the event that the Assets are failed to be transferred to the Buyer due to the fault of the Assets Transferors, the paid consideration shall be returned to the Buyer with interests accrued. If the failure of the transfer of the Assets is a result of the government policy changes or force majeure, the paid cash consideration shall be returned to the Buyer but without any interests. As of June 30, 2016, the transfer of the Assets had not been completed because the assets transfer crossed different provinces which resulted in a complicated interaction among the local administrations of Heilongjiang Province, where Huimeijia is located and Jilin Province, where the transferee is located. On October 12, 2016, the four parties agreed to rescind the Supplementary Agreement and entered into a new supplementary agreement (the “New Supplementary Agreement”), pursuant to which the four parties agreed to execute the transfer of the equity interests based on the Original Agreement and the Equity Holders agreed to sell their respective equity interests in Huimeijia to Xiuzheng Pharmacy. The transfer of 100% of the equity interests of Huimeijia to the Buyer was for a total cash consideration of RMB 8,000,000 (approximately $1,306,186) (the “Purchase Price”) to the Equity Holders. 40% of the Purchase Price was due within 10 business days after the signing of the New Supplementary Agreement; 40% of the Purchase Price was due within 10 business days after the completion of the changes in business registration described in the Original Agreement and Xiuzheng Pharmacy obtaining documents evidencing its ownership on Huimeijia; 15% of the Purchase Price is due within 10 business days after the transfer of all of the Assets is approved by Heilongjiang FDA; and 5% of the Purchase Price is due within 10 business days after all of the Assets have been transferred to Xiuzheng Pharmacy or its designee and Humankind and Mr. Xin Sun have instructed Xiuzheng Pharmacy to complete three-batches production of all forms of the drugs included in the Assets. As of the date of this report, 80% of the Purchase Price has been paid, the Company has completed changes in its business registration, and Xiuzheng Pharmacy has obtained a business license issued by the local State Administration of Industry and Commerce in Harbin (“Harbin SAIC”) to Huimeijia, in which the ownership of Huimeijia has been recorded as held by Xiuzheng Pharmacy, with Harbin SAIC and the legal representative (a person that is authorized to take most of the corporate actions on behalf of a company under the corporate laws in China) of Huimeijia has been appointed by the Buyer.

8000000

1306186

the four parties entered into a supplementary agreement (the “Supplementary Agreement”) to modify the terms of the Agreement, pursuant to which, the Equity Holders and Huimeijia (collectively the “Assets Transferors”) shall only sell the 19 drug approval numbers (including the tablet, capsule, powder, mixture, oral liquid, syrup and oral solution under the 19 approval numbers; licenses including the original copies of Business License, Organization Code Certificate, Tax Registration Certificate, Drug Production Permit and GMP Certificate, and other documents and original copies related to the production and operation of the 19 drugs) (the “Assets”) to Xiuzheng Pharmacy.

40% of the Purchase Price was due within 10 business days after the signing of the New Supplementary Agreement; 40% of the Purchase Price was due within 10 business days after the completion of the changes in business registration described in the Original Agreement and Xiuzheng Pharmacy obtaining documents evidencing its ownership on Huimeijia; 15% of the Purchase Price is due within 10 business days after the transfer of all of the Assets is approved by Heilongjiang FDA; and 5% of the Purchase Price is due within 10 business days after all of the Assets have been transferred to Xiuzheng Pharmacy or its designee and Humankind and Mr. Xin Sun have instructed Xiuzheng Pharmacy to complete three-batches production of all forms of the drugs included in the Assets. As of the date of this report, 80% of the Purchase Price has been paid, the Company has completed changes in its business registration, and Xiuzheng Pharmacy has obtained a business license issued by the local State Administration of Industry and Commerce in Harbin (“Harbin SAIC”) to Huimeijia, in which the ownership of Huimeijia has been recorded as held by Xiuzheng Pharmacy, with Harbin SAIC and the legal representative (a person that is authorized to take most of the corporate actions on behalf of a company under the corporate laws in China) of Huimeijia has been appointed by the Buyer. NOTE 4 - ACCOUNTS RECEIVABLE The Company’s accounts receivable amounted to $9,567 and $2,346,867 net of allowance for doubtful accounts amounting to $48,769 and $60,394 as of June 30, 2022 and 2021, respectively.

1860000 12800000 0.779 1448567 9702644 949040 6356767

If not utilized, the federal net operating loss for the fiscal years 2022 and 2021 in an amount of $223,833 and $187,462, respectively, will begin to expire in the years 2041 and 2040, respectively.

NOTE 12 - COMMITMENTS AND CONTINGENCIES The Company’s assets are located in the PRC and revenues are derived from operations in the PRC. In terms of industry regulations and policies, the economy of the PRC has been transitioning from a planned economy to market oriented economy. Although in recent years the Chinese government has implemented measures emphasizing the utilization of market forces for economic reforms, the reduction of state ownership of productive assets and the establishment of sound corporate governance in business enterprises, a substantial portion of productive assets in the PRC is still owned by the Chinese government. For example, there is no private land ownership in PRC and all land is leased by government to business entities or individuals through the government’s granting of Land Use Rights. The granting process is typically based on government policies at the time of granting and can be lengthy and complex. This process may adversely affect the Company’s future manufacturing expansions. The Chinese government also exercises significant control over the PRC’s economic growth through the allocation of resources and providing preferential treatment to particular industries or companies. Uncertainties may arise with changing of governmental policies and measures. The Company faces a number of risks and challenges not typically associated with companies in North America and Western Europe, since its assets exist solely in the PRC, and its revenues are derived from its operations therein. The PRC is a developing country with an early stage market economic system, overshadowed by the state. Its political and economic systems are very different from the more developed countries and are in a state of change. The PRC also faces many social, economic and political challenges that may produce major shocks, instabilities and even crises, in both its domestic arena and in its relationships with other countries, including the United States. Such shocks, instabilities and crises may in turn significantly and negatively affect the Company’s performance. The Company had no rental commitment as of June 30, 2022.

NOTE 13 - MAJOR SUPPLIERS AND CUSTOMERS For the year ended June 30, 2022, the Company had no suppliers due to its being temporarily out of production. For the year ended June 30, 2021, the Company had three suppliers that in aggregate accounted for approximately 78% of the Company’s purchases, with each supplier accounting for 40%, 22% and 16%, respectively. For the year ended June 30, 2022, the Company had no customers due to the enterprise Transformation and the COVID-19 resurgence. For the year ended June 30, 2021, the Company had six customers that in aggregate accounted for 91% of the Company’s total sales, with each customer accounting for 23%, 18%, 16%, 13%, 12%, and 9%, respectively.

3 0.78 0.40 0.22 0.16 6 0.91 0.23 0.18 0.16 0.13 0.12 0.09

5074 8582 13656 2994826 47724803 27889 50747518 3453342 50347870 86925 53888137

NOTE 15 - SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined that there are no additional items required to disclose.

-0.0054

0.0197

65539737

false 86-451- FY 0001309057 88100688

EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( Y(+U4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " .2"]5HH-A^>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$Y882;-I:.G#@8K;.QF;+4UBQUC:R1]^R5>FS*V!]C1TN]/ MGT"-#E+W$9]C'S"2Q70WNLXGJ<.:G8B"!$CZA$ZE,1@M(? MZHA0<;X"AZ2,(@4SL @+D;6-T5)'5-3'"][H!1\^8Y=A1@-VZ-!3 E$*8.T\ M,9S'KH$;8(811I>^"V@68J[^B\GK%M8G M4E[C]"M92>> :W:=_%IO'O=;UE:\J@K^4(C[O:@EYU*LWF?7'WXW8=<;>[#_ MV/@JV#;PZR[:+U!+ P04 " .2"]5F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M Y(+U4"F8:-*0< ',N 8 >&PO=V]R:W-H965T&UL MM9I="^DL/ECL[X:HO79$7XE^V2B:U.KN+Y(8EBGT:(D>?K MUL1\-[4'LB ]XJM/=O'19R1OY8G2GW)C[EVW#'E%)" NEQ)8_'LA#@D"J22N MX]^]:"L_IRP\_GQ0GZ4W+V[F"L>Q%&!/:HHL/8%UB\%9M49['V! M7;>@NR_HIF2R6TDY3#''XRM&=XC)HX6:_)#"3*O%[?N1_-U7G(EO?5''QU/J M)N)GY&@2>>@VXCY_0_,H:T_R=VFC+ZLI^NN/OZ\Z7)Q.%G7\LD!'7&=^L=;A8F\L4/&?)+I$MG&!+,.R%!?DP.4KLKU$9J^R M? J73XDKSFZFY29P-W:.WD[U[%/HCWG?BX/0G),P5@'/!+MJ0=E%O(NWV"77 M+=$'Q(2]D-;XS]_-OO%>!4NGV%236 ED-P?9A=3'^V;[0-9^S!D61!)"U9KMXU^VS94Q,#"IL0TB96(#7)B@SH/IT/#4'1O*T[=GQ=H MM<'B3.ASPF..(\^/UBIXH'#3WBX3ZZ5BT@R]C/N]GCT:V(.KSLLQ+$UG+<$: MYK"&=6 MDZ? =]$LH)BKP( B3<'H%)MF8OTCRKVNW;>M40ZYQ&64N?<1"KGD\'+&MZ\YK$2H1,HS!R1JT'35!BHFN:"\_UBCZ2 M-Z5Q@Z4,PS!M8V3T!BIF<'%3:+K4RM2.[*]9B]J^7W\@6\JXZ(]$3X5YHC1A M)Q2_$U65 UBTNGA=:F5LA8\W:QKY)6$^ M]4"3>D(J3]V5L1L6:$SN' ;?+!R^"9ORG-RQQY^)G>KN#1:K)*;5W^M2*Q,K M'+X)6_Q?B>V;7#4S6&[V74E,9QJ8ZE(K$RMLOEG+YZ]"' 3H)HG%U[$:%:S# M6:*TM7!98UB:U,JP"N]OPN9]#^LV)&PMG=D'H< W,E%N<:0>2/]G&H#K&F,[ M1QZPBCQ@UE+A@H:I^#"YK3.L< M.< JUAR@2ZU,K\@!5JVI_HGG"?7XXO A>Z?Y.5*W.5C2-D>CMHGN M:;1^];$P?P\4>TJ06N.!+K4RR"(>6+7B@1KDXTXU>W%S0G(E"#X1'TWE*U+? M50TY#BS1F.$Y4H-5I :K5FK(&3IR2W2"CW07*?G!8/?E1JJ)$IS4YZ%(K M+TLHDH-=*SD4Z+)Q0[D@ 59R%LJ%!UJ3@RZU,JPB.=BU7B#DL)941(< _?"W ME>/L"46S9QC64 E.:WC0I58&5X0'N]8[A'G$"(L(_6#,&^_Y!19SX+T7RJI 0K6(/^2(E)[WJ@+'$GO ;Z*/Z(H6/C1UC)3&MLT*569E;$!OO$JJ!T!& $5W?Y)T-"MV>V ME:"T)@1=:F5014*P83LO&U6 EAL:07G^A,AP:!I&?Z@>(;7& %UJ&:W.T2I= M.9>=KG:.D2O=5;9@-]^;KZB>I.N(.\7AV7+L3UA.A<&PO=V]R:W-H965T&ULK5EM M;]LV$/XKA%L4+>#&(JG7-C&0IBO6 MN"I%T_,Q)M"Y5$5:*<9+]^1TG1*T6W M6P,DD>2'Q^>HXSUW]/F]*+Z5!\XE>DB3K+Q8':3,WVPV97C@*2O/1,XS^&0G MBI1)N"WVFS(O.(OJ06FR(9;E;E(69ZOM>?WLNMB>BTHF<<:O"U16:G 3[P]2/=ALSW.VY[=)L@0\OK=&5]V< M:N#P^LGZA]IY<.:.E?Q*)%_C2!XN5OX*17S'JD3>B/O?>>N0H^R%(BGKO^B^ MQ5HK%%:E%&D[&!BD<=;\9P_M0@P&8'MA &D'D!\=0-L!M':T85:[]9Y)MCTO MQ#TJ%!JLJ8MZ;>K1X$V-1.0A0D^5=D9HM8:$8L0S?"K M'Q^.Q\,WX&KG+^G\);4]NN1O510\DXB5);BHV[?D!_)QOCD./=$!JNYYM=\ 16[MC:QO97H:AJ( ;$)V#"/#T![@13Z?CZ1AY?LR.L(:B>-01I)>1](SO^;H MJ%),B:0 ZO#=H"="4D=S*?6PDOV.Y:^D>5UP7/VF"YM%G^^ M,I9EV1-JH MGBBV>F6Q3BPB%!N%?%RC'&0%=K;*12H-Y6IA%X.SM3J.3L>OT_^(N0[HDB"P MG 7F TW$)_:X9-D^ACW4KO R63SC@&U,7(M.R6J @4L=O! /N!&'SXUZ2L%F3WO,=A]"-D&0/ MAN@U6_E9$6ZMC79B0)?BNQ[F<@?1" M0WNWT.7,Q=/UH$!PIRJK ?J6-P*.F?8J2\PJ^Y7M>1>M6HX:S72)36<4YS@H M MV!JHT9#GI%L[1^9@\G&,YU$E.H!:=5J@[G@?HO1";I]928]71<#IY(=V2N M@R#^MC?K\33 &/("0O%"NDUD]C&Q/P;E']2VSJ1_Z!HAK[[%UD;N]F+)#&+ MY)5(4ZC&($^$W];HY7/K#/H#K/8D@AZ\X@@*8U0>6 $]+H3+VFI^FT=0*%?R M((KX'QZMZRSN.FN'!FN/>D^(N"Q56E^.7&K, M\ E>0X]8YKP^/TL>M4)-S'WL913%JIB%P,Y9'+V& MFC9D>0R!KJ4Z;U.AYP[\:<(]C1O3[767G-3=*JV:I"MJ)0M%"E%U4&>=1PXE M.=SKL\=<4%4!1*PI=5V3Z[A>L)3@>N4E9N6]E4Q6ZC #M;M GS\,E@T=0Q+ B@RC7<]3H+G8#5T-3@R2@O"Y98$I[[:5F[6VR M<;WK#R*)H$2H^P+O;=WVZO,>G>NK3:#;]?#LY$V#A%[==NT%*::]%%.S%#?$ M#23G"KM$4H,TD^S5F)Y0XYKD0..Z X4%TF1V5+G0B>B0^DYD,SAI5U]S_,&* M?9R5*.$[&&J=>>!XT7QST-Q(D=>'[W="0M%87QXX@]!0 /A\)X1\NE'G^=WW M-]M_ 5!+ P04 " .2"]5V5A%?IP" !1!P & 'AL+W=O>WSM?SM.]5%M= !CR4'*A9UYA3#7Q M?9T54%(]D!4(?+.6JJ0&IVKCZTH!S1VHY'X8!(E?4B:\=.K6%BJ=RMIP)F"A MB*[+DJJ?-\#E?N8-O<>%>[8IC%WPTVE%-[ $\[E:*)SY'4O.2A":24$4K&?> M]7 R3VR\"_C"8*\/QL0Z64FYM9,/^3:_9-]$YM@ M<%9K(\L6C I*)IHG?6CS< 8CIX!A"T@/!40M8#(&6V4.5NWU-!TJN2>*!N- M;';@XI+H_ M0YQ)YU)HR5E.#>3DAG(J,B!+2Z?)Q76=,UR_)!<+ MJD"8 @S+*->7Y#5Y27RB"US64]^@$$OG9^VF-\VFX3.;?JS%@$3!%0F#,.R! MST^'#X_A/MKOZQ,0^2:W#&!.6"4DX74S)7:M^N5-@H+ M[GN?U89[U,]M/\*)KF@&,P^_,@UJ!U[ZZL4P"=[U&?]/9$=IB+HT1']CQU(H M2W2+)9=MKTA%%=E17@.Y8(+<2LZITJ0"U9SZ95\J&OZQX[?M8Y<&@R (\(QV MAR;_&78D?]3)'YTAORE-0FM32,5^0=ZGMR&,#X1$0?M[(OF4R"/5<:I-.;G*\7;P=MJ,B9V/2)3DX5?4)@(]H_ M:'CVLOE$U88)33BL$1H,QLBAF@;>3(RL7 ]<28,=U0T+O/- V0!\OY;2/$YL M6^UNT?0W4$L#!!0 ( Y(+U41G]I#P04 $L6 8 >&PO=V]R:W-H M965T&ULK5C;;N,V$/T5PBT666 3B91URSH&8D?)IMC8ANV] M $4?%(NQU95$5Z2=;+^^HTLD6Z+8%/6+=?',T9D9#@_)P3-+?_ -I0*]Q%'" MKWH;(;:7FL97&QK[_()M:0+_/+$T]@4\IFN-;U/J![E3'&E$URTM]L.D-QSD M[V;I<,!V(@H3.DL1W\6QG_X/ 3SZ',Z9M&W,!";JY[30P%] M\G>1F+/G3[0,R,SP5BSB^2]Z+FWU'EKMN&!QZ0P,XC IKOY+F8@#!VQU.)#2 M@30=^AT.1NE@Y($6S/*P;GSA#PT9I9@UHV4V>F]P;H@F3K(P+D<*_(?B) MX9@EG$5AX L:H(6 "]1(<,2>T'1+4S_+-4=^$J QBV&@;+(*[BFZ3U8LINCL M>A>$X/H>G:,OBQMT]NO[@2: 5X:NK4H.HX(#Z>" "7I@B=APY"4!#8X!- BH MBHJ\1C4B2L3?=LD%,O0/B.B$2 B-W^Z.%72,*LE&CF=TX)7)JM*+?K]^Y"*% M(?R'+%L%6%\.EO7U)=_Z*WK5@WIPFNYI;_CN%VSI'V61G@CL*.Y^%7=?A3Z< M>U^]R1=/%F/A:.6.V52S'Q++'FC[0^IM&ZOO$IOHE=T1*[-B92I9C:>+)9K> MHKOI]&:!%M//-S*"!89Y\'%L]YT&P[81<4S=)JZI%UEM;Y^COL.;G!L6QE6'[LNEG.T*XZVGD_N4/>]YDW M67@+&47[E$/Y1&!'X3I5N(ZR) L0FC!9?T!KFL"T&.53HA_ C!QFG9QI$:(O M(*Z<7%HYUTTW8LO5D5".9H6E; M=M>PKL44J]7T>)X<>;?3N5?.0&AY_5V^EL!M<3PW3*SC5OW;AME"WNR2?MO2<+!I&AVC@M0"2I1"!1N*A]G<^P2R M>?_5>T/"26M?/=LLR.!B2U]A'UCG1"!3J+&.?OM7(4PQ(+ M<9C;Z*64\TGWI*=".PZ^%E6B%E5%\&CD\W"%WOGQ]B,*PFB7'8NULQK6I#E MB.T$%[#RAT6TO,!*@?[/!3X1VG$2:J$F_R;4\B(N\ES(*]=696@S6%T835%\ MBV7!6SLXEHLIK!JRTTJ.5FR7B.(LJWI;G8A>Y^> C?&PO=V]R:W-H965T M&ULK55=;]HP%/TK5C95(*TD)'RL+40"NFF=U T5;7N8]F"2 M"['JV)GM0/?O=^V$E#) ?=@+L9U[CL^Y=@ZCK52/.@,PY"GG0H^]S)CBVO=U MDD%.=4<6(/#-2JJ<&IRJM:\+!31UH)S[81 ,_)PRX<4CMS97\4B6AC,!=4_9D"E]NQU_5V"P]LG1F[X,>C@JYA >9;,5M:W]:[@.X.MWAL3ZV0IY:.=W*5C+[""@$-B+ /%QP9FP+DE0AF_:TZOV=(" M]\<[]H_..WI94@TSR7^PU&1C[[U'4EC1DIL'N?T$M1\G,)%Z#WN [N $(*P!X2&@=P(0U8#(&:V4.5NWU-!XI.26*%N- M;';@>N/0Z(8)>XH+H_ M0YR)9U)HR5E*#:1D8?"!1V0TD2ORM0!%;:\UH2(E M,YGC/XK$>^0:UV M1S^I=4TK7>$)7=V0W$NDT^2#2"%]2>"CR<9IN',Z#<\R?BY%AT3!.Q(&87A$ MT.SU\.X9.5'3^,CQ12?XZ@8V+2<_)TMM%%[K7\>Z59'UCI/93_U:%S2!L8=G MI$%MP(LOWG0'PT&0@UJ[ M?-0DD:4PU9?2K#81/'')<[ ^Q6BNDO29ILKU>ZK6#".!PPHI@\X09:DJ*ZN) MD86+FZ4T&%YNF.'?"RA;@.]74IK=Q&[0_&'%?P%02P,$% @ #D@O52IY MJM/1! ^QP !@ !X;"]W;W)K]>*R#;7 "Y0HZ;;W\"$\Z 3'"CN3DPQ0O!HK-_ Z@*5#:?%7C/?Y MT3$HAO)(R%-Q$D1C12LRP@D.68% _.<93W&2%"2>QX\*JM0Q"\?CXU?ZHAP\ M'\PCRO&4)'_'$=N,%52)"__@OW!UN;&X2YG)*V< M>09IG!U^T<]J(HXO>9P58G]@E-^-N1^;3$F6DR2.$,,1>&#\ARN9Y8"L^!D)GS8DB3#- M/WYP=>A\ ?,?NYB]@(N;711SCT_@$GQ_F(&+WSZ-5,;3*:!J6(6^/8363X9. M4R[WAPVB.!>X3_O=;R*> G]>4 +N4!Q=QAF8HFW,4")@S?I9]YCQ=8'/P!S1 M+,[6HG3F_8AB[G:,T!=PCW-,G[$ L7AC1&&X2W=)68H_V093P*>(+V&;8FUY MQB#(0I)B<)&0/!?-][(?_XWPN>FIJH#H]Q._DNPR)!FC).&WUCQ!AGDMF8 4 M#,BMZ:9R)==RUFLYZR7'/,&Y10G*0@P0 [_OLBM@:)^!KNF:2)T'DEV2BCWA M>6);ECE2GX\UV#6R=.BY3M-LUC4S-$VK1=?J$MJ6ZYBP M:;@4X#R;\UR[:>CW3ENQHU[G6Q3BL<+U5LI7F0!1&0<$;!3.J MG#"K<1?RZ M(GP:5,0#U6H6T? S1RV\["QG3T8B)Q]<8Z M0UR2.#-)G+DDSL+J%-%P(=\6C-;N.=#.EY17\':\AKCL6ESVKS0]4"0=>TC3 M8W?R%#8]73-3URS-UEOMS+QK*&IZNE8ZM+A9ZU%?"L*:CF/:[>;([YVU,\HV M(&"C;DY=-^>]/8^PAL[0GJYY>Q)FCG^U0PU]F>D% Z(VA >U_]YV:K_2*NG" MMY?:D%Y)8"5LE@1V)K3+=R>M14A@*6J71($-U]5;*\)2%%AW-=V!+:+?/W?G M%G%(W&85C]Y9P_KC!Z^M!U.&-F6GV$>"6,D+0\W&$68%@;\_HH0 M]GI2?-FIOW=._@502P,$% @ #D@O5; 'V["K!P .B0 !@ !X;"]W M;W)K8FF8DC N";?+9F'"69 MI'--/?7U\ADB(0DM1:@@*-O]]5V0,BF2(&+9\@=+I!:+9Q<+/ ] 7MU+]6>Q MX5RCAVV6%]>3C=:[R^FT2#9\RXKW;OPFUAMM;DSG5SNV MYG=<_[Z[57 U;;RD8LOS0L@<*;ZZGMS@RX7OF0:5Q?\%OR^.OB,3RE+*/\W% MU_1ZXAE$/..)-BX8?.SY@F>9\00X_CHXG31]FH;'WY^\?ZZ"AV"6K. +F7T7 MJ=Y<3^()2OF*E9G^3=Y_X8> N,OD5E1_4?W!UMO@I*RT')[: P(MB*O/]G# M(1%'#7 XTH <&I!^ W^D 3TTH%6@-;(JK(],L_F5DO=(&6OP9KY4N:E:0S0B M-\-XIQ7\*J"=GB]D7LA,I$SS%-UI^( QT@62*[1@Q09]AG$NT)N;,A5@\19= MH-_O/J(W_WI[-=70O7$R30Y=?:B[(B-=88)^D;G>%.A3GO*TZV *N!OPY G\ M!^+T^'.9OT?4>X>(1X@%T.+YS;$##FUR22M_="R7;<)62F[1KSNNF!;Y&MV8 M8A5:\,*6MMJK;_=JYO%EL6,)OY[ 1"VXVO/)_-\_X=#[CRWD,SGK),!O$N"[ MO,^_P;+S)I-%\78J\D1N.6):*[$L-5MF'&F)%AN1,_2%LTQOT-<\A0)7D!7T M168I),J:GKK/L.K3K$K[^04-Z"SPKJ;[X\B'=IC,,#:5L;<$%31!! M*%O,HCB:^?9!CAK8D1/VK1FTBIJ &5$JRZ5>E1F,6B)+&'@;WF@ Y&(6!&$/ MKL4*TS ,[7#C!F[\@RRON%)08YH]P.Q9 UW;(,:#SDD<]J?-T(A2.I+.68-O MYEX)-RQ? S"1'T^!HN PATQ19((M138^'6;GG YGU'4!VHQ#,/(B\>0DA8I<2+]56^X.H)IG9,'']WIAOT^R*$5H:,(6_;'3FX% MHMBS/*G(H"AWNTQP55<[U-6.B=2Y^AU\]Y![9(!]:$?"6>R-@&^9&[NINRF$ M'7NLTELOWDFB2OX#Y/X0>1#-,.DCM]C1, A&EAK<\C-V$EJ3]TISU9+Y*?.R M*IJGD*SH@^'R%\0XFO71#^TPH6$\ KZE2^SFRYMMG?:TY+6ZR"HEOF-J3"WB M(0->8"^(O&" >6@Y"V%Y&0/=DB5VL^5W9A;W0UJM&"VTY\>Q/ZAFBUV,J3=6 MSBT_8C=!_J_B11?"(>U=^%X<#A8TBQV)?$SQ",26(K&3>"JQ_"S!:(4_LQ ' M#B+2UQ\6PP!42C@FF$A+;,0[:;=CB*YXQFZ'./GR5'(_E[=N$EK^)&[^_"[T M)E7LWNR7BPTH7:2YVH+N,;DP>P9K!IP^[9B1-?C7.^K&W;(Q<;/Q;:F2#2NX MB1OJ%ZI6/[Y#NXSENEIX^5^EV(W&[_1]2OP6NH^#>&3#1UHF)VXF_V3H+A6Z M5-Q(6-CPP3:UK,^=X!H"7@,P>W6_8/]MC\TB" (O&E$II"5ZXB;ZCZ+8R8)E M+QLYI^]3HGN]HV[\K5H@;K4 .[V$\_2P:#U_SKY@4VV/_/6.NI&W4H.XI48W M\O2H#HIR68A4,/LFQ>WVE-!?[Z@;>BM8B%NP-%S[IBR :$7^=GK,NJ*A+C?K MNGLY)1/V8X$@&)G=K>XA\4FD_%GDH(V?0*^A&E?&D_S7&[/&5H7^^H>_C<"C+J/FFX98]F]>I)D4RRW'[J_ +E9(WX M#(ZZ$;?JB[K5UP^F]:HI?O>T=O=R2B;.K,=HJ\>H6X]]6JUX4@T]?TBJPS<$ M^PC8 ATN0+A4B3(,7WTQ-+]G&1\YW*2V@Y0P(G[4/YJR6)*(PMYX9(-$CYZF MN%78M_I\77&C,\6I 0SED^]3$O2/DRUV,>SO2#2R!:6MT*)NH;48@_L.+?E: MY+DI3"/"N!(RM<8P/#&!&/PP&NRC+98T],QPC6SS:*N7J%LO.<+@YH3%&<#P MT,3WHW@&?_T ;):]4+L!M+*'ADY*O#-G<=5331 [H'J23!9&V /R*J05L"64 M5_U$'!2^-9 7*!?'([HS>>LFI!5#U"V&ON9 #*!WD#F4M$9[+IES!D?=&%L= M1)]W_C,2X OTB3W X>G0+*(^&5L\6@E#W0]0OLG\HE[OW,\-Z5F?E)S+6_?A M<2M@?+> ^2](%9MH,X_D](9W]^$P?1E:L<0\1K)N6]R=G3#(!T?'#Y9#' -+ M] 9Y>O06QI:K=?5R"C"P.>"MWVEH[C8OP-Q4KWWT[G_ EXOZ-9;63?U6S2], M 7,4*.,K<.F]CZ#R5/VB2GVAY:YZUV,IM9;;ZNN&LY0K8P"_KZ343Q>F@^9U MH?D_4$L#!!0 ( Y(+U7!,K3X" \ XJ 8 >&PO=V]R:W-H965T M&ULK5K9WAG[U:V4*L6W=9:[ M5SNKLBR>[^VY9*76THU,H7+\LC!V+4M\M,L]5U@E4]ZTSO:FX_'AWEKJ?.?U M2_[NVKY^::HRT[FZML)5Z[6T]RO=B8[]1>?]')5TA=[KU\6<'?M+ISG;\%:3(WYBM]>)>^VAF3 M0"I324DG2/QSJTY5EM%!$../<.9.D:B&KK/QD[LY5T.8S/'_Q9U?>X#%2>5*LPZ;(<%:Y_Y?^2W8H;/A M:/S AFG8,&6Y_44LY9DLY>N7UMP)2ZMQ&OW!JO)N"*=SQ"QD7-:RWDR??3$]U4^$OOC6$S'T^DCY^TW>N_S>?O_@][BG[.Y M*RV \Z\A$_@+#H8OH&!Z[@J9J%<[B!:G[*W:>?WS#Y/#\8M'Q#]HQ#]X[/37 M5Y]^G5V^^\?L\[NK2S&[/!,G7V[>7;ZYN1$GL],/OWZZ^G)Y-B3SXZ=>FE*) MB?A%?,_QXG2E=T'EB;&&L+%6*#Z)<*7%3XI,P"S&S^D^#F^"H]U5V+R:3 M6$R.CP_9;;2;5KLJ2> ]8VD'?3&O_?DU-W=PL6O.N="NC".6[6ZEDY68*V"! MKIT<'QV/Q%4N+N2].":LC9_&0I="Y:6R+%IIA!2(RN2K*"J;K$ (0BZM4B"J MDB6Z64FKQ)MO^"U?*K&K%@MBH'R)C5;=*HL=:V67RD)W7:ZB-^G:Y*D3AQL& M:[ZO317CA#.5R3NZH#88\!OSO?X^R%@ZD3DQKU1G^))/%1KS5!8Q!+YQ\>QE*-F2DSQ_@927]N MX(L/]#_$N+*,EE.S+L 'N//*XDI)JN L*;)PZO(?RM/2^+W5T_H$O MIRR)U?B'CP5$"N,8Q4ZIKPP"2ER2_S>_%V M=G,B9J=DV6HM6I&<>W(J#Z\V?$H'83C3Z%_#(/K#,[[70/NXMJ:6\)= MS.:^5J;(%!TU>?;"B4^JJ.89U('YO;-V:56X^OK3:7UI!'.?J42MYW##Y("A MLA__!0"VT',O/LJ[FGYP^JAC#TW^6\IE2V_XI5H@M52V1@7"3D78OO*PAK_2 M*D'%180TJY8(B@;&7EUVJR.Z0921++6>;61L,1>3TP!S=2WC&>RZ7C2K%[4^ M(FC2!HIKZ^C>1M668"(F&"4>.B[NQSV$K>5*Q60\_JDVI;^$,-N#&,68%(ET M*XXGG=9$A&T_'H[C@_$1:Q4-:M5B]P:LI/ZH5,V(BAV&+Q MW>X]E]SX2I',*:8^BJ(Y3XG+Z M3#\CRX'V=(*\UN0K*AMD&:WDK?)Y#=T M0IMA"XX#VAL5S16)O9X!44^$SKR@*HG6X M:B0N@/G?(,9-E9!KU-%";V B 'X8)U$')]M, MP19N^7TQ%Y2$+$FY MA;)4R5!6JH;X@]SEA/]T?CUA);ZF^='?'9H\$>:JC7^LYV&$*_57-;$2%,?(_I M>\Y+<^N#:#JE;R?[79X*Y*\8DE&W3: 8[U;$;91?0Z&U3!3HA*C8U]]EVC:8 MYQ_?BRW>"G65MT]3*,+9"7/LCY/#>'__.#XZ/(YV/UV<3+R#Z3_J [HGAH:( MRF1NQ&H>]E,<+K"_LS)N>3$D/^0K_(R49\ G3$UQ9*LYG5Y(AVRPZS,:XP@M MF0'M@I%+:FXH\YFL\D'NJ@(-FJ9TI>"A3.?:E\/M?F(<-C79<$4$3K05TH#Z MQO,ARE\X7^4T,>6@1O.2X3CX*74;=FEH&U&:JC"U@!EZ;ORM4N*L>M"'L6B[ M<@4(@QU!B1Z0.; MYJ/O4LH<"*KT-B4B"TPGC<"-7>H:BTG@EKM*4-2/IU\1 M$$6'&6534O1&$-SI(Y3?H]GKCGN13G1# MI"WC,82:',HI=/+46PC9AC* Y8YEH^1DQF-U:-L#DX_>FFTPX2"$HEYX L/Q MZP8-0U8K6LM&/H)H9=]*?0^*W02-M3=-=M\%QXS:,E\[(@Y,:]ZN=4T>-DV. M16JKY1:]1;M]"J! 5I 4!:RK,B34PMREU$*L];>08=M$AG1Y;ZE;JO-;G4<[ MHS!BWQ*+WH.84/"A.%?R[T!1T ML?@LOXE/:MGR<._7,[)!8&SZ\1H>TWY,_^O%=6^MS]H0RXK4))7O=[RF?2FM MRCC<0[04[>F\NNB,H3J><$]Z0&-ONBZN:IA'+/X0(GJ4AFT5U@YID$:[6&:*\ M:8KJ+-L5)CB:VEP7!/7M#T$L6J*VLCD3:6$0Y_2 @BJ3A*K.WQ532*O 7Z-A M6 M&+S1!OR9\=O8*]><[OF\Z'$@%S/9T9H1=B0Z=_0-LSW&\,3>GFO9[$L@E MUOU%$FG3 @W(V[0P+' 8K:I!_VP%[IR'YR9_( R:F4:?5:+VMO]?COZ\(6]W MHK]U7G=0%?7QZQ^JA7YT>-K_W5'=>_Q3M[;7U-IVF;@U4!0,-!('K?#]C2P@ M!3/!DQXAC]LQ7RKOX4)?4LO9/L^YI_:P58'G#S%& *H[W>V M+4@G>03R,Z]F;R@\HZ:IY_NI8[X*HJ*7)10T3Z&;Z9G_ M>#-[=]IECT[-A5];>F_0'W7)KC5/_2R(2IF5REC8+47#0X7.U0VE9VH)I9K1 MKV3BWI7TL,IQ0D"E0H%0(8OR\(9Y5GY%GJ9'335#U$VO"%,MBM6Y6LELP: 9 M>/C=;N'FN!XV/!'#>B(2:6C7>",*-=_6 '=C9K_1@T;]*9!_(Z;3.5D5(@X% MO2(L&Q'>%*I?(0FO<=2MN ?X^RI7S6MFPP];>C'X)4/_'36Q<>BKKG0R]X M[77>T>.G'O0F(IV&NMJ_KM=\V[SL.//O^+7+_9N2%]*"E(%NM<#6\>C9TQUA M_=N'_D-I"G[C;V[*TJSYSY62?VI4Q7?QY75;MCP]67;=Y]OAQ MFZW,.FUG]<94\,NB;M9I!Q^;Y>-VTY@TIT'K\O'QX>'YXW5:5 ]>/*?O/C0O MGM=]5Q:5^=#$;;]>I\WNI2GK[8\/CA[8+SX6RU6'7SQ^\7R3+LV-Z7[;?&C@ MTV,W2UZL3=46=14W9O'C@\NC9R]/\7EZX/?";%OU=XP[F=?U)_QPG?_XX! ! M,J7).IPAA?_=F2M3EC@1@/&GS/G +8D#]=]V]C>T=]C+/&W-55W^N\B[U8\/ M+A[$N5FD?=E]K+<_&]G/&,^$1\?Q MN[KJ5FW\NLI-'D[P&*!S(!Y;$%\>WSOC+WTUBT\.D_CX\/CXGOE.W)9/:+Z3 M/?.];Y9I5?R5,E54>?RR;^&1MHU?IMFG90,XR./_OIRW70,T\S]3*. %3J<7 MP'OTK-VDF?GQ 5R4UC1WYL&+?_[CZ/SPAWO /W7@G]XW^XN;ZY]^O7YS?77Y MZVU\>77U_K=?;Z]__2G^\/[M]=7UZYLI<.^?\->Z,_%Q?!!_869 3UNT<;V( M/^"NJHXQ>+N"+^5.XX^MHJC44]1&*"J"1[J5B:_J]2:M=C$,WO!T)H^[.DY; M6*2+BRJ&8S!-V\$)X7@UYI__N#@^>O)#&V=UU<*T>8IC%T655EF1EC&,Z0PP M#N!6 )V9_"7"@Z]@YVV<-@;8RT;MB38YM> ZK8!3X01)O%T5V0K!AX$;&%/, M2UBJ;G!@T< &.K-LBFY')%;/_T V= >?":;6*-Q$%C>X(>2SB(>EJ4R3EN4. M'S0;W*'&9E/ CC8EC %,(:B_504^7V6S*PN21S ?XV*0-'[%@XRO0_<'#!8.NW F%-XT MH10W\<7Y ):L[',XAQ7\&O]LTK);Q; GW$;1M8#N'@7,O"WR LF/)P=,)C$/ MQ66"P3__*XE_[N$BDKMT7(;F&N.O\/G6?R^BG^M[\QZ;IKX^!A9 MW-%),MQN M@'KK1<1;CG[:I&JJBW%:R@]NYVE1 :2D,7BG#^9U^TA3W)P7Z# MCXP0CQZX&70+Y?C7ZYIVU#5UB??X73.+_PLV>=-7"=^7U^\'5P=P A1M:.)T MT.3T(*)P86 :MZB[:T/> 12:UQN[J64/.(6C0'*]O+F*+P[/#LX.#_!? M>PG=[+A2!?H-L!8#")R;;DL'!9-W>.MXB^'VB!7!C8!5X[7I5C7@&LZU3!O\ MA2Y(#5!5RX-Z<4 T8MJN%> C'C\G( R[!7S&:IFB=CL9AOEW!U4>N5#<= M,AC0,>@)4,8:85%VE_!-41.M,4?2.X_J+.L;P&4+7R,%W8>750I\"I]OD-=T M].C<+(NJPC.08^759O''>V""L0+4MH!==*N^C9 DFP+8WKSN$(JZ-6[*QMP5 M==\"KEOF.<:?#=\6Y ]-O;X/)'LL1%K!+HO67PAB^\'J;@&]#5X+]L&S\P5;4@H-PL$2@@0+P; MB(@WESUSK] S;#%@2H4<@?)MD.;CDW M75J4N)=H"N;1 JQ660Z_(MIKC!'4I:@(C3'U3$NHL=1YC^0O,]LA$0H@5,@W M<$IH>^6(;KKL/T7&/)/8LID6$->G: MH(>"!JP) -R1GXD \224YP7S!DL]/7U-; !ZEF&*4C6:E)R>JQE5[QGWV-_P.YAQ8"H@!P777,JODFPW=: M'A?6*R6SMQ:"8P\!:07:(/$P1;+9A][6&<-@M5:/JB2V^FJ,NA9\SH B@"T@ MUH%LNVSVR )RX@#1(/35O4!,$0Z8*XB$?KUA%:L(J&^"+_)I$RT_8HK+TJ8A MNW&"=][#*9NN(V"LJBO_F22[5HOVJ%;A?##%@9LC M8NT J84U3T<\CG10\?'@T=U, XS#8>#1DS8_E+XH <:H&) :(J\0_7<$ZV"[ M<D@#>@.$A>B:- MX@46P#EJTNOTM4.]B)>WDZ"CRA 3&8AA/ K1P",0N7!+$F6'@&1�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
,:;[,# P%P &0 @(&1 $ >&PO=V]R:W-H965T&UL4$L! A0#% M @ #D@O57:!H.=- @ T@4 !D ("!"@T! 'AL+W=O&UL4$L! A0#% @ #D@O5657/4CC M @ +@L !D ("!HQ0! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ #D@O5&PO=V]R M:W-H965T&UL M4$L! A0#% @ #D@O54O),F;* @ KPH !D ("!<"@! M 'AL+W=O&PO=V]R:W-H965T2?P( .H& 9 M " @=@O 0!X;"]W;W)K&UL4$L! A0#% @ M#D@O55QH&S][ P ?@H !D ("!CC(! 'AL+W=O&UL4$L! A0#% @ #D@O5>@$6D<' P M3@D !D ("!13P! 'AL+W=O&PO=V]R:W-H965T%# 0!X;"]W;W)K&UL4$L! A0#% @ #D@O56X7 X[=!@ =BD !D M ("!/T8! 'AL+W=O&PO ! #L( &@ @ $P5@$ >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " .2"]5%-1QY- ! "M( $P M @ %(6 $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 /P _ + # 1 !)6@$ ! end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 125 248 1 false 52 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://chinahealth.me/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Audited) Sheet http://chinahealth.me/role/ConsolidatedBalanceSheet Consolidated Balance Sheets (Audited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Audited) (Parentheticals) Sheet http://chinahealth.me/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Audited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Audited) Sheet http://chinahealth.me/role/ConsolidatedIncomeStatement Consolidated Statements of Operations and Comprehensive Income (Audited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Audited) (Parentheticals) Sheet http://chinahealth.me/role/ConsolidatedIncomeStatement_Parentheticals Consolidated Statements of Operations and Comprehensive Income (Audited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Stockholders??? Equity (Audited) Sheet http://chinahealth.me/role/ShareholdersEquityType2or3 Consolidated Statements of Stockholders??? Equity (Audited) Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Cash Flows (Audited) Sheet http://chinahealth.me/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows (Audited) Statements 7 false false R8.htm 007 - Disclosure - Organization and Business Background Sheet http://chinahealth.me/role/OrganizationandBusinessBackground Organization and Business Background Notes 8 false false R9.htm 008 - Disclosure - Significant Accounting Policies Sheet http://chinahealth.me/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Assets Sale Sheet http://chinahealth.me/role/AssetsSale Assets Sale Notes 10 false false R11.htm 010 - Disclosure - Accounts Receivable Sheet http://chinahealth.me/role/AccountsReceivable Accounts Receivable Notes 11 false false R12.htm 011 - Disclosure - Inventories Sheet http://chinahealth.me/role/Inventories Inventories Notes 12 false false R13.htm 012 - Disclosure - Construction in Progress Sheet http://chinahealth.me/role/ConstructioninProgress Construction in Progress Notes 13 false false R14.htm 013 - Disclosure - Property, Plants and Equipment Sheet http://chinahealth.me/role/PropertyPlantsandEquipment Property, Plants and Equipment Notes 14 false false R15.htm 014 - Disclosure - Intangible Assets Sheet http://chinahealth.me/role/IntangibleAssets Intangible Assets Notes 15 false false R16.htm 015 - Disclosure - Related Party Debts Sheet http://chinahealth.me/role/RelatedPartyDebts Related Party Debts Notes 16 false false R17.htm 016 - Disclosure - Income Taxes Sheet http://chinahealth.me/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 017 - Disclosure - Earnings Per Share Sheet http://chinahealth.me/role/EarningsPerShare Earnings Per Share Notes 18 false false R19.htm 018 - Disclosure - Commitments and Contingencies Sheet http://chinahealth.me/role/CommitmentsandContingencies Commitments and Contingencies Notes 19 false false R20.htm 019 - Disclosure - Major Suppliers and Customers Sheet http://chinahealth.me/role/MajorSuppliersandCustomers Major Suppliers and Customers Notes 20 false false R21.htm 020 - Disclosure - Segment Reporting Sheet http://chinahealth.me/role/SegmentReporting Segment Reporting Notes 21 false false R22.htm 021 - Disclosure - Subsequent Events Sheet http://chinahealth.me/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 022 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://chinahealth.me/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://chinahealth.me/role/SignificantAccountingPolicies 23 false false R24.htm 023 - Disclosure - Significant Accounting Policies (Tables) Sheet http://chinahealth.me/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://chinahealth.me/role/SignificantAccountingPolicies 24 false false R25.htm 024 - Disclosure - Inventories (Tables) Sheet http://chinahealth.me/role/InventoriesTables Inventories (Tables) Tables http://chinahealth.me/role/Inventories 25 false false R26.htm 025 - Disclosure - Construction in Progress (Tables) Sheet http://chinahealth.me/role/ConstructioninProgressTables Construction in Progress (Tables) Tables http://chinahealth.me/role/ConstructioninProgress 26 false false R27.htm 026 - Disclosure - Property, Plants and Equipment (Tables) Sheet http://chinahealth.me/role/PropertyPlantsandEquipmentTables Property, Plants and Equipment (Tables) Tables http://chinahealth.me/role/PropertyPlantsandEquipment 27 false false R28.htm 027 - Disclosure - Intangible Assets (Tables) Sheet http://chinahealth.me/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://chinahealth.me/role/IntangibleAssets 28 false false R29.htm 028 - Disclosure - Related Party Debts (Tables) Sheet http://chinahealth.me/role/RelatedPartyDebtsTables Related Party Debts (Tables) Tables http://chinahealth.me/role/RelatedPartyDebts 29 false false R30.htm 029 - Disclosure - Income Taxes (Tables) Sheet http://chinahealth.me/role/IncomeTaxesTables Income Taxes (Tables) Tables http://chinahealth.me/role/IncomeTaxes 30 false false R31.htm 030 - Disclosure - Earnings Per Share (Tables) Sheet http://chinahealth.me/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://chinahealth.me/role/EarningsPerShare 31 false false R32.htm 031 - Disclosure - Segment Reporting (Tables) Sheet http://chinahealth.me/role/SegmentReportingTables Segment Reporting (Tables) Tables http://chinahealth.me/role/SegmentReporting 32 false false R33.htm 032 - Disclosure - Organization and Business Background (Details) Sheet http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails Organization and Business Background (Details) Details http://chinahealth.me/role/OrganizationandBusinessBackground 33 false false R34.htm 033 - Disclosure - Significant Accounting Policies (Details) Sheet http://chinahealth.me/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://chinahealth.me/role/SignificantAccountingPoliciesTables 34 false false R35.htm 034 - Disclosure - Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets Sheet http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets Details http://chinahealth.me/role/SignificantAccountingPoliciesTables 35 false false R36.htm 035 - Disclosure - Assets Sale (Details) Sheet http://chinahealth.me/role/AssetsSaleDetails Assets Sale (Details) Details http://chinahealth.me/role/AssetsSale 36 false false R37.htm 036 - Disclosure - Accounts Receivable (Details) Sheet http://chinahealth.me/role/AccountsReceivableDetails Accounts Receivable (Details) Details http://chinahealth.me/role/AccountsReceivable 37 false false R38.htm 037 - Disclosure - Inventories (Details) Sheet http://chinahealth.me/role/InventoriesDetails Inventories (Details) Details http://chinahealth.me/role/InventoriesTables 38 false false R39.htm 038 - Disclosure - Inventories (Details) - Schedule of inventory Sheet http://chinahealth.me/role/ScheduleofinventoryTable Inventories (Details) - Schedule of inventory Details http://chinahealth.me/role/InventoriesTables 39 false false R40.htm 039 - Disclosure - Construction in Progress (Details) Sheet http://chinahealth.me/role/ConstructioninProgressDetails Construction in Progress (Details) Details http://chinahealth.me/role/ConstructioninProgressTables 40 false false R41.htm 040 - Disclosure - Construction in Progress (Details) - Schedule of construction in progress Sheet http://chinahealth.me/role/ScheduleofconstructioninprogressTable Construction in Progress (Details) - Schedule of construction in progress Details http://chinahealth.me/role/ConstructioninProgressTables 41 false false R42.htm 041 - Disclosure - Property, Plants and Equipment (Details) Sheet http://chinahealth.me/role/PropertyPlantsandEquipmentDetails Property, Plants and Equipment (Details) Details http://chinahealth.me/role/PropertyPlantsandEquipmentTables 42 false false R43.htm 042 - Disclosure - Property, Plants and Equipment (Details) - Schedule of property, plants and equipment Sheet http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable Property, Plants and Equipment (Details) - Schedule of property, plants and equipment Details http://chinahealth.me/role/PropertyPlantsandEquipmentTables 43 false false R44.htm 043 - Disclosure - Intangible Assets (Details) Sheet http://chinahealth.me/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://chinahealth.me/role/IntangibleAssetsTables 44 false false R45.htm 044 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets Sheet http://chinahealth.me/role/ScheduleofintangibleassetsTable Intangible Assets (Details) - Schedule of intangible assets Details http://chinahealth.me/role/IntangibleAssetsTables 45 false false R46.htm 045 - Disclosure - Related Party Debts (Details) - Schedule of related party debts Sheet http://chinahealth.me/role/ScheduleofrelatedpartydebtsTable Related Party Debts (Details) - Schedule of related party debts Details http://chinahealth.me/role/RelatedPartyDebtsTables 46 false false R47.htm 046 - Disclosure - Income Taxes (Details) Sheet http://chinahealth.me/role/IncomeTaxesDetails Income Taxes (Details) Details http://chinahealth.me/role/IncomeTaxesTables 47 false false R48.htm 047 - Disclosure - Income Taxes (Details) - Schedule of taxes payable Sheet http://chinahealth.me/role/ScheduleoftaxespayableTable Income Taxes (Details) - Schedule of taxes payable Details http://chinahealth.me/role/IncomeTaxesTables 48 false false R49.htm 048 - Disclosure - Income Taxes (Details) - Schedule of provision for income taxes and the provision at the statutory rate Sheet http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable Income Taxes (Details) - Schedule of provision for income taxes and the provision at the statutory rate Details http://chinahealth.me/role/IncomeTaxesTables 49 false false R50.htm 049 - Disclosure - Income Taxes (Details) - Schedule of provision for income taxes Sheet http://chinahealth.me/role/ScheduleofprovisionforincometaxesTable Income Taxes (Details) - Schedule of provision for income taxes Details http://chinahealth.me/role/IncomeTaxesTables 50 false false R51.htm 050 - Disclosure - Income Taxes (Details) - Schedule of components of deferred tax assets Sheet http://chinahealth.me/role/ScheduleofcomponentsofdeferredtaxassetsTable Income Taxes (Details) - Schedule of components of deferred tax assets Details http://chinahealth.me/role/IncomeTaxesTables 51 false false R52.htm 051 - Disclosure - Earnings Per Share (Details) - Schedule of basic and diluted net income per share Sheet http://chinahealth.me/role/ScheduleofbasicanddilutednetincomepershareTable Earnings Per Share (Details) - Schedule of basic and diluted net income per share Details http://chinahealth.me/role/EarningsPerShareTables 52 false false R53.htm 052 - Disclosure - Major Suppliers and Customers (Details) Sheet http://chinahealth.me/role/MajorSuppliersandCustomersDetails Major Suppliers and Customers (Details) Details http://chinahealth.me/role/MajorSuppliersandCustomers 53 false false R54.htm 053 - Disclosure - Segment Reporting (Details) Sheet http://chinahealth.me/role/SegmentReportingDetails Segment Reporting (Details) Details http://chinahealth.me/role/SegmentReportingTables 54 false false R55.htm 054 - Disclosure - Segment Reporting (Details) - Schedule of information by segment Sheet http://chinahealth.me/role/ScheduleofinformationbysegmentTable Segment Reporting (Details) - Schedule of information by segment Details http://chinahealth.me/role/SegmentReportingTables 55 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: dei:CityAreaCode, dei:LocalPhoneNumber, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - f10k2022_chinahealth.htm 8595, 8596, 8597, 8598, 8675, 8678 f10k2022_chinahealth.htm chhe-20220630.xsd chhe-20220630_cal.xml chhe-20220630_def.xml chhe-20220630_lab.xml chhe-20220630_pre.xml f10k2022ex23-1_chinahealth.htm f10k2022ex31-1_chinahealth.htm f10k2022ex31-2_chinahealth.htm f10k2022ex32-1_chinahealth.htm f10k2022ex4-2_chinahealth.htm img_001.jpg img_002.jpg http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10k2022_chinahealth.htm": { "axisCustom": 3, "axisStandard": 11, "contextCount": 125, "dts": { "calculationLink": { "local": [ "chhe-20220630_cal.xml" ] }, "definitionLink": { "local": [ "chhe-20220630_def.xml" ] }, "inline": { "local": [ "f10k2022_chinahealth.htm" ] }, "labelLink": { "local": [ "chhe-20220630_lab.xml" ] }, "presentationLink": { "local": [ "chhe-20220630_pre.xml" ] }, "schema": { "local": [ "chhe-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 420, "entityCount": 1, "hidden": { "http://chinahealth.me/20220630": 16, "http://fasb.org/us-gaap/2022": 67, "http://xbrl.sec.gov/dei/2022": 5, "total": 88 }, "keyCustom": 46, "keyStandard": 202, "memberCustom": 33, "memberStandard": 16, "nsprefix": "chhe", "nsuri": "http://chinahealth.me/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://chinahealth.me/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Assets Sale", "role": "http://chinahealth.me/role/AssetsSale", "shortName": "Assets Sale", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "chhe:AccountsReceivableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Accounts Receivable", "role": "http://chinahealth.me/role/AccountsReceivable", "shortName": "Accounts Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "chhe:AccountsReceivableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Inventories", "role": "http://chinahealth.me/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "chhe:ConstructionInProgressDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Construction in Progress", "role": "http://chinahealth.me/role/ConstructioninProgress", "shortName": "Construction in Progress", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "chhe:ConstructionInProgressDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Property, Plants and Equipment", "role": "http://chinahealth.me/role/PropertyPlantsandEquipment", "shortName": "Property, Plants and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Intangible Assets", "role": "http://chinahealth.me/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Related Party Debts", "role": "http://chinahealth.me/role/RelatedPartyDebts", "shortName": "Related Party Debts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Income Taxes", "role": "http://chinahealth.me/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Earnings Per Share", "role": "http://chinahealth.me/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Commitments and Contingencies", "role": "http://chinahealth.me/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets (Audited)", "role": "http://chinahealth.me/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Balance Sheets (Audited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Major Suppliers and Customers", "role": "http://chinahealth.me/role/MajorSuppliersandCustomers", "shortName": "Major Suppliers and Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Segment Reporting", "role": "http://chinahealth.me/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Subsequent Events", "role": "http://chinahealth.me/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://chinahealth.me/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "chhe:ScheduleofusefullifeofpropertyplantandequipmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://chinahealth.me/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "chhe:ScheduleofusefullifeofpropertyplantandequipmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Inventories (Tables)", "role": "http://chinahealth.me/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "chhe:ConstructionInProgressTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Construction in Progress (Tables)", "role": "http://chinahealth.me/role/ConstructioninProgressTables", "shortName": "Construction in Progress (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "chhe:ConstructionInProgressTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Property, Plants and Equipment (Tables)", "role": "http://chinahealth.me/role/PropertyPlantsandEquipmentTables", "shortName": "Property, Plants and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Intangible Assets (Tables)", "role": "http://chinahealth.me/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Related Party Debts (Tables)", "role": "http://chinahealth.me/role/RelatedPartyDebtsTables", "shortName": "Related Party Debts (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Audited) (Parentheticals)", "role": "http://chinahealth.me/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Consolidated Balance Sheets (Audited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Income Taxes (Tables)", "role": "http://chinahealth.me/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Earnings Per Share (Tables)", "role": "http://chinahealth.me/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Segment Reporting (Tables)", "role": "http://chinahealth.me/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c40", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Organization and Business Background (Details)", "role": "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails", "shortName": "Organization and Business Background (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c40", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ForeignCurrencyTranslationAdjustmentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Significant Accounting Policies (Details)", "role": "http://chinahealth.me/role/SignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ForeignCurrencyTranslationAdjustmentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "chhe:ScheduleofusefullifeofpropertyplantandequipmentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c52", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets", "role": "http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable", "shortName": "Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "chhe:ScheduleofusefullifeofpropertyplantandequipmentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c52", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c61", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Assets Sale (Details)", "role": "http://chinahealth.me/role/AssetsSaleDetails", "shortName": "Assets Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c61", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c63", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Accounts Receivable (Details)", "role": "http://chinahealth.me/role/AccountsReceivableDetails", "shortName": "Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c63", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Inventories (Details)", "role": "http://chinahealth.me/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Inventories (Details) - Schedule of inventory", "role": "http://chinahealth.me/role/ScheduleofinventoryTable", "shortName": "Inventories (Details) - Schedule of inventory", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Audited)", "role": "http://chinahealth.me/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statements of Operations and Comprehensive Income (Audited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c65", "decimals": "-4", "first": true, "lang": null, "name": "chhe:EstimatedTotalCostOfConstruction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Construction in Progress (Details)", "role": "http://chinahealth.me/role/ConstructioninProgressDetails", "shortName": "Construction in Progress (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c65", "decimals": "-4", "first": true, "lang": null, "name": "chhe:EstimatedTotalCostOfConstruction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "chhe:ConstructionInProgressTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConstructionInProgressGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Construction in Progress (Details) - Schedule of construction in progress", "role": "http://chinahealth.me/role/ScheduleofconstructioninprogressTable", "shortName": "Construction in Progress (Details) - Schedule of construction in progress", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "chhe:ConstructionInProgressTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConstructionInProgressGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Property, Plants and Equipment (Details)", "role": "http://chinahealth.me/role/PropertyPlantsandEquipmentDetails", "shortName": "Property, Plants and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Property, Plants and Equipment (Details) - Schedule of property, plants and equipment", "role": "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable", "shortName": "Property, Plants and Equipment (Details) - Schedule of property, plants and equipment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Intangible Assets (Details)", "role": "http://chinahealth.me/role/IntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets", "role": "http://chinahealth.me/role/ScheduleofintangibleassetsTable", "shortName": "Intangible Assets (Details) - Schedule of intangible assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Related Party Debts (Details) - Schedule of related party debts", "role": "http://chinahealth.me/role/ScheduleofrelatedpartydebtsTable", "shortName": "Related Party Debts (Details) - Schedule of related party debts", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c88", "decimals": "0", "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c92", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Income Taxes (Details)", "role": "http://chinahealth.me/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c92", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedIncomeTaxes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Income Taxes (Details) - Schedule of taxes payable", "role": "http://chinahealth.me/role/ScheduleoftaxespayableTable", "shortName": "Income Taxes (Details) - Schedule of taxes payable", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedIncomeTaxes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Income Taxes (Details) - Schedule of provision for income taxes and the provision at the statutory rate", "role": "http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable", "shortName": "Income Taxes (Details) - Schedule of provision for income taxes and the provision at the statutory rate", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": "2", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Audited) (Parentheticals)", "role": "http://chinahealth.me/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Consolidated Statements of Operations and Comprehensive Income (Audited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c5", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentForeignTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Income Taxes (Details) - Schedule of provision for income taxes", "role": "http://chinahealth.me/role/ScheduleofprovisionforincometaxesTable", "shortName": "Income Taxes (Details) - Schedule of provision for income taxes", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c5", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentForeignTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Income Taxes (Details) - Schedule of components of deferred tax assets", "role": "http://chinahealth.me/role/ScheduleofcomponentsofdeferredtaxassetsTable", "shortName": "Income Taxes (Details) - Schedule of components of deferred tax assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Earnings Per Share (Details) - Schedule of basic and diluted net income per share", "role": "http://chinahealth.me/role/ScheduleofbasicanddilutednetincomepershareTable", "shortName": "Earnings Per Share (Details) - Schedule of basic and diluted net income per share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": "4", "lang": null, "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c5", "decimals": "0", "first": true, "lang": null, "name": "chhe:NumberOfSuppliers", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Major Suppliers and Customers (Details)", "role": "http://chinahealth.me/role/MajorSuppliersandCustomersDetails", "shortName": "Major Suppliers and Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c5", "decimals": "0", "first": true, "lang": null, "name": "chhe:NumberOfSuppliers", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "chhe:NumberOfBusinessSegments", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Segment Reporting (Details)", "role": "http://chinahealth.me/role/SegmentReportingDetails", "shortName": "Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "chhe:NumberOfBusinessSegments", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c109", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Segment Reporting (Details) - Schedule of information by segment", "role": "http://chinahealth.me/role/ScheduleofinformationbysegmentTable", "shortName": "Segment Reporting (Details) - Schedule of information by segment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c109", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Stockholders\u2019 Equity (Audited)", "role": "http://chinahealth.me/role/ShareholdersEquityType2or3", "shortName": "Consolidated Statements of Stockholders\u2019 Equity (Audited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Cash Flows (Audited)", "role": "http://chinahealth.me/role/ConsolidatedCashFlow", "shortName": "Consolidated Statements of Cash Flows (Audited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Organization and Business Background", "role": "http://chinahealth.me/role/OrganizationandBusinessBackground", "shortName": "Organization and Business Background", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Significant Accounting Policies", "role": "http://chinahealth.me/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_chinahealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 52, "tag": { "chhe_AccountsReceivableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Receivable (Details) [Line Items]" } } }, "localname": "AccountsReceivableDetailsLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "chhe_AccountsReceivableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Receivable (Details) [Table]" } } }, "localname": "AccountsReceivableDetailsTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "chhe_AccountsReceivableDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Abstract]" } } }, "localname": "AccountsReceivableDisclosureAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_AccountsReceivableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts receivable.", "label": "Accounts Receivable Disclosure Text Block", "terseLabel": "ACCOUNTS RECEIVABLE" } } }, "localname": "AccountsReceivableDisclosureTextBlock", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AccountsReceivable" ], "xbrltype": "textBlockItemType" }, "chhe_AdvancesToSuppliers": { "auth_ref": [], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of advances made as of the period end.", "label": "Advances To Suppliers", "terseLabel": "Advances to suppliers", "verboseLabel": "Advance to suppliers" } } }, "localname": "AdvancesToSuppliers", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet", "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "chhe_AdvancesToSuppliersPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advances to suppliers.", "label": "Advances To Suppliers Policy Policy Text Block", "terseLabel": "Advance to Suppliers" } } }, "localname": "AdvancesToSuppliersPolicyPolicyTextBlock", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "chhe_AgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement Axis", "terseLabel": "Agreement [Axis]" } } }, "localname": "AgreementAxis", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails", "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "stringItemType" }, "chhe_AgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement [Domain]" } } }, "localname": "AgreementDomain", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails", "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "domainItemType" }, "chhe_AgreementTermsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement terms, description", "label": "Agreement Terms Description", "terseLabel": "Agreement terms, description" } } }, "localname": "AgreementTermsDescription", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails" ], "xbrltype": "stringItemType" }, "chhe_AgreementsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreements Axis", "terseLabel": "Agreements [Axis]" } } }, "localname": "AgreementsAxis", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "chhe_AgreementsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreements [Domain]" } } }, "localname": "AgreementsDomain", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "chhe_AllowanceForDoubtfulAccounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Allowance for doubtful accounts", "label": "Allowance For Doubtful Accounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccounts", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofcomponentsofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "chhe_AssetsSaleDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Sale (Details) [Line Items]" } } }, "localname": "AssetsSaleDetailsLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails" ], "xbrltype": "stringItemType" }, "chhe_AssetsSaleDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Sale (Details) [Table]" } } }, "localname": "AssetsSaleDetailsTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails" ], "xbrltype": "stringItemType" }, "chhe_BankCharges": { "auth_ref": [], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of bank charges.", "label": "Bank Charges", "negatedLabel": "Bank charges" } } }, "localname": "BankCharges", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "chhe_BusinessCombinationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination Member", "terseLabel": "Business Combination [Member]" } } }, "localname": "BusinessCombinationMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "domainItemType" }, "chhe_ChinaHealthIndustriesHoldingsLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "China Health Industries Holdings Limited Member", "terseLabel": "China Health Industries Holdings Limited [Member]" } } }, "localname": "ChinaHealthIndustriesHoldingsLimitedMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "domainItemType" }, "chhe_CommercialPurposeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commercial Purpose Member", "terseLabel": "Commercial Purpose [Member]" } } }, "localname": "CommercialPurposeMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "chhe_ConcentrationOfRiskTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Of Risk Type Axis", "terseLabel": "Concentration Of Risk Type [Axis]" } } }, "localname": "ConcentrationOfRiskTypeAxis", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "stringItemType" }, "chhe_ConcentrationOfRiskTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConcentrationOfRiskType [Domain]" } } }, "localname": "ConcentrationOfRiskTypeDomain", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "chhe_ConcentrationRiskThresholdPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration risk threshold percentage.", "label": "Concentration Risk Threshold Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskThresholdPercentage", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "percentItemType" }, "chhe_ConsolIdatedOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consol Idated Operations Member", "terseLabel": "Consolidated operations [Member]" } } }, "localname": "ConsolIdatedOperationsMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "domainItemType" }, "chhe_ConstructionInProgress": { "auth_ref": [], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount related to construction in progress.", "label": "Construction In Progress", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgress", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "chhe_ConstructionInProgressAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Construction in progress.", "label": "Construction In Progress Amount", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressAmount", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConstructioninProgressDetails" ], "xbrltype": "monetaryItemType" }, "chhe_ConstructionInProgressDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Construction In Progress Disclosure Abstract" } } }, "localname": "ConstructionInProgressDisclosureAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ConstructionInProgressDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived assets under construction in progress.", "label": "Construction In Progress Disclosure Text Block", "terseLabel": "CONSTRUCTION IN PROGRESS" } } }, "localname": "ConstructionInProgressDisclosureTextBlock", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConstructioninProgress" ], "xbrltype": "textBlockItemType" }, "chhe_ConstructionInProgressPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Construction in progress percentage.", "label": "Construction In Progress Percentage", "terseLabel": "Construction in progress, percentage" } } }, "localname": "ConstructionInProgressPercentage", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConstructioninProgressDetails" ], "xbrltype": "percentItemType" }, "chhe_ConstructionInProgressPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for construction in progress.", "label": "Construction In Progress Policy Text Block", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressPolicyTextBlock", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "chhe_ConstructionInProgressTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the Cost relating to construction work in progress.", "label": "Construction In Progress Table Text Block", "terseLabel": "Schedule of construction in progress" } } }, "localname": "ConstructionInProgressTableTextBlock", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConstructioninProgressTables" ], "xbrltype": "textBlockItemType" }, "chhe_ConstructioninProgressDetailsScheduleofconstructioninprogressLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Construction in Progress (Details) - Schedule of construction in progress [Line Items]" } } }, "localname": "ConstructioninProgressDetailsScheduleofconstructioninprogressLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofconstructioninprogressTable" ], "xbrltype": "stringItemType" }, "chhe_ConstructioninProgressDetailsScheduleofconstructioninprogressTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Construction in Progress (Details) - Schedule of construction in progress [Table]" } } }, "localname": "ConstructioninProgressDetailsScheduleofconstructioninprogressTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofconstructioninprogressTable" ], "xbrltype": "stringItemType" }, "chhe_CustomerFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Five Member", "terseLabel": "Customer Five [Member]" } } }, "localname": "CustomerFiveMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "chhe_CustomerFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Four Member", "terseLabel": "Customer Four [Member]" } } }, "localname": "CustomerFourMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "chhe_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer One Member", "terseLabel": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "chhe_CustomerSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Six Member", "terseLabel": "Customer Six [Member]" } } }, "localname": "CustomerSixMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "chhe_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Three Member", "terseLabel": "Customer Three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "chhe_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Two Member", "terseLabel": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "chhe_DeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Abstract", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsAbstract", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofcomponentsofdeferredtaxassetsTable" ], "xbrltype": "stringItemType" }, "chhe_DepreciationExpenseChargedToCostOfGoodsSold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation expense charged to cost of goods sold.", "label": "Depreciation Expense Charged To Cost Of Goods Sold", "terseLabel": "Depreciation expense charged to cost of goods sold" } } }, "localname": "DepreciationExpenseChargedToCostOfGoodsSold", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/PropertyPlantsandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "chhe_DepreciationExpenseChargedToOperations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation expense charged to operations.", "label": "Depreciation Expense Charged To Operations", "terseLabel": "Depreciation expense charged to operations" } } }, "localname": "DepreciationExpenseChargedToOperations", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/PropertyPlantsandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "chhe_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_EnterpriseIncomeTaxPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Enterprise Income Tax.", "label": "Enterprise Income Tax Policy Text Block", "terseLabel": "Enterprise Income Tax" } } }, "localname": "EnterpriseIncomeTaxPolicyTextBlock", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "chhe_EquityInterestHuimeijiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Interest Huimeijia Member", "terseLabel": "Equity Interests Huimeijia [Member]" } } }, "localname": "EquityInterestHuimeijiaMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails", "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "domainItemType" }, "chhe_EstimatedTotalCostOfConstruction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents estimated total cost of construction.", "label": "Estimated Total Cost Of Construction", "terseLabel": "Estimated total cost of construction" } } }, "localname": "EstimatedTotalCostOfConstruction", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConstructioninProgressDetails" ], "xbrltype": "monetaryItemType" }, "chhe_HLJHuimeijiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HLJHuimeijia Member", "terseLabel": "HLJ Huimeijia [Member]" } } }, "localname": "HLJHuimeijiaMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofinformationbysegmentTable", "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "chhe_HarbinHuimeijiaMedicineCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Harbin Huimeijia Medicine Company Member", "terseLabel": "Harbin Huimeijia Medicine Company [Member]" } } }, "localname": "HarbinHuimeijiaMedicineCompanyMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "domainItemType" }, "chhe_HarbinHumankindBiologyTechnologyCoLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Harbin Humankind Biology Technology Co Limited Member", "terseLabel": "Harbin Humankind Biology Technology Co., Limited [Member]" } } }, "localname": "HarbinHumankindBiologyTechnologyCoLimitedMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "domainItemType" }, "chhe_HealthSupplementProductPatentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Health Supplement Product Patents Member", "terseLabel": "Health Supplement Product Patents [Member]" } } }, "localname": "HealthSupplementProductPatentsMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "chhe_HeilongjiangHuimeijiaPharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Heilongjiang Huimeijia Pharmaceutical Co Ltd Member", "terseLabel": "Heilongjiang Huimeijia Pharmaceutical Co., Ltd. [Member]" } } }, "localname": "HeilongjiangHuimeijiaPharmaceuticalCoLtdMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "domainItemType" }, "chhe_HumankindMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Humankind Member", "terseLabel": "Humankind [Member]" } } }, "localname": "HumankindMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofinformationbysegmentTable", "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "chhe_IncomeTaxServicesRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Services Rate Percentage", "terseLabel": "Income tax services rate percentage" } } }, "localname": "IncomeTaxServicesRatePercentage", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "chhe_IncomeTaxesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Line Items]" } } }, "localname": "IncomeTaxesDetailsLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "chhe_IncomeTaxesDetailsScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes Details Scheduleofprovisionforincometaxesandtheprovisionatthestatutoryrate Line Items", "terseLabel": "Schedule of Provision For Income Taxes And The Provision at The Statutory Rate [Abstract]" } } }, "localname": "IncomeTaxesDetailsScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable" ], "xbrltype": "stringItemType" }, "chhe_IncomeTaxesDetailsScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) - Schedule of provision for income taxes and the provision at the statutory rate [Table]" } } }, "localname": "IncomeTaxesDetailsScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable" ], "xbrltype": "stringItemType" }, "chhe_IncomeTaxesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "localname": "IncomeTaxesDetailsTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "chhe_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes Line Items", "terseLabel": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IncomeTaxes" ], "xbrltype": "stringItemType" }, "chhe_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IncomeTaxes" ], "xbrltype": "stringItemType" }, "chhe_IncomeTaxesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes Tables Line Items", "terseLabel": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxesTablesLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "chhe_IncomeTaxesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Tables) [Table]" } } }, "localname": "IncomeTaxesTablesTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "chhe_IntangibleAssetsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) [Line Items]" } } }, "localname": "IntangibleAssetsDetailsLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "chhe_IntangibleAssetsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) [Table]" } } }, "localname": "IntangibleAssetsDetailsTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "chhe_InterestExpensesOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest Expenses Other", "terseLabel": "Interest expense" } } }, "localname": "InterestExpensesOther", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "monetaryItemType" }, "chhe_LandUseRightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Land Use Right Member", "terseLabel": "Land Use Rights [Member]" } } }, "localname": "LandUseRightMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "chhe_LoanFromRelatedPartyForTheConstructionOfAFacility": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loan from related party for construction of facility.", "label": "Loan From Related Party For The Construction Of AFacility", "terseLabel": "Loan from related party for the construction of a facility" } } }, "localname": "LoanFromRelatedPartyForTheConstructionOfAFacility", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "chhe_MajorSuppliersandCustomersDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major Suppliers and Customers (Details) [Line Items]" } } }, "localname": "MajorSuppliersandCustomersDetailsLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "stringItemType" }, "chhe_MajorSuppliersandCustomersDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major Suppliers and Customers (Details) [Table]" } } }, "localname": "MajorSuppliersandCustomersDetailsTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "stringItemType" }, "chhe_MrKaiSunMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mr Kai Sun Member", "terseLabel": "Mr. Kai Sun [Member]" } } }, "localname": "MrKaiSunMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofrelatedpartydebtsTable" ], "xbrltype": "domainItemType" }, "chhe_MrXinSunMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mr Xin Sun Member", "terseLabel": "Mr. Xin Sun [Member]" } } }, "localname": "MrXinSunMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails", "http://chinahealth.me/role/ScheduleofrelatedpartydebtsTable" ], "xbrltype": "domainItemType" }, "chhe_NetIncomeLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income Loss Per Share Abstract", "terseLabel": "Net income/(loss) per share:" } } }, "localname": "NetIncomeLossPerShareAbstract", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofbasicanddilutednetincomepershareTable" ], "xbrltype": "stringItemType" }, "chhe_NetLossIncomePerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Income Per Share Abstract", "terseLabel": "Net (loss)/income per share:" } } }, "localname": "NetLossIncomePerShareAbstract", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "chhe_NewSupplementaryAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "New Supplementary Agreement Member", "terseLabel": "New Supplementary Agreement [Member]" } } }, "localname": "NewSupplementaryAgreementMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails", "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "domainItemType" }, "chhe_NumberOfBusinessSegments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of business segments.", "label": "Number Of Business Segments", "terseLabel": "Number of business segments" } } }, "localname": "NumberOfBusinessSegments", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SegmentReportingDetails" ], "xbrltype": "integerItemType" }, "chhe_NumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of customers.", "label": "Number Of Customers", "terseLabel": "Number of customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "integerItemType" }, "chhe_NumberOfIndividuals": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of individuals.", "label": "Number Of Individuals", "terseLabel": "Number of individuals" } } }, "localname": "NumberOfIndividuals", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "integerItemType" }, "chhe_NumberOfSharesHeld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares held by majority shareholder.", "label": "Number Of Shares Held", "terseLabel": "Number of shares held (in Shares)" } } }, "localname": "NumberOfSharesHeld", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "sharesItemType" }, "chhe_NumberOfSharesTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares transferred.", "label": "Number Of Shares Transferred", "terseLabel": "Number of shares transferred (in Shares)" } } }, "localname": "NumberOfSharesTransferred", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "sharesItemType" }, "chhe_NumberOfSuppliers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of suppliers.", "label": "Number Of Suppliers", "terseLabel": "Number of suppliers" } } }, "localname": "NumberOfSuppliers", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "integerItemType" }, "chhe_OperatingLossCarryoverIsExpiredTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryover is expired term.", "label": "Operating Loss Carryover Is Expired Term", "terseLabel": "Operating loss carryover is expired term" } } }, "localname": "OperatingLossCarryoverIsExpiredTerm", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IncomeTaxesDetails" ], "xbrltype": "durationItemType" }, "chhe_OrganizationandBusinessBackgroundDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Business Background (Details) [Line Items]" } } }, "localname": "OrganizationandBusinessBackgroundDetailsLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "stringItemType" }, "chhe_OrganizationandBusinessBackgroundDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Business Background (Details) [Table]" } } }, "localname": "OrganizationandBusinessBackgroundDetailsTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "stringItemType" }, "chhe_OthersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Others Member", "terseLabel": "Others [Member]" } } }, "localname": "OthersMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "domainItemType" }, "chhe_PaymentsToExpenditureInConstructionInProgress": { "auth_ref": [], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount related to expenditure in construction in progress.", "label": "Payments To Expenditure In Construction In Progress", "negatedLabel": "Expenditure in construction in progress" } } }, "localname": "PaymentsToExpenditureInConstructionInProgress", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "chhe_PeoplesRepublicOfChinaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Peoples Republic Of China Member", "terseLabel": "People\u2019s Republic of China [Member]" } } }, "localname": "PeoplesRepublicOfChinaMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "chhe_PercentageOfEnterprisesTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of enterprises income tax rate.", "label": "Percentage Of Enterprises Tax Rate", "terseLabel": "Percentage of enterprises rate" } } }, "localname": "PercentageOfEnterprisesTaxRate", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "chhe_PercentageOfPurchasePricePaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of purchase price paid.", "label": "Percentage Of Purchase Price Paid", "terseLabel": "Percentage of purchase price paid" } } }, "localname": "PercentageOfPurchasePricePaid", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "percentItemType" }, "chhe_PercentageOfSharesHeld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of share held.", "label": "Percentage Of Shares Held", "terseLabel": "Percentage of shares held" } } }, "localname": "PercentageOfSharesHeld", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "percentItemType" }, "chhe_PharmaceuticalPatentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pharmaceutical Patents Member", "terseLabel": "Pharmaceutical Patents [Member]" } } }, "localname": "PharmaceuticalPatentsMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "chhe_PlantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Plant Member", "terseLabel": "Plant - HLJ Huimeijia [Member]" } } }, "localname": "PlantMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofconstructioninprogressTable" ], "xbrltype": "domainItemType" }, "chhe_PropertyPlantsandEquipmentDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plants and Equipment (Textual)" } } }, "localname": "PropertyPlantsandEquipmentDetailsLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/PropertyPlantsandEquipmentDetails" ], "xbrltype": "stringItemType" }, "chhe_PropertyPlantsandEquipmentDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plants and Equipment (Details) [Table]" } } }, "localname": "PropertyPlantsandEquipmentDetailsTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/PropertyPlantsandEquipmentDetails" ], "xbrltype": "stringItemType" }, "chhe_PurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase Member", "terseLabel": "Purchase [Member]" } } }, "localname": "PurchaseMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "chhe_PurchasePriceDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price description.", "label": "Purchase Price Description", "terseLabel": "Purchase price, description" } } }, "localname": "PurchasePriceDescription", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "stringItemType" }, "chhe_PurchasesPriceDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchases Price Description", "terseLabel": "Purchase Price, description" } } }, "localname": "PurchasesPriceDescription", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails" ], "xbrltype": "stringItemType" }, "chhe_ResidentialPurposeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Residential Purpose Member", "terseLabel": "Residential Purpose [Member]" } } }, "localname": "ResidentialPurposeMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "chhe_SalesRelatedTaxesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for sales related taxes.", "label": "Sales Related Taxes Policy Text Block", "terseLabel": "Sales-Related Taxes" } } }, "localname": "SalesRelatedTaxesPolicyTextBlock", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "chhe_ScheduleOfBasicAndDilutedNetIncomePerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Basic And Diluted Net Income Per Share [Abstract]" } } }, "localname": "ScheduleOfBasicAndDilutedNetIncomePerShareAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ScheduleOfComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Components Of Deferred Tax Assets Abstract" } } }, "localname": "ScheduleOfComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ScheduleOfConstructionInProgressAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Construction In Progress Abstract" } } }, "localname": "ScheduleOfConstructionInProgressAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ScheduleOfInformationBySegmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Information By Segment Abstract" } } }, "localname": "ScheduleOfInformationBySegmentAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ScheduleOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Intangible Assets Abstract" } } }, "localname": "ScheduleOfIntangibleAssetsAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ScheduleOfInventoryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Inventory Abstract" } } }, "localname": "ScheduleOfInventoryAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ScheduleOfPropertyPlantsAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Property Plants And Equipment Abstract" } } }, "localname": "ScheduleOfPropertyPlantsAndEquipmentAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ScheduleOfProvisionForIncomeTaxesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "ScheduleOfProvisionForIncomeTaxesAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ScheduleOfProvisionForIncomeTaxesAndTheProvisionAtTheStatutoryRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Provision For Income Taxes And The Provision at The Statutory Rate [Abstract]" } } }, "localname": "ScheduleOfProvisionForIncomeTaxesAndTheProvisionAtTheStatutoryRateAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ScheduleOfRelatedPartyDebtsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Related Party Debts Abstract" } } }, "localname": "ScheduleOfRelatedPartyDebtsAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ScheduleOfStraightLineBasisOverTheEstimatedUsefulLifeOfTheAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Straight Line Basis Over The Estimated Useful Life Of The Assets Abstract" } } }, "localname": "ScheduleOfStraightLineBasisOverTheEstimatedUsefulLifeOfTheAssetsAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ScheduleOfTaxesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of taxes payable [Abstract]" } } }, "localname": "ScheduleOfTaxesPayableAbstract", "nsuri": "http://chinahealth.me/20220630", "xbrltype": "stringItemType" }, "chhe_ScheduleofusefullifeofpropertyplantandequipmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scheduleofusefullifeofpropertyplantandequipment Table Text Block", "terseLabel": "Schedule of straight-line basis over the estimated useful life of the assets" } } }, "localname": "ScheduleofusefullifeofpropertyplantandequipmentTableTextBlock", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "chhe_SegmentReportingLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Line Items", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SegmentReporting" ], "xbrltype": "stringItemType" }, "chhe_SegmentReportingTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Table]" } } }, "localname": "SegmentReportingTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SegmentReporting" ], "xbrltype": "stringItemType" }, "chhe_SegmentReportingTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Tables Line Items", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingTablesLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SegmentReportingTables" ], "xbrltype": "stringItemType" }, "chhe_SegmentReportingTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting (Tables) [Table]" } } }, "localname": "SegmentReportingTablesTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SegmentReportingTables" ], "xbrltype": "stringItemType" }, "chhe_SignificantAccountingPoliciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies (Details) [Line Items]" } } }, "localname": "SignificantAccountingPoliciesDetailsLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "chhe_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets [Line Items]" } } }, "localname": "SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsLineItems", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable" ], "xbrltype": "stringItemType" }, "chhe_SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies (Details) - Schedule of straight-line basis over the estimated useful life of the assets [Table]" } } }, "localname": "SignificantAccountingPoliciesDetailsScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable" ], "xbrltype": "stringItemType" }, "chhe_SignificantAccountingPoliciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies (Details) [Table]" } } }, "localname": "SignificantAccountingPoliciesDetailsTable", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "chhe_StatementOfCashFlowsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash flow statement.", "label": "Statement Of Cash Flows Policy Policy Text Block", "terseLabel": "Statement of Cash Flows" } } }, "localname": "StatementOfCashFlowsPolicyPolicyTextBlock", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "chhe_StatutoryReserves": { "auth_ref": [], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount related to statutory reserves.", "label": "Statutory Reserves", "terseLabel": "Statutory reserves" } } }, "localname": "StatutoryReserves", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "chhe_StatutoryReservesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statutory Reserves Member", "terseLabel": "Statutory Reserve" } } }, "localname": "StatutoryReservesMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "chhe_SupplementaryAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplementary Agreement Member", "terseLabel": "Supplementary Agreement [Member]" } } }, "localname": "SupplementaryAgreementMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails", "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "domainItemType" }, "chhe_SupplierOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplier One Member", "terseLabel": "Supplier One [Member]" } } }, "localname": "SupplierOneMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "chhe_SupplierThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplier Three Member", "terseLabel": "Supplier Three [Member]" } } }, "localname": "SupplierThreeMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "chhe_SupplierTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplier Two Member", "terseLabel": "Supplier Two [Member]" } } }, "localname": "SupplierTwoMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "chhe_TaxesOnMaintainingAndBuilding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percventage of taxes on maintaining and building.", "label": "Taxes On Maintaining And Building", "terseLabel": "Annual aggregate, percentage" } } }, "localname": "TaxesOnMaintainingAndBuilding", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "chhe_TotalAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total Assets", "terseLabel": "Total assets" } } }, "localname": "TotalAssets", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "monetaryItemType" }, "chhe_TotalCapitalExpenditure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of total capital expenditures.", "label": "Total Capital Expenditure", "terseLabel": "Total capital expenditures" } } }, "localname": "TotalCapitalExpenditure", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "monetaryItemType" }, "chhe_TotalCashConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total cash consideration.", "label": "Total Cash Consideration", "terseLabel": "Total cash consideration" } } }, "localname": "TotalCashConsideration", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "monetaryItemType" }, "chhe_TotalProvisionForIncomeTaxes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Total Provision For Income Taxes", "terseLabel": "Total provision for income taxes" } } }, "localname": "TotalProvisionForIncomeTaxes", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesTable", "http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable" ], "xbrltype": "monetaryItemType" }, "chhe_TotalSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Sales Member", "terseLabel": "Total sales [Member]" } } }, "localname": "TotalSalesMember", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "chhe_ValueAddedTaxPayables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Value Added Tax Payables", "terseLabel": "Value added tax payables" } } }, "localname": "ValueAddedTaxPayables", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "chhe_ValueAddedTaxPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Value Added Tax.", "label": "Value Added Tax Policy Text Block", "terseLabel": "Value Added Tax" } } }, "localname": "ValueAddedTaxPolicyTextBlock", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "chhe_ValueAddedTaxRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of value added tax.", "label": "Value Added Tax Rate Percentage", "terseLabel": "VAT payable, percentage" } } }, "localname": "ValueAddedTaxRatePercentage", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "chhe_WeightedAverageSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Shares Outstanding Abstract", "terseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageSharesOutstandingAbstract", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "chhe_WeightedAverageSharesOutstandingAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Shares Outstanding Abstract0", "terseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageSharesOutstandingAbstract0", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ScheduleofbasicanddilutednetincomepershareTable" ], "xbrltype": "stringItemType" }, "chhe_costOfConstructionInProgress": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the cost of construction in progress.", "label": "cost Of Construction In Progress", "terseLabel": "Cost of construction in progress" } } }, "localname": "costOfConstructionInProgress", "nsuri": "http://chinahealth.me/20220630", "presentation": [ "http://chinahealth.me/role/ConstructioninProgressDetails" ], "xbrltype": "monetaryItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HONG KONG", "terseLabel": "China Health HK [Member]" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States [Member]", "verboseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r434", "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r434", "r435", "r436" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r434", "r435", "r436" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r434", "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails", "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r434", "r435", "r436" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails", "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://chinahealth.me/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "srt_CondensedBalanceSheetStatementTable": { "auth_ref": [ "r103", "r304", "r441" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.", "label": "Condensed Balance Sheet Statement [Table]" } } }, "localname": "CondensedBalanceSheetStatementTable", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/ScheduleoftaxespayableTable" ], "xbrltype": "stringItemType" }, "srt_CondensedBalanceSheetStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Condensed Balance Sheet Statements, Captions [Line Items]", "terseLabel": "Schedule of taxes payable [Abstract]" } } }, "localname": "CondensedBalanceSheetStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/ScheduleoftaxespayableTable" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails", "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r228", "r229", "r230", "r231", "r246", "r247", "r257", "r260", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r406", "r408", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable", "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r228", "r229", "r230", "r231", "r246", "r247", "r257", "r260", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r406", "r408", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable", "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r223", "r228", "r229", "r230", "r231", "r246", "r247", "r254", "r257", "r260", "r261", "r262", "r263", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r406", "r408", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable", "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r223", "r228", "r229", "r230", "r231", "r246", "r247", "r254", "r257", "r260", "r261", "r262", "r263", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r406", "r408", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r113", "r118", "r227", "r258" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable", "http://chinahealth.me/role/ScheduleoftaxespayableTable" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "auth_ref": [ "r103", "r441" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.", "label": "Condensed Balance Sheet [Table Text Block]", "terseLabel": "Schedule of taxes payable" } } }, "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails", "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "stringItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r177", "r178", "r251", "r252", "r407", "r416", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxesDetails", "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r113", "r118", "r227", "r258", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable", "http://chinahealth.me/role/ScheduleoftaxespayableTable" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Business Background [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountsReceivableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r182", "r183" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountsReceivableDetails", "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetNoncurrent": { "auth_ref": [ "r182", "r379", "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.", "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent": { "auth_ref": [ "r267", "r380", "r398" ], "calculation": { "http://chinahealth.me/role/ScheduleoftaxespayableTable": { "order": 3.0, "parentTag": "us-gaap_TaxesPayableCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes.", "label": "Accrual for Taxes Other than Income Taxes", "terseLabel": "Other taxes payable" } } }, "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleoftaxespayableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxes": { "auth_ref": [ "r18", "r19", "r275", "r377", "r392" ], "calculation": { "http://chinahealth.me/role/ScheduleoftaxespayableTable": { "order": 1.0, "parentTag": "us-gaap_TaxesPayableCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.", "label": "Accrued Income Taxes", "terseLabel": "Income tax payable" } } }, "localname": "AccruedIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleoftaxespayableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r10", "r39" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Wages payable" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r14", "r219" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r45", "r47", "r48", "r394", "r413", "r414" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r44", "r48", "r55", "r56", "r57", "r105", "r106", "r107", "r310", "r337", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21", "r348" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r105", "r106", "r107", "r264", "r265", "r266", "r314" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r27", "r188", "r195", "r196", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for doubtful accounts", "verboseLabel": "Net of allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountsReceivableDetails", "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r86", "r206", "r213" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense (in Dollars)" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r17", "r98", "r155", "r166", "r172", "r193", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r245", "r307", "r311", "r321", "r346", "r348", "r376", "r391" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r36", "r98", "r193", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r245", "r307", "r311", "r321", "r346", "r348" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building, Warehouse and Improvements [Member]", "verboseLabel": "Building, Warehouses and Improvements [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable", "http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r256", "r259", "r302" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r256", "r259", "r300", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Ownership percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r4", "r104", "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "ORGANIZATION AND BUSINESS BACKGROUND" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackground" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r12", "r88" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r81", "r88", "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r81", "r325" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount", "terseLabel": "Uninsured bank balances" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r224", "r225", "r226", "r232", "r418" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r105", "r106", "r314" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r20", "r248" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20", "r348" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, ($0.0001 par value per share, 300,000,000 shares authorized, and 65,539,737 shares issued and outstanding as of June 30, 2022 and June 30, 2021, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r50", "r52", "r53", "r63", "r384", "r402" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE (LOSS)/INCOME" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r140", "r141", "r180", "r319", "r320", "r417" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r140", "r141", "r180", "r319", "r320", "r415", "r417" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountsReceivableDetails", "http://chinahealth.me/role/MajorSuppliersandCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r137", "r389" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Business and Credit Risks" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "MAJOR SUPPLIERS AND CUSTOMERS" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/MajorSuppliersandCustomers" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r94", "r309" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Total" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofconstructioninprogressTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r68", "r98", "r193", "r233", "r234", "r235", "r238", "r239", "r240", "r241", "r242", "r244", "r245", "r321" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "COST OF GOODS SOLD", "verboseLabel": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement", "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Goods Sold" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Current provision:" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesTable" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r99", "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r99", "r283", "r290", "r292" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "terseLabel": "Total current provision" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r99", "r283", "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "Domestic" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerAdvancesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current portion of prepayments received from customers for goods or services to be provided in the future.", "label": "Customer Advances, Current", "terseLabel": "Advances from customers" } } }, "localname": "CustomerAdvancesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Deferred provision:" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesTable" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r99", "r284", "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r270", "r271" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r86", "r99", "r284", "r290", "r291", "r292" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Total deferred provision" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r87" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred taxes gain" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r99", "r284", "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "Domestic" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofcomponentsofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "terseLabel": "Valuation allowance for the deferred tax assets" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxesDetails", "http://chinahealth.me/role/ScheduleofcomponentsofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r86", "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/PropertyPlantsandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r86", "r217" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expenses", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow", "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r86", "r153" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expenses" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r3", "r222" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "ASSETS SALE" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AssetsSale" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r37", "r102", "r236", "r238", "r239", "r243", "r244", "r245", "r341" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Related party debts", "verboseLabel": "Related Party Debts, Held for Continuing Operations" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet", "http://chinahealth.me/role/ScheduleofrelatedpartydebtsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r64", "r110", "r111", "r112", "r113", "r114", "r119", "r121", "r124", "r125", "r126", "r130", "r131", "r315", "r316", "r385", "r403" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net (loss)/income per share Basic & diluted (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r64", "r110", "r111", "r112", "r113", "r114", "r121", "r124", "r125", "r126", "r130", "r131", "r315", "r316", "r385", "r403" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net (loss)/income per share Basic & diluted (in Dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r127", "r128" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r127", "r128", "r129", "r132" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r325" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rates change on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r100", "r273", "r293" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory rate", "verboseLabel": "Standard EIT rate under EIT law" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxesDetails", "http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r55", "r56", "r57", "r105", "r106", "r107", "r109", "r115", "r117", "r134", "r194", "r248", "r249", "r264", "r265", "r266", "r286", "r287", "r314", "r327", "r328", "r329", "r330", "r331", "r333", "r337", "r409", "r410", "r411" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity interests, percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails", "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r15", "r212" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Less: Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r207", "r208", "r212", "r214", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r212", "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r207", "r211" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r212", "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible Assets, net, Held for Continuing Operations" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Transaction" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyTranslationAdjustmentDescription": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of the translation adjustment. Includes an analysis of the change during the period in the accumulated adjustment and explanation of items creating the change.", "label": "Foreign Currency Translation Adjustment, Description", "terseLabel": "Foreign currency translation, description" } } }, "localname": "ForeignCurrencyTranslationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r67", "r98", "r155", "r165", "r168", "r171", "r174", "r193", "r233", "r234", "r235", "r238", "r239", "r240", "r241", "r242", "r244", "r245", "r321" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross profit (loss)", "totalLabel": "GROSS PROFIT/(LOSS)" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement", "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r216", "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r60", "r155", "r165", "r168", "r171", "r174", "r375", "r382", "r387", "r404" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Pre-tax book income", "totalLabel": "(LOSS)/INCOME BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement", "http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r61", "r64", "r122", "r124", "r125", "r385", "r399", "r401", "r403" ], "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "terseLabel": "Net income (loss) per share Basic & diluted" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofbasicanddilutednetincomepershareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r100", "r274", "r276", "r281", "r288", "r294", "r296", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r116", "r117", "r154", "r272", "r289", "r295", "r405" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes", "terseLabel": "Income tax" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement", "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r54", "r268", "r269", "r276", "r277", "r280", "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r273" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r273" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income tax computed at U.S. federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r273" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "terseLabel": "Non-deductible staff welfare" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxSettlementsForeign": { "auth_ref": [ "r273" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax settlement.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Amount", "terseLabel": "Foreign rate differential" } } }, "localname": "IncomeTaxReconciliationTaxSettlementsForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofprovisionforincometaxesandtheprovisionatthestatutoryrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r83", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r85" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payables and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r85" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "auth_ref": [ "r85" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.", "label": "Increase (Decrease) in Accrued Taxes Payable", "terseLabel": "Taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r85" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties", "terseLabel": "Amounts due to related parties" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r85" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r85" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Advance from customers and other payables" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities": { "auth_ref": [ "r85" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in employer-related costs classified as other and current.", "label": "Increase (Decrease) in Other Employee-Related Liabilities", "terseLabel": "Wages payable" } } }, "localname": "IncreaseDecreaseInOtherEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r85" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "Increase (Decrease) in Other Receivables", "negatedLabel": "Other receivables" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r85" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Advance to suppliers and prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r205", "r210" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r58", "r152", "r335", "r336", "r386" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r66" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest Income, Operating", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r80", "r82", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r28" ], "calculation": { "http://chinahealth.me/role/ScheduleofinventoryTable": { "order": 4.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished Goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r6", "r34", "r348" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://chinahealth.me/role/ScheduleofinventoryTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet", "http://chinahealth.me/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of valuation reserves, other allowances, and customer advances received on long-term contracts or programs, of inventory expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Net of Allowances, Customer Advances and Progress Billings", "terseLabel": "Inventory net of allowances", "verboseLabel": "Inventory allowance" } } }, "localname": "InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/InventoriesDetails", "http://chinahealth.me/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r11", "r32", "r95", "r133", "r199", "r200", "r201", "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r30" ], "calculation": { "http://chinahealth.me/role/ScheduleofinventoryTable": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw Materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r34" ], "calculation": { "http://chinahealth.me/role/ScheduleofinventoryTable": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Supplies and Packing Materials" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r29" ], "calculation": { "http://chinahealth.me/role/ScheduleofinventoryTable": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-Progress" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofinventoryTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r98", "r193", "r321", "r348", "r378", "r396" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r40", "r98", "r193", "r233", "r234", "r235", "r238", "r239", "r240", "r241", "r242", "r244", "r245", "r308", "r311", "r312", "r321", "r346", "r347", "r348" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable", "http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Majority ownership, percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in)/provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r81" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in)/provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r81", "r84", "r87" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r49", "r51", "r57", "r62", "r87", "r98", "r108", "r110", "r111", "r112", "r113", "r116", "r117", "r123", "r155", "r165", "r168", "r171", "r174", "r193", "r233", "r234", "r235", "r238", "r239", "r240", "r241", "r242", "r244", "r245", "r316", "r321", "r383", "r400" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net income/(loss)", "terseLabel": "Net income (loss)", "totalLabel": "NET (LOSS)/INCOME", "verboseLabel": "Net (loss)/income attributable to China Health Industries Holdings" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow", "http://chinahealth.me/role/ConsolidatedIncomeStatement", "http://chinahealth.me/role/ScheduleofbasicanddilutednetincomepershareTable", "http://chinahealth.me/role/ScheduleofinformationbysegmentTable", "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r105", "r106", "r107", "r249", "r305" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r70" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER INCOME/(EXPENSES)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/SegmentReportingDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable", "http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r155", "r165", "r168", "r171", "r174" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "(LOSS)/INCOME FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r282" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carry forward", "verboseLabel": "Operating loss carry forwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxesDetails", "http://chinahealth.me/role/ScheduleofcomponentsofdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.", "label": "Operating Loss Carryforwards, Limitations on Use", "terseLabel": "Federal net operating loss, description" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized.", "label": "Other Capitalized Property Plant and Equipment [Member]", "terseLabel": "Others [Member]" } } }, "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r43", "r45", "r322", "r323", "r326" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Other comprehensive income (loss) - Translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r42", "r46", "r324", "r332" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "negatedLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r381" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "terseLabel": "Other payables" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r71" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables, net" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromShortTermInvestments": { "auth_ref": [ "r72", "r75", "r89" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments for (Proceeds from) Short-Term Investments", "negatedLabel": "Proceeds from short term investment", "terseLabel": "Withdraw of short term investment" } } }, "localname": "PaymentsForProceedsFromShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r76", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Total purchase price" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r77" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r7", "r35", "r202", "r203" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepayments" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseNoncurrent": { "auth_ref": [ "r16" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "Prepaid Expense, Noncurrent", "terseLabel": "Prepayments \u2013 Non-Current" } } }, "localname": "PrepaidExpenseNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates": { "auth_ref": [ "r73" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.", "label": "Proceeds from Divestiture of Interest in Subsidiaries and Affiliates", "negatedLabel": "Proceeds from disposal of subsidiary" } } }, "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r78" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Proceed from related party debts" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Proceeds from Sale of Equity Method Investments", "terseLabel": "Total cash consideration" } } }, "localname": "ProceedsFromSaleOfEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AssetsSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r74" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Disposal of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plants and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofconstructioninprogressTable", "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable", "http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r222", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY, PLANTS AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/PropertyPlantsandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r13", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plants and equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r220", "r348", "r388", "r397" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plants and equipment, net", "verboseLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet", "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r220", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plants and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/PropertyPlantsandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofconstructioninprogressTable", "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r65", "r197" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r255", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails", "http://chinahealth.me/role/ScheduleofrelatedpartydebtsTable" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofrelatedpartydebtsTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r255", "r340", "r343", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails", "http://chinahealth.me/role/ScheduleofrelatedpartydebtsTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r338", "r339", "r341", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY DEBTS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/RelatedPartyDebts" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r79" ], "calculation": { "http://chinahealth.me/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-Term Debt", "negatedLabel": "Payment of short term loans" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r249", "r348", "r395", "r412", "r414" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r105", "r106", "r107", "r109", "r115", "r117", "r194", "r264", "r265", "r266", "r286", "r287", "r314", "r409", "r411" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r59", "r98", "r150", "r151", "r164", "r169", "r170", "r176", "r177", "r180", "r193", "r233", "r234", "r235", "r238", "r239", "r240", "r241", "r242", "r244", "r245", "r321", "r387" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "REVENUE", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement", "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major Suppliers and Customers [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent": { "auth_ref": [ "r380", "r398" ], "calculation": { "http://chinahealth.me/role/ScheduleoftaxespayableTable": { "order": 2.0, "parentTag": "us-gaap_TaxesPayableCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax.", "label": "Sales and Excise Tax Payable", "terseLabel": "Value-added tax payable" } } }, "localname": "SalesAndExciseTaxPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleoftaxespayableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of provision for income taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of components of deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net income per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of provision for income taxes and the provision at the statutory rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r207", "r211", "r361" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r207", "r211" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r31", "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofrelatedpartydebtsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of related party debts" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/RelatedPartyDebtsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r155", "r156", "r167", "r204" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r155", "r156", "r167", "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of information by segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r146", "r148", "r149", "r155", "r157", "r168", "r172", "r173", "r174", "r175", "r176", "r179", "r180", "r181" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT REPORTING" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofinformationbysegmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r158", "r159", "r160", "r161", "r162", "r163", "r177" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r69" ], "calculation": { "http://chinahealth.me/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r93", "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r41", "r55", "r56", "r57", "r105", "r106", "r107", "r109", "r115", "r117", "r134", "r194", "r248", "r249", "r264", "r265", "r266", "r286", "r287", "r314", "r327", "r328", "r329", "r330", "r331", "r333", "r337", "r409", "r410", "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r105", "r106", "r107", "r134", "r360" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r24", "r25", "r98", "r190", "r193", "r321", "r348" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet", "http://chinahealth.me/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r56", "r98", "r105", "r106", "r107", "r109", "r115", "r193", "r194", "r249", "r264", "r265", "r266", "r286", "r287", "r305", "r306", "r313", "r314", "r321", "r327", "r328", "r333", "r337", "r410", "r411" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Transaction and subsequent reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/OrganizationandBusinessBackgroundDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r349", "r351" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://chinahealth.me/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxesPayableCurrentAndNoncurrent": { "auth_ref": [ "r18", "r377", "r393" ], "calculation": { "http://chinahealth.me/role/ScheduleoftaxespayableTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.", "label": "Taxes Payable", "totalLabel": "Total" } } }, "localname": "TaxesPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleoftaxespayableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r184", "r185", "r186", "r187", "r189", "r191" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r135", "r136", "r138", "r139", "r142", "r143", "r144" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates and Assumptions" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]", "terseLabel": "Vehicles [Member]" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofpropertyplantsandequipmentTable", "http://chinahealth.me/role/ScheduleofstraightlinebasisovertheestimatedusefullifeoftheassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Basic & diluted" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ScheduleofbasicanddilutednetincomepershareTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r120", "r126" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Basic & diluted (in Shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r119", "r126" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic & diluted (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://chinahealth.me/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "https://asc.fasb.org/topic&trid=2122478" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r345": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r351": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(9))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r433": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r434": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r435": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r436": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r437": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r438": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r439": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r440": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r441": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04" }, "r442": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3098-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 78 0001213900-22-056075-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-056075-xbrl.zip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